

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number  
**WO 01/64752 A2**

(51) International Patent Classification<sup>7</sup>: C07K 16/10, C12N 5/20, A61K 39/21, 39/39, 39/00, A01K 67/027, A61K 39/395, C07K 14/705, A61K 38/17, C12N 5/10, G01N 33/53, A61P 31/18

(21) International Application Number: PCT/US01/06322

(22) International Filing Date: 28 February 2001 (28.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/517,605 2 March 2000 (02.03.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/517,605 (CIP)  
Filed on 2 March 2000 (02.03.2000)

(71) Applicants (for all designated States except US): NEW YORK UNIVERSITY [US/US]; 70 Washington Square South, New York, NY 10012 (US). KATHolieKE UNIVERSITEIT NIJMEGEN [NL/NL]; Posibus 9101, NL-6500 HB Nijmegen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LITTMAN, Dan, R. [US/US]; 29 Washington Square Park West, Apt. 14D, New York, NY 10011 (US). KWON, Douglas [US/US]; 35-13 30th Street, Apt. 2RR, Long Island City, NY 11106

(US). VAN KOOYK, Yvette [NL/NL]; Tumor Immunology Laboratory, University Hospital Nijmegen, Philips van Leydenlaan 25, NL-6525 EX Nijmegen (NL). GEIJTENBEEK, Teunis [NL/NL]; Tumor Immunology Laboratory, University Hospital Nijmegen, Philips van Leydenlaan 25, NL-6525 EX Nijmegen (NL).

(74) Agent: DAVIS, Michael, A.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EB, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/64752 A2

(54) Title: METHODS OF USING A FACILITATOR OF RETROVIRAL ENTRY INTO CELLS

(57) Abstract: The present invention demonstrates that a receptor, named DC-SIGN, is specifically expressed on dendritic cells, and facilitates infection of T lymphocytes with HIV. Assays for identifying compounds that modulate the interaction of DC-SIGN and HIV and/or T cells and macrophage are provided. Compounds so identified are also part of the present invention.

**METHODS OF USING A FACILITATOR  
OF RETROVIRAL ENTRY INTO CELLS**

5

**GOVERNMENTAL SUPPORT**

The research leading to the present inventions was funded in part by Grant No. AI 33856 from the National Institutes of Health. The government may have certain rights in the invention.

10

**TECHNICAL FIELD OF THE INVENTION**

The present invention relates generally to the binding, transport and infection of cells by retroviruses including HIV-1, and HIV-2. Methods of identifying agents that 15 modulate such processes, the agents themselves and therapeutic uses of such agents are also provided. Related diagnostic methods are also included.

**BACKGROUND OF THE INVENTION**

20 The human immunodeficiency viruses infect CD4<sup>+</sup> macrophages and T helper cells. Although HIV-1 entry requires cell surface expression of CD4, to which the viral envelope glycoproteins bind, several studies have suggested that it is not sufficient for fusion of the viral envelope to the cellular plasma membrane. Early studies have shown that while human cells expressing a transfected CD4 gene were permissive for 25 virus entry, murine cells expressing human CD4 were not. These findings led to the suggestion that there is a species-specific cell surface cofactor required in addition to CD4 for HIV-1 entry. Subsequent studies have shown that strains of HIV-1 that had been adapted for growth in transformed T-cell lines (T-tropic strains) could not infect primary monocytes or macrophages; in contrast, primary viral strains were found to 30 infect monocytes and macrophages, but not transformed T cell lines. This difference in tropism was found to be a consequence of specific sequence differences in the gp120 subunit of the envelope glycoprotein, suggesting that multiple cell type-specific cofactors may be required for entry in addition to CD4.

The nature of the cofactors required for HIV entry proved elusive until it was discovered that the principal receptor for entry of macrophage-tropic (M-tropic) HIV-1 strains was CCR5, whereas the principal receptor for entry of T-cell line-tropic (T-tropic) strains was CXCR4. On the other hand, both M-tropic and T-tropic strains of 5 simian immunodeficiency virus (SIV) can be mediated by CCR5, but not CXCR4 [Chew *et al.*, *J. Virol.*, 71:2705-2714 (1997); Marcon *et al.*, *J. Virol.*, 71:2522-2527 (1997); and Edinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 94:4005-4010 (1997)]. More importantly, SIV strains were also found to infect CD4<sup>+</sup> cells that lack CCR5 [Chen *et al.*, *J. Virol.*, 71:2705-2714 (1997); and Edinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 10 94:4005-4010 (1997)].

In humans, CCR5-tropic viruses are primarily involved in transmission, while viruses with broader tropism, particularly for CXCR4, emerge during progression to immunodeficiency [Fauci, *Nature*, 384:529-534 (1996)]. It is not yet known whether 15 appearance of CXCR4-tropic viruses is a consequence or the cause of immune system decline. Insight into this key problem of virus evolution is likely to require experimental manipulation in animal models. Infection of non-human primates with SIV remains the only good animal model for studying pathogenesis of the immunodeficiency viruses [Desrosiers, *Annu Rev Immunol*, 8:557-578 (1990)]. 20 Moreover, different species of non-human primates vary widely in their responses to SIV infection. For example, Rhesus macaques succumb to immunodeficiency that closely resembles AIDS in humans, but sooty mangabeys and African green monkeys can sustain infection with little evidence of immune system damage [Kestler, *Science*, 248:1109-1112 (1990)]. These interspecies differences provide important clues for 25 understanding and combating disease progression in HIV-infected humans.

Transmission of Human Immunodeficiency Virus Type 1 (HIV-1) infection in humans requires the dissemination of virus from sites of infection at mucosal surfaces to T cell zones in secondary lymphoid organs, where extensive viral replication occurs in CD4<sup>+</sup> 30 T-helper cells and macrophages [Fauci, *Nature*, 384(6609):529-534 (1996)]. These cells express both CD4 and the chemokine receptor CCR5, which together form the

receptor complex required for entry by the R5 viral isolates that are prevalent early after infection [Littman, *Cell*, 93:677-680 (1998); Lu *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 94(12):6426-6431 (1997); Dragic *et al.*, *Nature*, 381:667-673 (1996); US Patent No: 5,939,320, Issued August 17, 1999; and U.S. Patent Application

5 09/116,498, Filed July 7, 1998, the contents of which are hereby incorporated by reference in their entireties]. Viruses with tropism for other chemokine receptors, particularly CXCR4, are rarely transmitted, and generally appear only late in infection. Such CXCR4-tropic isolates replicate poorly in macrophages, and it has hence been proposed that infection of macrophages is a requisite component of viral transmission.

10

The mechanism of early viral dissemination remains vague, but based on anatomical distribution of different hematopoietic lineage cells and on *in vitro* infectivity studies it has been inferred that immature dendritic cells (DC) residing in the skin and at mucosal surfaces are the first cells targeted by HIV-1. DC are the most potent

15 antigen-presenting cells *in vivo* [Banchereau and Steinman, *Nature*, 392:245-252 (1998); Valitutti *et al.*, *Nature*, 375:148-151 (1995)]. Immature DC in peripheral tissues capture antigens efficiently and have a unique capacity to subsequently migrate to the T cell areas of secondary lymphoid organs. As the cells travel, they mature and alter their profile of expression of cell surface molecules, including chemokine  
20 receptors, lose their ability to take up antigen, and acquire competence to attract and activate resting T cells in the lymph nodes [Banchereau and Steinman, *Nature*, 392:245-252 (1998); Adema *et al.*, *Nature*, 387(6634):713-717 (1997)]. HIV-1 is thought to subvert the trafficking capacity of DC to gain access to the CD4<sup>+</sup> T cell compartment in the lymphoid tissues [Steinman and Inaba, *J. Leukoc. Biol.*, 66(2):205-208 (1999); Rowland-Jones, S.L., *Curr. Biol.*, 9(7):R248-R250 (1999); and Grouard and Clark, *Curr. Opin. Immunol.*, 9(4):563-567 (1997)].

30 Immature DC express CD4 and CCR5, albeit at levels that are considerably lower than on T cells [Granelli-Piperno *et al.*, *J. Exp. Med.*, 184:2433-2438 (1996); Rubbert *et al.*, *J. Immunol.*, 160(8):3933-3941 (1998)], and they have been reported to be infectable with R5 strains of HIV-1. In contrast, immature DC do not express

CXCR4 and are resistant to infection with CXCR4-tropic isolates of HIV-1 [Granelli-Piperno *et al.*, *J. Virol.*, 72:2733-2737 (1998); Blauvelt *et al.*, *J. Clin. Invest.*, 100:2043-2053 (1997); and Weissman *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 92:826-830 (1995)]. Entry of HIV-1 into immature DC has also been reported to proceed

5 through a CD4-independent mechanism [Blauvelt *et al.*, *J. Clin. Invest.*, 100:2043-2053 (1997)], suggesting that receptors other than CD4 could be involved. There have been conflicting reports regarding the significance of HIV-1 replication within DC [Canque *et al.*, *Blood*, 93(11):3866-3875 (1999); Ayehunie *et al.*, *Blood*, 90(4):1379-1386 (1997); Cameron *et al.*, *J. Leukoc. Biol.*, 56(3):257-265 (1994)].

10 Although replication can be observed in some circumstances, it has also been reported that, in immature DC, replication is incomplete and that only early HIV-1 genes are transcribed.

It has been proposed that virus-infected immature DC migrate to the draining lymph nodes where they initiate both a primary anti-viral immune response and a vigorous productive infection of T cells, allowing systemic distribution of HIV-1 [Cameron *et al.*, *Science*, 257(5068):383-387 (1992); Weissman *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 92:826-830 (1995)]. However, in a non-human primate model of mucosal infection with the simian immunodeficiency virus, it has been difficult to demonstrate

15 productive infection of DC despite rapid dissemination of virus [Stahl-Henning *et al.*, *Science*, 285(5431):1261-1265 (1999)]. Other efforts to model primary HIV-1 infection *in vitro* by exposing DC derived from skin or blood to HIV-1 have indicated that these cells are poorly infected. Nevertheless, only DC, and not other leukocytes including monocytes, macrophages, B cells and T cells were able to induce high levels

20 of infection upon co-culture with mitogen-activated CD4<sup>+</sup> T cells after being pulsed with HIV-1 [Cameron *et al.*, *Science*, 257(5068):383-387 (1992); Granelli-Piperno *et al.*, *Curr. Biol.*, 9:21-29 (1999); Weissman *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 92:826-830 (1995); Blauvelt *et al.*, *J. Clin. Invest.*, 100:2043-2053 (1997); Cameron *et al.*, *J. Leukoc. Biol.*, 59(2):158-171 (1996)]. In an early study, Cameron *et al.*

25 [Science, 257(5068):383-387 (1992)] proposed that DC have a unique ability to "catalyze" infection of T cells with HIV, but do not become infected themselves.

30

Therefore, there is a need to identify the protein or proteins involved in the mediation of HIV from the mucosal surfaces to the T cell areas of secondary lymphoid organs. Further, there is a need to design methods of identifying agents that will interfere with this mediation.

5

The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.

#### SUMMARY OF THE INVENTION

10

The present invention provides the missing link between viral breach of host mucosal defense and infection of T cells in the lymphatic organs by demonstrating that a membrane-bound receptor that is specifically expressed on dendritic cells, DC-SIGN, and which has the amino acid sequence of SEQ ID NO:2, facilitates infection of T 15 lymphocytes by HIV. The present invention further provides new intervention strategies and novel approaches towards prevention, preventive vaccination and therapy against HIV infection based, at least in part, on this finding.

The present invention therefore provides an antibody that is specific for an antigenic 20 fragment of gp120. In one embodiment the antigenic fragment is obtained from a portion of gp120 that binds to DC-SIGN. In another embodiment the antigenic fragment is obtained from the portion of gp120 that is exposed upon gp120 binding of DC-SIGN due to the concomitant conformational change that occurs upon DC-SIGN binding gp120. The present invention also provides antibodies to the portion of DC- 25 SIGN that interacts with T cells and/or macrophages. In a preferred embodiment the antibody is specific for the DC-SIGN-gp120 binding complex. The antibodies of the present invention preferably interfere with dendritic cells facilitating the trans-enhancement of HIV entry into T cells or macrophages.

30 In a particular embodiment the antibody is a polyclonal antibody. In another embodiment the antibody is a monoclonal antibody. In still another embodiment the

antibody is a chimeric antibody. In one such embodiment the antibody is a humanized antibody. The present invention also provides immortal cell lines that produce the monoclonal antibodies of the present invention.

- 5 The present invention also provides vaccines and immunogenic compositions. Such vaccines and immunogenic compositions preferably comprise adjuvants. One such immunogenic composition comprises an adjuvant and an antigenic fragment obtained from a portion of gp120 that binds to DC-SIGN. In another embodiment the immunogenic composition comprises an adjuvant and an antigenic fragment obtained
- 10 from the portion of gp120 that is exposed upon gp120 binding of DC-SIGN due to the concomitant conformational change that occurs upon DC-SIGN binding gp120. In yet another embodiment the immunogenic composition comprises an adjuvant and an antigenic fragment of DC-SIGN that interacts with T cells and/or macrophages. In still another embodiment the immunogenic composition comprises an adjuvant and
- 15 the DC-SIGN-gp120 binding complex or fragment thereof.

The present invention further provides a soluble form of human DC-SIGN. The soluble form of human DC-SIGN can be used in drug assays or in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

- 20 In addition, the present invention provides a mammalian cell that is transfected with a vector encoding human DC-SIGN. Preferably this cell can facilitate the trans-enhancement of HIV entry into a T cell or macrophage. More preferably, the cell lacks the translocation promoting agent and/or CD4 required for HIV entry. In a
- 25 particular embodiment the mammalian cell is not a dendritic cell. In a preferred embodiment the mammalian cell is a human cell. In particular embodiment, the cell is attached to a solid support matrix.

- 30 The present invention further provides methods of filtering a biological fluid to remove a virus expressing an HIV envelope glycoprotein that binds DC-SIGN. In one embodiment the method comprises passing the biological fluid through a solid

support comprising DC-SIGN. A related embodiment comprises passing the biological fluid through a solid support comprising a mammalian cell that is transfected with a vector encoding human DC-SIGN. In another embodiment the biological fluid is contacted with a mammalian cell that is transfected with a vector 5 encoding human DC-SIGN and then the cell is removed. In still another embodiment the biological fluid is contacted with a dendritic cell and then the dendritic cell is removed

The present invention further provides transgenic non-human mammals. In one 10 embodiment the transgenic non-human mammal comprises DNA constructs encoding CD4, one or more translocation promoting agents, and DC-SIGN. Preferably the CD4, the translocation promoting agent(s), and the DC-SIGN are human proteins. In a preferred embodiment, the transgenic non-human mammal is capable of/susceptible to mucosal uptake of HIV, transport of the HIV to lymphatic organs and infection of a 15 target T cell and/or macrophage by HIV. More preferably the infection with HIV (or suitable vector analog) is greatly enhanced relative to a transgenic non-human mammal that does not contain a DNA construct encoding DC-SIGN. In a preferred embodiment the transgenic non-human mammal further comprises a DNA construct encoding cyclin T (which is preferably human cyclin T).

20 In one embodiment the human translocation promoting agent is CCR3. In another embodiment the human translocation promoting agent is CXCR4. In yet another embodiment the human translocation promoting agent is CCR2b. In still another embodiment the human translocation promoting agent is Bob. In yet another 25 embodiment the human translocation promoting agent is Bonzo. In a preferred embodiment the human translocation promoting agent is CCR5.

The transgenic non-human mammal can be any mammal including a primate or rodent including rabbits, rats or monkeys and chimpanzees. In a preferred 30 embodiment the transgenic non-human mammal is a mouse.

The present invention further provides methods of treating or preventing HIV infection by inhibiting dendritic cells from facilitating the trans-enhancement of HIV entry into a cell. One such embodiment comprises administering a humanized form of an antibody of the present invention to the subject. Another embodiment

5 comprises administering a soluble form of DC-SIGN of the present invention to the subject. Yet another embodiment comprises administering a compound identified through an assay of the present invention to the subject. In a preferred embodiment, the cell for which the trans-enhancement of HIV entry is inhibited is a T cell or macrophage.

10 The present invention further provides methods of identifying a compound that interferes with the trans-enhancement of HIV entry into a cell. In one such embodiment, the compound interferes with viral capture. One such embodiment comprises contacting a first cell with a vector in the presence of a test compound.

15 The vector comprises a viral envelope protein that binds DC-SIGN, whereas the first cell expresses DC-SIGN. A DC-SIGN-viral envelope protein complex forms between the first cell and the vector in the absence of the test compound and the effect of the test compound on the formation of the complex is thus being tested. The unbound vector is separated from the first cell (preferably so is the test compound) and the first

20 cell is next contacted with a second cell. The second cell is susceptible to entry of vectors comprising the viral envelope protein. The amount of vector that has entered the second cell is determined. A test compound is identified as a compound that interferes with the trans-enhancement of HIV entry into a cell when the amount of vector entry determined is less for the case when the test compound was present

25 during the incubation with the first cell and the vector, than when the test compound was absent.

In a particular embodiment removal of the unbound vector (and the test compound) from first cell comprises washing the unbound vector (and the test compound) away from the first cell. In a particular embodiment the second cell is a T cell or macrophage. In another embodiment the second cell expresses human CD4 and a

human translocation promoting agent. In one embodiment the human translocation promoting agent is CCR3. In another embodiment the human translocation promoting agent is CXCR4. In yet another embodiment the human translocation promoting agent is CCR2b. In still another embodiment the human translocation promoting agent is Bob. In yet another embodiment the human translocation promoting agent is Bonzo. In a preferred embodiment the human translocation promoting agent is CCR5.

In a particular embodiment the human translocation promoting agent is CCR5 and the 10 viral envelope glycoprotein is JRFL. In another embodiment the vector contains a marker protein. In one such embodiment the amount of vector that has entered the second cell is determined by detecting the amount of marker protein expressed in the cell. In a particular embodiment the marker protein is luciferase. In another embodiment the marker protein is green fluorescent protein. The present invention 15 further provides the compounds identified by these methods.

The present invention also provides an assay for identifying an agent for use in the treatment or prevention of HIV infection using a transgenic non-human mammal of the present invention. One such method comprises administering a test compound to 20 the transgenic non-human mammal and infecting the transgenic non-human mammal with a virus or viral vector having an HIV envelope glycoprotein. The ability of the transgenic non-human mammal to resist the infection is then determined or measured. A test compound is identified as an agent for use in the treatment or prevention of HIV infection when the measured ability of the transgenic mammal to resist the 25 infection is statistically greater in the presence of the test compound than in the absence of the test compound. Again the compounds identified by this method are also part of the present invention.

The present invention further provides a method of identifying a compound that 30 interferes with the trans-enhancement of HIV entry into a cell. One such embodiment comprises

contacting a first cell, a vector and a second cell in the presence of a test compound. The vector comprises a viral envelope protein that binds DC-SIGN, the first cell expresses DC-SIGN, and a DC-SIGN-viral envelope protein complex forms between the first cell and the vector in the absence of the test compound. In addition, the 5 second cell is susceptible to entry of vectors comprising the viral envelope protein. The amount of vector that has entered the second cell is then determined. A test compound is identified as a compound that interferes with the trans-enhancement of HIV entry into a cell when the amount of vector entry is less in the presence of the test compound than in its absence. In a particular embodiment the second cell is a T cell 10 or macrophage. In another embodiment the second cell expresses human CD4 and a human translocation promoting agent. In one embodiment the human translocation promoting agent is CCR3. In another embodiment the human translocation promoting agent is CXCR4. In yet another embodiment the human translocation promoting agent is CCR2b. In still another embodiment the human translocation promoting 15 agent is Bob. In yet another embodiment the human translocation promoting agent is Bonzo. In a preferred embodiment the human translocation promoting agent is CCR5.

In a particular embodiment the human translocation promoting agent is CCR5 and the 20 viral envelope glycoprotein is JRFL. In another embodiment the vector contains a marker protein. In one such embodiment the amount of vector that has entered the second cell is determined by detecting the amount of marker protein expressed in the cell. In a particular embodiment the marker protein is luciferase. In another embodiment the marker protein is green fluorescent protein. The present invention 25 further provides the compounds identified by these methods.

Accordingly, it is a principal object of the present invention to provide compounds that can be used in the treatment of AIDS.

It is a further object of the present invention to provide assays for identifying new 30 compounds in the treatment of HIV infection.

It is a further object of the present invention to provide soluble fragments of DC-SIGN.

It is a further object of the present invention to generate a soluble form of DC-SIGN  
5 that inhibits trans-enhancement of HIV entry into T cells that is facilitated by DC-SIGN.

It is a further object of the present invention to identify DC-SIGN polymorphisms that  
do enable dendritic cells to facilitate trans-enhancement of HIV entry in T cells.

10

It is a further object of the present invention to provide methods of identifying drugs  
that can treat HIV infection.

15

It is a further object of the present invention to provide methods for making a  
transgenic animal model for AIDS.

It is a further object of the present invention to provide a vaccine to prevent or retard  
the onset of AIDS.

20

These and other aspects of the present invention will be better appreciated by  
reference to the following drawings and Detailed Description.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 Figures 1A-1D show that DC-SIGN is a dendritic cell (DC) specific receptor for  
HIV-1 gp120. Figure 1A shows that DC-SIGN is expressed specifically by DC.  
Immature DC, cultured from monocytes in the presence of GM-CSF and IL-4, express  
high levels of DC-SIGN, whereas resting peripheral blood lymphocytes or monocytes  
do not express DC-SIGN. Expression of DC-SIGN (AZN-D1) was determined by  
30 FACScan analysis. One representative experiment out of 3 is shown. Figure 1B  
shows that DC-SIGN, but not CD4, mediates binding of HIV-1 gp120 to DC. DC

were allowed to bind HIV-1 gp120-coated fluorescent beads. Adhesion was blocked by anti-DC-SIGN antibodies (20  $\mu$ g/ml), mannan (20 $\mu$ g/ml) and EGTA (5mM) and not by neutralizing anti-CD4 antibodies (20  $\mu$ g/ml). One representative experiment out of 3 is shown. Figures 1C-1D show immature DC (Fig. 1D) express low levels of

5 CD4 (RPA-T4) and CCR5 (2D7/CCR5) and high levels of DC-SIGN (AZN-D1). THP-1 cells stably transfected with DC-SIGN (THP-DC-SIGN, Fig. 1C) express high levels of DC-SIGN (AZN-D1) while CD4 and CCR5 are not expressed (filled histograms). Antibodies against CD4 and DC-SIGN were isotype matched and the appropriate isotype controls are represented by dotted lines. Figure 1E shows

10 DC-SIGN transfectants (THP-DC-SIGN) bind HIV-1 gp120. THP-DC-SIGN and mock transfectants were allowed to bind HIV-1gp120 coated fluorescent beads. Adhesion was blocked by anti-DC-SIGN antibodies (20  $\mu$ g/ml) and EGTA (5mM) and not by neutralizing anti-CD4 (RPA-T4) antibodies (20  $\mu$ g/ml). One representative experiment out of 3 is shown.

15 Figures 2A-2C show that DC-SIGN mediates HIV-1 infection in a DC-T cell co-culture. Figure 2A shows that antibodies against DC-SIGN inhibit HIV-1 infection as measured in a DC-T cell co-culture. DC ( $50 \times 10^3$ ) were pre-incubated for 20 min at room temperature with blocking mAb against CD4 (RPA-T4) or DC-SIGN (AZN-D1

20 and AZN-D2) (20  $\mu$ g/ml) or with a combination of CCR5-specific chemokines (CCR5 trio: RANTES, MIP-1 $\alpha$  and MIP1 $\beta$ ; 500 ng/ml). Pre-incubated immature DC were pulsed for 2 hours with HIV-1 (M-tropic HIV-1<sub>Ba-L</sub> strain) and unbound virus particles and mAb were washed away. Subsequently, DC were co-cultured with activated PBMC ( $50 \times 10^3$ ) for 9 days. Co-culture supernatants were collected and p24

25 antigen levels were measured by ELISA. One representative experiment of 2 is shown. Figure 2B shows the inhibition of HIV-1 infection in a DC-T cell co-culture by blocking DC-SIGN, CD4 and CCR5. HIV-1 replication in the DC-T cell co-culture at day 5 of the experiment is described in Figure 5A. The results of day 5 are representative for day 6, 7 and 9 of DC-T cell co-culture. DC were also

30 pre-incubated with mAb against DC-SIGN together with anti-CD4 and CCR5 specific chemokines. p24 values represent mean  $\pm$  SD of triplicate cultures. One representative

experiment out of 2 is shown. Figure 2C shows the DC-SIGN interactions with ICAM-3 are not involved in the transmission of DC-bound-HIV-1 to T cells. DC (50x10<sup>3</sup>) were pulsed for 2 hours with HIV-1 (M-tropic HIV-1<sub>Ba-L</sub> strain), washed and co-cultured with activated PBMC (50x10<sup>3</sup>) for 9 days in the presence of the CCR5 specific chemokines (CCR5 trio: RANTES, MIP-1 $\alpha$  and MIP1 $\beta$ ; 500 ng/ml) or mAb against CD4 (RPA-T4) and DC-SIGN (AZN-D1 and AZN-D2) (20  $\mu$ g/ml). Antibodies were added post HIV-1infection of DC, prior to the addition of PBMC. One representative experiment out of 2 is shown.

10 Figures 3A-3B show that DC-SIGN expressed on target cells does not mediate HIV-1 entry. Figure 3A shows the results from 293T cells that were transfected with DC-SIGN or CD4 and CCR5 and pulsed for 2 hour with HIV-1 (CCR5-tropic HIV-1<sub>Ba-L</sub> strain). Subsequently, cells were cultured for 9 days. Supernatants were collected and p24 antigen levels were measured by ELISA. One representative experiment of 2 is shown. Figure 3B shows the results from 293T cells and 293T cells stably expressing either CD4, CCR5 or CD4 and CCR5 that were transiently transfected with DC-SIGN and subsequently infected with pseudotyped CCR5-tropic HIV-1<sub>ADA</sub> virus in the presence of polybrene (20  $\mu$ g/ml). Luciferase activity was evaluated after 2 days. One representative experiment out of 3 is shown.

15 20 Figures 4A-4C show that DC-SIGN captures HIV-1 that retains infectivity for CD4 $^+$ T cells. Figure 4A shows that DC-SIGN captures HIV-1 and facilitates infection of HIV-1 permissive cells *in trans*. THP-1 transfectants (100x10<sup>3</sup>) were pre-incubated for 20 min at room temperature with blocking mAb against DC-SIGN (AZN-D1 and AZN-D2; 20  $\mu$ g/ml). The THP-DC-SIGN cells were infected with HIV-luciferase virus pseudotyped with R5 strain HIV-1<sub>ADA</sub> Env. Alternatively activated T cells were infected with pseudotyped HIV-1<sub>ADA</sub> virus. After 2 hours at 37°C the infected cells were extensively washed and added to either 293T-CD4-CCR5 cells or activated primary T cells (100x10<sup>3</sup>). HIV-1 infection was determined after 2 days by measuring

25 30 the luciferase activity. One representative experiment out of 3 is shown. Figure 4B shows that DC-SIGN is able to mediate capture of HIV-1 viruses pseudotyped with

M-tropic HIV-1 envelopes from different primary isolates. DC-SIGN mediated capture was performed as described in Fig. 4A on 293T-CD4-CCR5 cells with HIV-luciferase viruses pseudotyped with the CCR5-specific HIV-1 envelopes from JRFL, JRCSF and from primary viruses 92US715.6, 92BR020.4 and 93TH966.8.

5 One representative experiment out of 2 is shown. Figure 4C shows that activated T cells are infected by HIV-1 in the T cell/THP-DC-SIGN co-culture. THP-DC-SIGN cells were incubated with HIV-eGFP viruses pseudotyped with M-tropic HIV-1<sub>ADA</sub> and subsequently co-cultured with activated T cells. The CD3-negative THP-DC-SIGN cells were not infected by HIV-1 whereas the CD3-positive T cells were infected. T

10 cells, gated by staining for CD3 (tricolor), were positive for GFP, whereas CD3-negative THP-DC-SIGN that initially captured HIV-GFP did not express GFP.

One representative experiment out of 2 is shown.

Figure 5A-5B show that DC-SIGN enhances HIV-1 infection of T cells by acting *in trans*. At a low virus load, DC-SIGN *in trans* is crucial for the infection of HIV-1 permissive cells. THP-1 transfectants ( $100 \times 10^3$ ) were pre-incubated for 20 min at room temperature with blocking mAb against DC-SIGN (AZN-D1 and AZN-D2; 20  $\mu$ g/ml). The THP-1 were infected by low amounts of pseudotyped HIV-1<sub>ADA</sub> virus (Fig. 5A) or other R5 isolates of HIV-1 (5B), *i.e.* at the threshold of detection in a single round infection assay. After 1 hour at 37°C the cell/virus suspension was directly added to either 293T-CD4-CCR5 or activated T cells ( $100 \times 10^3$ ). The infectivity was determined after 2 days by measuring the luciferase activity. One representative experiment out of 2 is shown.

25 Figures 6A-6I show that DC-SIGN is expressed on DC present in mucosal tissue that do not express CCR5. Immunohistochemical analysis of DC-SIGN expression on mucosal tissue sections. Figure 6A-6C show different tissue sections that were stained with anti-DC-SIGN mAb: cervix (Fig. 6A) rectum (Fig. 6B) and uterus (Fig. 6C) (original magnification: 200x). All mucosal tissues contain DC-SIGN positive

30 cells in the lamina propria. Staining of serial sections demonstrate that these DC-SIGN positive cells do not express CD3, CD20, CD14 and CD68. Figure 6D-6I

show the immunohistochemical staining of serial sections of rectum (Fig. 6D-6F) and uterus (Fig. 6G-6I) with antibodies against DC-SIGN (Fig. 6A and 6D), CD4 (Fig. 6B and 6E) or CCR5 (Fig. 6C and 6F).

5 Figures 7A-7C show that DC-SIGN captures HIV-1 and retains long-term infectivity. Figure 7A shows the time course of HIV-1<sub>MN</sub> gp120 binding to THP-DC-SIGN. DC-SIGN positive cells were incubated with gp120 coated beads. Beads bound for more than 60 hrs as determined by FACS analysis. Figure 7B shows that DC-SIGN binds HIV-1 and retains for more than four days virus that infects T cells *in* 10 *trans*. THP/THP-SIGN cells were pulsed for 4 hours with HIV-1 pseudotyped virus in the presence or absence of anti-DC-SIGN antibodies (AZN-D1 and AZN-D2, 20  $\mu$ g/ml). After washing the HIV-1 pulsed cells were cultured at 37°C for several days. As a control identical amounts of virus were incubated at 37°C in medium without 15 cells. Every day aliquots of the HIV-1 pulsed cells were added to HIV-1 permissive 293T-CD4-CCR5 cells in order to measure infectivity. Lysates to examine luciferase activity were obtained after 2 days of co-culture. Figure 7C depicts a model of HIV-1 co-opting DC-SIGN as a *trans*-receptor after initial exposure. DC are the primary cells targeted by HIV-1 during mucosal exposure and are DC-SIGN-positive. HIV-1 adheres to DC-SIGN via a high affinity interaction, and the immature DC carrying 20 HIV-1 migrates to the lymphoid tissues. Upon arrival, DC will cluster with T cells and DC-SIGN enhances HIV-1 infection of T cells *in trans* leading to a productive and sustained infection.

Figure 8 shows that DC-SIGN mediates capture of SIV and R5, X4, and dual tropic 25 HIV. Viruses encoding the reporter gene luciferase were pseudotyped with envelopes from the CCR5 tropic strains JRFL, ADA, and JRCSF; the CXR4 tropic strains HxB2 and LAI; the dual tropic strain 89.6; and SIV 1A11. THP or THP-DCSIGN cells were pulsed with these viruses, washed, and then added to target cells. Luciferase activity 30 was measured as an indicator of viral infection of targets.

Figure 9 shows that DC-SIGN mediates capture of HIV pseudotyped with envelopes from primary viral strains. (See Figure 8 for assay conditions; the same assay was performed except different viruses were examined)

- 5 Figure 10 shows the enhancement of CXR4 tropic HIV infection of activated T cells. THP, THP-DCSIGN cells, DC (dendritic cells), or DC preincubated with anti DCSIGN antibody, were incubated with HxB2 pseudotyped virus encoding the luciferase reporter gene, followed by addition of activated T cell targets.
- 10 Figure 11 shows the enhancement of CXR4 tropic HIV infection of unactivated T cells. (See Figure 10 for assay conditions; the same assay was performed except unactivated T cells were examined).

Figure 12 shows that binding to DC-SIGN extends the longevity of HxB2. THP or THP-DCSIGN cells were pulsed with HxB2, washed, and then added to target cells at different time points as indicated following the viral pulse. "HxB2 capture virus" refers to virus in medium alone.

Figures 13A-13B show the protease protection of HIV pseudotyped particles. Figure 20 13A shows the results of THP DC-SIGN cells that were incubated on ice with pseudotyped nonreplication competent HIV JRFL particles containing the luciferase reporter gene. Cells were then washed twice and half the cells were shifted to 37°C for 20 minutes to allow internalization, while the remaining half were maintained on ice. The cells were then returned to ice and incubated with pseudotyped HIV JRFL encoding the reporter GFP. After washing, the cells were either treated with trypsin or mock treated and then incubated with 293T.CD4.CCR5 target cells. Infection by both HIV luciferase and HIV GFP particles was determined 48 hours post infection. Figure 25 13B is the same as Figure 13A except the HIV particles were bound to human blood-derived DC.

Figures 14A-14B show the internalization of HIV gp120-FITC by DC-SIGN. THP cells expressing DC-SIGN were stained on ice with HIV gp120 directly conjugated to FITC. Stained cells were then shifted to 37°C and aliquots were taken at the indicated times. For each time point, cells were treated with trypsin or mock treated. Cells 5 were then stained for surface expression of DC-SIGN to verify the effectiveness of protease treatment. Figure 14A is the FACS analysis of stained THP DC-SIGN cells. Figure 14B shows a plot of the fraction of HIV gp120-FITC protected from trypsin treatment over time. HIV gp120-FITC bound to THP DC-SIGN cells that were fixed 10 with paraformaldehyde prior to staining did not show protection from trypsin treatment.

Figures 15A-15B is a bar graph depicting the recycling of transferrin and HIV by THP DC-SIGN cells. In Figure 15A THP DC-SIGN cells were incubated with transferrin on ice, washed, and then shifted to 37°C for 1 hour. Cells were then acid-stripped of 15 any remaining surface transferrin and placed in medium. At the times indicated, aliquots of the supernatant were taken and assayed for released transferrin by ELISA. After 5 hours, the amount of transferrin remaining associated with cells was assayed by pelleting the cells, lysing, and measuring transferrin by ELISA. In Figure 15B THP DC-SIGN cells were incubated with HIV particles on ice and treated in the same way 20 as in the transferrin experiment. Released HIV was measured using a p24 ELISA.

Figures 16A-16B show the internalization of HIV particles imaged by fluorescent confocal microscopy. HIV MN particles were bound to THP DC-SIGN cells on ice and free virus was washed away. Bound particles were detected using a polyclonal 25 human serum against HIV followed by an anti-human secondary antibody conjugated to Cy3. In Figure 16A cells were assayed immediately after staining or following a 4 hour incubation at 37°C. In Figure 16B HIV was allowed to internalize for 1 hour at 37°C. Cells were then fixed, permeabilized, and stained with a FITC conjugated antibody against human LAMP-1, a lysosomal marker.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides the properties of a dendritic cell-specific C-type lectin, DC-SIGN, that is highly expressed on dendritic cells (DC) present in mucosal tissues

5 and binds to the HIV-1 envelope glycoprotein gp120. DC-SIGN does not function as a receptor for viral entry into DC, but instead promotes efficient infection in *trans* of cells that express CD4 and chemokine receptors. Indeed, DC-SIGN, which is highly expressed on DC present at mucosal sites, specifically captures HIV-1 and promotes infection in *trans* of target cells that express CD4 and an appropriate chemokine

10 receptor(s). These findings demonstrate that during transmission of HIV-1, the virus initially binds to mucosal DC by way of DC-SIGN, allowing subsequent transport to secondary lymphoid organs and highly efficient infection of CD4<sup>+</sup> T cells by a novel *trans* infection mechanism.

15 These results predict a model in which DC-SIGN efficiently captures HIV-1 in the periphery, facilitates its transport to sites in secondary lymphoid organs rich in T cells, and enhances infection in *trans* of these target cells. These studies indicate that the interaction between DC-SIGN and gp120 is an important target for therapeutic intervention and vaccine development.

20

The present invention therefore provides a greater understanding of the mechanism through which HIV and SIV gain entrance into target cells. It has been known that the virus binds to CD4 with the aid of a chemokine receptor (such as CCR5 or CXCR4) and that cyclin T is involved. Now, with the present disclosure it is possible to

25 describe the biochemical events involved from the initial contact of the virus with the peripheral mucosal tissues through to the initiation of fusion between the viral envelope and the cellular plasma membrane. This, in turn, allows the construction of drug screening assays to identify compounds that can interfere with these processes and thereby prevent or treat AIDS. These findings also now allow the development of

30 small animal models for HIV infection, thus providing a better understanding of the pathogenesis of AIDS as well as a system for testing potential therapies. Indeed, such

animal models, which heretofore have not been available, allow testing of drugs in an animal system prior to human trials.

The inhibition of HIV-1 infection observed in the presence of anti-DC-SIGN  
5 antibodies indicates that interfering with the gp120-DC-SIGN interaction either during  
the capture phase of DC in the mucosa or during DC-T cell interactions in lymphoid  
organs could inhibit dissemination of the virus. Small molecule inhibitors, potentially  
carbohydrate-based, that block the ability of gp120 to bind to DC-SIGN may be  
effective in prophylaxis or therapeutic intervention. Vaccine strategies aimed at  
10 eliciting mucosal antibodies that inhibit gp120 binding to DC-SIGN may also be  
efficacious in preventing early establishment of infection. The efficacy of gp120  
vaccines has been measured as a function of the levels of neutralizing antibodies that  
inhibit HIV entry through CD4 and CCR5. The present results indicate that levels of  
antibodies that block virus binding to DC-SIGN or the DC-SIGN-mediated  
15 enhancement of infection could also be predictive of protection.

Furthermore, based on the data disclosed in Example 2, it appears that HIV interaction  
with DC-SIGN results in the uptake of HIV into a specialized endosomal  
compartment, where the virus can be protected from enzymatic inactivation. In  
20 addition, the viral envelope glycoprotein appears to undergo a conformational change  
in this recycling endosomal compartment, that enhances the fusogenic activity of HIV.  
This may be a consequence of an irreversible pH-induced conformational change, for  
which there are precedents in influenza and avian leukosis virus; or of interactions  
with other molecules within the recycling endosomes. These results could also  
25 explain why HIV exposed to DC-SIGN-expressing cells is more infectious than the  
HIV exposed to control cells. Because dendritic cells (and THP cells) cannot be  
readily infected by way of CD4 plus chemokine receptor, the enhanced fusogenic  
activity of the virus would be demonstrated in trans (on target T cells), after it is  
recycled to the surface of the DC-SIGN-expressing dendritic cell.

Therefore, the present invention provides compounds that interfere with internalization of HIV after binding to DC-SIGN (DCS) on dendritic cells and other cells. Compounds that inhibit of this internalization process reduce the ability of virus to survive the host environment, and thereby can act as a prophylactic against HIV infection and are included in the present invention.

5 Various terms are used in the specification, which are defined as follows:

The term "translocation promoting agent" is used herein interchangeably with the  
10 terms "translocating promoter", "translocating promoting agent" and "translocating  
promoting protein", and refer to receptor proteins found on, or in membranes of CD4+  
cells that interact with and/or in conjunction in "cis" with CD4 (the human protein  
having the amino acid sequence of SEQ ID NO:3) in HIV and/or SIV translocation  
into the cell. Two translocation promoting agents exemplified in the present invention  
15 are CXCR4 (the human protein having the amino acid sequence of SEQ ID NO:4) and  
CCR5 (the human protein having the amino acid sequence of SEQ ID NO:5). There  
are at least six "known" members of the chemokine receptor family that have been  
shown to function in HIV-1 entry in cis with CD4 (i.e., known human translocation  
promoting agents) CCR5, CXCR4, CCR2b, CCR3, Bonzo (SEQ ID NO:9) and BOB  
20 (SEQ ID NO:10).

As used herein the term "conformer" is used interchangeably with the term  
"conformer of HIV envelope glycoprotein" and is a HIV glycoprotein (e.g., gp120-  
gp41) that has assumed a novel conformation and/or related characteristic (e.g.,  
25 charge) due to direct interaction with DC-SIGN, and/or as a consequence of being  
endocytosed into an endosome, and/or as a consequence of being placed into an  
environment that mimics the effect of an endosome on the HIV glycoprotein.

As used herein a factor that acts with a second factor to aid in the entry of HIV into a  
30 cell is said to act in "cis" when the factor is in the same membrane as the other factor,  
whereas a factor that acts with a second factor to aid in the entry of HIV into a cell is

said to act in "trans" when the factor is in a different membrane than the other factor. Thus CD4 and CCR5 are both present in the T cell membrane and act in "cis", whereas DC-SIGN is present in the dendritic cell membrane and therefore acts in "trans" relative to either CD4 or CCR5.

5

As used herein, and unless otherwise specified, the terms "agent", "potential drug", "compound", "test compound" or "potential compound" are used interchangeably, and refer to chemicals which potentially have a use as an inhibitor of HIV infection and/or for use in a treatment/prevention of AIDS. Therefore, such "agents", "potential drugs", "compounds" and "potential compounds" may be used, as described herein, in drug assays and drug screens and the like.

As used herein a "small organic molecule" is an organic compound, including a peptide [or organic compound complexed with an inorganic compound (e.g., metal)] that has a molecular weight of less than 3 Kilodaltons. Such small organic molecules can be included as agents, etc. as defined above.

A molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. An antigenic polypeptide contains at least about 5, and preferably at least about 10, amino acids. An antigenic portion of a molecule can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization. A molecule that is antigenic need not be itself immunogenic, *i.e.*, capable of eliciting an immune response without a carrier.

A composition comprising "A" (where "A" is a single protein, DNA molecule, vector, recombinant host cell, etc.) is substantially free of "B" (where "B" comprises one or more contaminating proteins, DNA molecules, vectors, etc.) when at least about 75% by weight of the proteins, DNA, vectors (depending on the category of species to

which A and B belong) in the composition is "A". Preferably, "A" comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by weight. It is also preferred that a composition, which is substantially free of contamination, contain only a single molecular weight species having the 5 activity or characteristic of the species of interest.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, 10 when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is 15 administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical 20 carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically 25 significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.

In a specific embodiment, the term "about" means within 20%, preferably within 10%, 30 and more preferably within 5%.

Nucleic Acids and Proteins

The present invention contemplates the use of the nucleic acids encoding DC-SIGN (e.g., encoding the human protein having the amino acid sequence of SEQ ID NO:2) and encoding fragments thereof including chimeric/fusion proteins. In a preferred 5 embodiment the nucleic acid encodes a soluble form/portion of DC-SIGN. Similarly, the present invention also contemplates the use of the nucleic acids encoding the translocating promoters, cyclin T (e.g., encoding the human protein having the amino acid sequence of SEQ ID NO:6) and CD4. These nucleic acids can be used for example, to make transgenic animals that contain the human homologs of such 10 proteins, thereby making a transgenic animal susceptible to HIV infection. The use of the proteins, fragments thereof including chimeric/fusion proteins are also part of the present invention.

In accordance with the present invention there may be employed conventional 15 molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II 20 (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel et al. (eds.), *Current 25 Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

Therefore, if appearing herein, the following terms shall have the definitions set out below.

30 A "vector" is a replicon, such as plasmid, phage, virus, or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached

segment. A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*, i.e., capable of replication under its own control.

5 A cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change.

Preferably, the transforming DNA should be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.

10

"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.

15 A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded

20 helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and

25 chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological

30 manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al., *supra*).

- 5 The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a  $T_m$  of 55°, can be used, *e.g.*, 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5x SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher  $T_m$ ,
- 10 *e.g.*, 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond to the highest  $T_m$ , *e.g.*, 50% formamide, 5x or 6x SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the
- 15 length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of  $T_m$  for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher  $T_m$ ) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.
- 20 For hybrids of greater than 100 nucleotides in length, equations for calculating  $T_m$  have been derived (see Sambrook et al., *supra*, 9.50-10.51). For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*, 11.7-11.8). Preferably a minimum length for a hybridizable
- 25 nucleic acid is at least about 18 nucleotides; preferably at least about 36 nucleotides; and more preferably the length is at least about 48 nucleotides. Such nucleic acids can be used as primers or nucleic acid probes for the nucleic acids encoding the translocation promoting agents of the present invention.
- 30 In a specific embodiment, the term "standard hybridization conditions" refers to a  $T_m$  of 55°C, and utilizes conditions as set forth above. In a preferred embodiment, the  $T_m$

is 60°C; in a more preferred embodiment, the T<sub>m</sub> is 65°C.

"Homologous recombination" as used herein refers to one method of inserting a foreign DNA sequence of a vector into chromosome. The vector targets a specific 5 chromosomal site for homologous recombination. For specific homologous recombination, the vector will contain sufficiently long regions of homology to sequences of the chromosome to allow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.

10

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop 15 codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding 20 sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are 25 control sequences.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is 30 bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate

transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

5

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

10

A "signal sequence" is included at the beginning of the coding sequence of a protein to be secreted or expressed on the surface of a cell. This sequence encodes a signal peptide, N-terminal to the mature polypeptide, that directs the host cell to translocate the polypeptide. The term "translocation signal sequence" is used herein to refer to 15 this sort of signal sequence. Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes, and are often functional in both types of organisms.

As used herein, the term "sequence homology" in all its grammatical forms refers to 20 the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck et al., 1987, Cell 50:667).

25 A "heterologous nucleotide sequence" as used herein is a nucleotide sequence that is added to the nucleotide sequence of a nucleic acid of the present invention by recombinant methods to form a nucleic acid which is not naturally formed in nature. Such nucleic acids can encode fusion (e.g. chimeric) proteins. Thus the heterologous nucleotide sequence can encode peptides and/or proteins which contain regulatory 30 and/or structural properties. In another such embodiment the heterologous nucleotide sequence can encode a protein or peptide that functions as a means of detecting the

protein or peptide encoded by the nucleotide sequence of the present invention after the recombinant nucleic acid is expressed. In still another embodiment the heterologous nucleotide sequence can function as a means of detecting a nucleotide sequence of the present invention. A heterologous nucleotide sequence can comprise 5 non-coding sequences including restriction sites, regulatory sites, promoters and the like.

As used herein the terms "fusion protein" and "fusion peptide" are used interchangeably and encompass "chimeric proteins and/or chimeric peptides" and 10 fusion "intein proteins/peptides". A fusion protein comprises at least a portion of a particular protein of the present invention such as DC-SIGN joined *via* a peptide bond to at least a portion of another protein or peptide in a chimeric fusion protein. In a particular embodiment the portion of the DC-SIGN is antigenic. For example, fusion proteins can comprise a marker protein or peptide, or a protein or peptide that aids in 15 the isolation and/or purification of DC-SIGN.

In a specific embodiment, two DNA sequences are "substantially homologous" or "substantially similar" when at least 50% (preferably at least 75%, and most preferably at least 90 to 95%) of the nucleotides match over the defined length of the DNA 20 coding sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See *e.g.*, Maniatis *et al.*, *supra*; DNA Cloning, Vols. I & II, 25 *supra*; Nucleic Acid Hybridization, *supra*.

Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 75% of the amino acids are identical, or preferably greater than about 90% are identical. Preferably, the similar or 30 homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, *Version 7*,

Madison, Wisconsin) pileup program using the default parameters.

The term "corresponding to" is used herein to refer similar or homologous sequences, more preferably substantially similar or substantially homologous sequences, whether

5 the exact position is identical or different from the molecule to which the similarity or homology is measured. The term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.

Expression of Nucleic Acids/Recombinant Proteins

10 A nucleic acid encoding DC-SIGN, or a translocation promoting agent, or CD4, or cyclin T, or antigenic fragment, derivative or analog thereof, including a chimeric protein, thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such elements include a "promoter." Such a

15 nucleic acid can be operationally associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can be cloned and expressed under control of such regulatory sequences. An expression vector also preferably includes a replication origin.

20 The necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by the native gene encoding the protein and/or its flanking regions.

25 The present invention also relates to nucleic acids encoding analogs and derivatives of the DC-SIGN. The production and use of derivatives and analogs are within the scope of the present invention. In a specific embodiment, the derivative or analog is a soluble fragment of DC-SIGN that is capable of inhibiting the HIV gp120-DC-SIGN interaction.

30 Derivatives of DC-SIGN can be made by altering nucleic acids encoding DC-SIGN by substitutions, additions or deletions that provide for functionally modified molecules.

Preferably, derivatives are made that interfere with HIV infection. Such derivatives may encode soluble fragments of the extracellular domain of DC-SIGN that retain an affinity for an HIV or SIV envelope protein. Such soluble derivatives may be potent inhibitors of HIV or SIV binding.

5

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as DC-SIGN may be used in the practice of the present invention. These include but are not limited to allelic genes, homologous genes from other species, and nucleotide sequences comprising all or 10 portions of DC-SIGN which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Likewise, DC-SIGN derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of DC-SIGN including altered sequences in which functionally equivalent 15 amino acid residues are substituted for residues within the sequence resulting in one or more conservative amino acid substitutions. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration.

Substitutes for an amino acid within the sequence may be selected from other 20 members of the class to which the amino acid belongs. Such substitutions are defined herein as conservative substitutions. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, 25 threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- 5 - Gln for Asn such that a free NH<sub>2</sub> can be maintained.

Nucleic acids encoding DC-SIGN derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned DC-10 SIGN sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, *supra*). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the nucleic acid encoding a derivative or analog of DC-SIGN care should be taken to ensure that the modified 15 nucleic acid remains within the same translational reading frame uninterrupted by translational stop signals, in the region where the desired activity is encoded.

Additionally, a nucleic acid encoding DC-SIGN can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create 20 variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Preferably, such mutations diminish the ability of dendritic cells to transport HIV. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis [Hutchinson, et al., *J. Biol. Chem.* 253:6551 (1978); Zoller and 25 Smith, *DNA* 3:479-488 (1984); Oliphant et al., *Gene* 44:177 (1986); Hutchinson et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:710 (1986)], use of TAB® linkers (Pharmacia), etc. PCR techniques are preferred for site-directed mutagenesis [*see* Higuchi, "Using 30 PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70 (1989)]. The identified and isolated nucleic acid can then be inserted into an appropriate cloning vector. Any of a large number of vector-host systems known in the art may be used.

Potential chimeric partners for DC-SIGN can include other transmembrane domains, or a domain for modification with a phospholipid anchor. Indeed, all of the proteins/fragments of the present invention can be modified by being placed in a fusion or chimeric peptide or protein, or labeled *e.g.*, to have an N-terminal FLAG-  
5 tag, or H6 tag. In a particular embodiment DC-SIGN can be modified to contain a marker protein such as green fluorescent protein as described in U.S. Patent No. 5,625,048 filed April 29, 1997 and WO 97/26333, published July 24, 1997 each of which are hereby incorporated by reference herein in their entireties.

10 Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities.  
15 Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

A recombinant protein of the present invention, or fragment, derivative, chimeric construct, or analog thereof, may be expressed chromosomally, after integration of the 20 coding sequence by recombination. In this regard, any of a number of amplification systems may be used to achieve high levels of stable gene expression (*See* Sambrook et al., 1989, *supra*).

The cell into which the recombinant vector comprising the nucleic acid is cultured in 25 an appropriate cell culture medium under conditions that provide for expression of the protein by the cell. Any of a number of methods may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombination (genetic 30 recombination).

Expression of a nucleic acid of the present invention may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. In one embodiment a translocation promoting agent is under the control of the CD4 enhancer/promoter/silencer, as 5 described [Killeen *et al.* *EMBO* 12:1547-1553 (1993)].

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and 10 processes the gene product in the specific fashion desired. Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification of proteins, *e.g.*, glycosylation, or cleavage of a signal sequence for example. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For 15 example, expression in a bacterial system can be used to produce an nonglycosylated core protein product. However, DC-SIGN expressed in bacteria may not be properly folded. Expression in yeast can produce a glycosylated product. Expression in eukaryotic cells can increase the likelihood of "native" glycosylation and folding of a heterologous protein. Moreover, expression in mammalian cells can provide a tool for 20 reconstituting, or constituting, translocation promoting activity. Furthermore, different vector/host expression systems may affect processing reactions, such as proteolytic cleavages, to a different extent.

Vectors are introduced into the desired host cells by methods known in the art, *e.g.*, 25 transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter [see, *e.g.*, Wu *et al.*, *J. Biol. Chem.* 267:963-967 (1992); Wu and Wu, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990].

30

DC-SIGN expressed as an integral membrane protein can be isolated and purified by

standard methods. Generally, the integral membrane protein can be obtained by lysing the membrane with detergents, such as but not limited to, sodium dodecyl sulfate (SDS), Triton X-100, nonidet P-40 (NP-40), digoxin, sodium deoxycholate, and the like, including mixtures thereof. Solubilization can be enhanced by sonication of the

5 suspension. Soluble forms of the protein can be obtained by collecting culture fluid, or solubilizing inclusion bodies, *e.g.*, by treatment with detergent, and if desired sonication or other mechanical processes, as described above. The solubilized or soluble protein can be isolated using various techniques, such as polyacrylamide gel electrophoresis (PAGE), isoelectric focusing, 2-dimensional gel electrophoresis,

10 chromatography (*e.g.*, ion exchange, affinity, immunoaffinity, and sizing column chromatography), centrifugation, differential solubility, immunoprecipitation, or by any other standard technique for the purification of proteins. Soluble forms of the gp120 binding portion of DC-SIGN can also be obtained through proteolysis and/or expression of the extracellular domain minus the transmembrane domains.

15

A consequence of the present results is that mutations in DC-SIGN could result in either loss of binding of gp120 or in loss of a conformational change in envelope glycoprotein after binding (such that fusogenic activity of gp120 would be compromised) would protect an individual from transmission of infection or from

20 progression to disease. Therefore, the present invention provides a test for polymorphisms in the DC-SIGN gene to predict an individual's predisposition to infection and disease progression. The polymorphisms that are protective are also part of the present invention (see PCT/US97/13946, Landau *et al.*, where such a CCR5 variant was identified)

25

Therefore, the present invention includes mutations in the DC-SIGN gene that protect individuals from HIV infection as well as the means of detecting these variants. Methods of screening for such mutations can be performed either by genetic approaches or by cellular approaches. One genetic approach uses PCR-based analysis

30 to amplify a segment of the DC-SIGN gene. The amplified nucleic acid can then be sequenced or analyzed using gel mobility (which can detect single strand

conformational polymorphisms). The results obtained are then compared to the same segment from a wild-type gene. Amplification of any of the 7 coding exons and the flanking intron/exon borders, of the 5' non-coding and 3' non-coding exons of the gene encoding DC-SIGN and/or of the promoter will identify such mutant alleles.

5

Alternatively, a cellular approach is to obtain peripheral blood mononuclear cells from individuals. These cells are then cultured for 2-6 days in GM-CSF and IL-4 so as to differentiate into immature dendritic cells. The dendritic cells can then be (i) stained with anti-DC-SIGN antibody; (ii) stained with a combination of soluble gp120 and 10 labeled anti-gp120 antibody or soluble CD4; and/or (iii) applied to the capture/enhancement assays described herein with reporter virus and target cells. In the first case, (i) cells that lack DC-SIGN will not stain with a detectable anti-DC-SIGN antibody, whereas, cells either lacking DC-SIGN or encoding a mutant DC-SIGN can be identified for lack of binding to gp120 (ii) or inability to capture/enhance 15 HIV infectivity (iii).

#### Antibodies to Proteins of the Present invention

According to the invention, DC-SIGN, or a translocation promoting agent, or CD4, or cyclin T produced recombinantly or by chemical synthesis, and fragments or other 20 derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize the protein or a particular epitope of the protein. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. The antibodies of the invention may be cross reactive, e.g., they may recognize antigens from 25 different species. Polyclonal antibodies have greater likelihood of cross reactivity. Alternatively, an antibody of the invention may be specific for a single form of a protein, such as the being specific for human DC-SIGN, or an epitope thereof.

In a particular embodiment, the site on gp120 that binds to DC-SIGN can be used as 30 the basis for an immunogen to elicit antibodies that prevent binding to DC-SIGN. A vaccine that elicits mucosal antibody responses as well as generalized humoral

responses against gp120 can prevent binding of HIV to DC-SIGN and, therefore, limit infection of T-cells. Antibodies that prevent HIV binding to DC-SIGN or DC-SIGN-mediated enhancement of target cell infection are therefore part of the invention. Such antibodies would preferably inhibit across viral clades and inhibit broadly within viral 5 clades. These antibodies are in contrast to antibodies that are neutralizing (*i.e.*, inhibit infection of target cells with high concentrations of HIV) and which have not been shown to be broadly neutralizing in humans. Vaccine vectors that preferentially elicit mucosal antibody responses (*e.g.*, recombinant salmonella vectors) would constitute one approach, particularly if the site on gp120 required for binding to DC-SIGN does 10 not require glycosylation.

One particular approach is to deliver fragments of gp120 that contain the DC-SIGN binding site to mucosal surfaces in appropriate adjuvants. In addition, a DC-SIGN altered form of envelope protein can be used as a candidate vaccine for eliciting 15 humoral responses (*i.e.*, a novel form of a fusion-competent envelope vaccine). Thus, the present invention provides a complex of DC-SIGN with monomeric gp120 or gp140 oligomers as an immunogen to elicit broadly-neutralizing antibodies that will bind to DC-SIGN-induced epitopes on the envelope glycoprotein and thus block the trans-enhancement of infection. Antibodies raised by such means are more likely to 20 inhibit DC-SIGN-enhanced infection of target cells than DC-SIGN-independent infection.

DC-SIGN can also be used as an immunogen to elicit anti-DC-SIGN antibodies that block binding of HIV. A soluble form of DC-SIGN, which has been modified to 25 prevent its ability to enhance viral entry (due to loss of binding to gp120 or to loss of trans-enhancement function after binding to gp120), can be used as the immunogen.

In a specific embodiment, an antibody of the invention is specific for a masked 30 epitope on gp120 that is exposed on binding to DC-SIGN. In another embodiment, an antibody of the invention is specific for an epitope created by the binding of DC-SIGN and HIV to a translocation promoting agent and/or CD4. For example, the binding of

HIV envelope protein to CD4 induces a conformational change in gp120 or gp130, which results in an increased affinity of gp120 or gp130 for the translocating promoter, and possibly a concomitant unmasking of a translocating promoter epitope. Similarly, the binding of DC-SIGN to gp120 or gp130 also has the same effect. Such 5 antibodies can be selected on the basis of binding under conditions of HIV or SIV binding to DC-SIGN, *e.g.*, at 4°C to inhibit binding, and screened for non-binding to free DC-SIGN.

Various procedures known in the art may be used for the production of polyclonal 10 antibodies to DC-SIGN for example, or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with DC-SIGN for example, or a derivative (*e.g.*, fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, DC-SIGN or fragment thereof can be conjugated to an immunogenic carrier, *e.g.*, bovine serum 15 albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and 20 potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward DC-SIGN for example, or 25 fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein [*Nature* 256:495-497 (1975)], as well as the trioma technique, the human B-cell hybridoma technique [Kozbor et al.; *Immunology Today* 4:72 (1983); Cote et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030 (1983)], and the EBV-hybridoma 30 technique to produce human monoclonal antibodies [Cole et al., in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)]. In an

additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing technology described in [PCT/US90/02545]. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" [Morrison et al., *J. Bacteriol.* 159:870 (1984); Neuberger et al., *Nature* 312:604-608 (1984); Takeda et al., *Nature* 314:452-454 (1985)] by splicing the genes from a mouse antibody molecule specific for DC-SIGN, for example, together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.

According to the invention, techniques described for the production of single chain antibodies [U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778] can be adapted to produce DC-SIGN-specific single chain antibodies for example. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries [Huse et al., *Science* 246:1275-1281 (1989)] to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for a translocation promoting protein, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the  $F(ab')_2$  fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

30 In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA

(enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel 5 agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further 10 embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of DC-SIGN, for example, one may assay generated hybridomas for a product which binds to a translocation promoting agent fragment containing such epitope. For 15 selection of an antibody specific to a DC-SIGN from a particular species of animal, one can select on the basis of positive binding with DC-SIGN expressed by or isolated from cells of that species of animal.

The foregoing antibodies can be used in methods known in the art relating to the 20 localization and activity of DC-SIGN, e.g., for Western blotting, imaging DC-SIGN *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques mentioned above or known in the art.

Suitable labels for antibodies (as well as for the other proteins, peptides and nucleic 25 acids of the present invention) include enzymes, fluorophores (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, free or chelated lanthanide series salts, especially Eu<sup>3+</sup> green fluorescent protein, to name a few fluorophores), chromophores, radioisotopes, chelating agents, dyes, colloidal gold, latex particles, ligands (e.g., biotin), and chemiluminescent agents. When a 30 control marker is employed, the same or different labels may be used for the receptor and control marker. In the instance where a radioactive label, such as the isotopes <sup>3</sup>H,

<sup>14</sup>C, <sup>32</sup>P, <sup>35</sup>S, <sup>59</sup>Fe, <sup>90</sup>Y, <sup>125</sup>I, <sup>131</sup>I, and <sup>186</sup>Re are used, known currently available counting procedures may be utilized. In the instance where the label is a protein, *e.g.*, an enzyme or fluorescent protein, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or 5 gasometric techniques known in the art.

Direct labels are one example of labels which can be used according to the present invention. A direct label has been defined as an entity, which in its natural state, is readily visible, either to the naked eye, or with the aid of an optical filter and/or 10 applied stimulation, *e.g.*, U.V. light to promote fluorescence. Among examples of colored labels, which can be used according to the present invention, include metallic sol particles, for example, gold sol particles such as those described by Leuvering (U.S. Patent 4,313,734); dye sole particles such as described by Gribnau *et al.* (U.S. Patent 4,373,932) and May *et al.* (WO 88/08534); dyed latex such as described by 15 May, *supra*, Snyder (EP-A 0 280 559 and 0 281 327); or dyes encapsulated in liposomes as described by Campbell *et al.* (U.S. Patent 4,703,017). Other direct labels include a radionucleotide, a fluorescent moiety or a luminescent moiety including proteins comprising such moieties such as green fluorescent protein. In addition to these direct labeling devices, indirect labels comprising enzymes can also be used 20 according to the present invention.

Various types of enzyme linked immunoassays are well known in the art, for example, alkaline phosphatase and horseradish peroxidase, lysozyme, glucose-6-phosphate dehydrogenase, lactate dehydrogenase, urease, these and others have been discussed in 25 detail by Eva Engvall in Enzyme Immunoassay ELISA and EMIT in *Methods in Enzymology*, 70:419-439, (1980) and in U.S. Patent 4,857,453. Suitable enzymes include, but are not limited to, alkaline phosphatase and horseradish peroxidase.

Other labels for use in the invention include magnetic beads or magnetic resonance 30 imaging labels.

In another embodiment, a phosphorylation site can be created on an antibody of the invention for labeling with  $^{32}\text{P}$ , *e.g.*, as described in European Patent No. 0372707 (Application No. 89311108.8) by Sidney Pestka, or U.S. Patent No. 5,459,240, issued October 17, 1995 to Foxwell et al.

5

Proteins, including antibodies, can be labeled by metabolic labeling. Metabolic labeling occurs during *in vitro* incubation of the cells that express the protein in the presence of culture medium supplemented with a metabolic label, such as  $[^{35}\text{S}]$ -methionine or  $[^{32}\text{P}]$ -orthophosphate. In addition to metabolic (or biosynthetic)

10 labeling with  $[^{35}\text{S}]$ -methionine, the invention further contemplates labeling with  $[^{14}\text{C}]$ -amino acids and  $[^3\text{H}]$ -amino acids (with the tritium substituted at non-labile positions).

In a specific embodiment, antibodies that agonize or antagonize the activity of DC-SIGN can be generated. Such antibodies, when conjugated with a toxin or radioactive element, can be used to target HIV-facilitative cells for destruction. Thus, cells harboring HIV, particularly in its dormant phase, can be destroyed with antibodies, *e.g.*, conjugated to a toxin such as ricin or a radioisotope such as  $^{32}\text{P}$  or  $^{125}\text{I}$ , when such antibodies are specific for the DC-SIGN-HIV gp120 complex.

20

#### Vaccination and Passive Immune Therapy

Active immunity against a virus such as HIV can be induced by immunization (vaccination) with an adjuvant and a protein of the present invention, and/or protein complex of the present invention, and/or antigenic fragment thereof, and/or derivative thereof. For example, either an immunogenic amount of a portion of gp120 that is required for binding DC-SIGN or an immunogenic amount of a portion of gp120 that is exposed upon gp120 binding of DC-SIGN due to the concomitant conformational change (herein referred to collectively as particular gp120 epitopes) can serve as the antigenic component of the vaccine.

30

For example, the particular gp120 epitope alone or conjugated to a capsule or capsules

cannot cause AIDS, and the active immunity elicited by vaccination with the particular gp120 epitope according to the present invention can result in both an immediate immune response and in immunological memory, and thus provide long-term protection against infection by HIV, particularly when the particular gp120 epitope is a conserved region of gp120. The particular gp120 epitope, or derivatives thereof, can be prepared in an admixture with an adjuvant to prepare a vaccine. Preferably, the particular gp120 epitope or derivative or fragment thereof, used as the antigenic component of the vaccine is an antigen common to all or many strains of HIV. The antigenic component of the vaccine is therefore preferably a common 10 antigen.

Selection of an adjuvant depends on the subject to be vaccinated. Preferably, a pharmaceutically acceptable adjuvant is used. For example, a vaccine for humans should avoid oil or hydrocarbon emulsion adjuvants, including complete and 15 incomplete Freund's adjuvant. One example of an adjuvant suitable for use with humans is alum (alumina gel). A vaccine for an animal, however, may contain adjuvants not appropriate for use with humans.

An alternative to a traditional vaccine comprising an antigen and an adjuvant involves 20 the direct *in vivo* introduction of DNA encoding the antigen into tissues of a subject for expression of the antigen by the cells of the subject's tissue. Such vaccines are termed herein "nucleic acid-based vaccines." The expression vector can be engineered to contain an autologous signal sequence. For example, a naked DNA vector (see, e.g., Ulmer et al., 1993, *Science* 259:1745-1749), a DNA vector transporter (e.g., Wu 25 et al., 1992, *J. Biol. Chem.* 267:963-967; Wu and Wu, 1988, *J. Biol. Chem.* 263:14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990), or a viral vector containing a nucleic acid encoding a particular gp120 epitope can be injected into tissue. Suitable viral vectors include retroviruses that are packaged in cells with amphotropic host range (see Miller, 1990, *Human Gene 30 Ther.* 1:5-14; Ausubel et al., *Current Protocols in Molecular Biology*, § 9), and attenuated or defective DNA virus, such as but not limited to herpes simplex virus

(HSV) (see, e.g., Kaplitt et al., 1991, *Molec. Cell. Neurosci.* 2:320-330), papillomavirus, Epstein Barr virus (EBV), adenovirus (see, e.g., Stratford-Perricaudet et al., 1992, *J. Clin. Invest.* 90:626-630), adeno-associated virus (AAV) (see, e.g., Samulski et al., 1987, *J. Virol.* 61:3096-3101; Samulski et al., 1989, *J. Virol.* 63:3822-3828), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not infective after introduction into a cell.

Vectors containing the nucleic acid-based vaccine of the invention can be introduced into the desired host by methods known in the art, e.g., transfection, electroporation, 10 microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter [see, e.g., Wu et al., *J. Biol. Chem.* 267:963-967 (1992); Wu and Wu, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990)].

15 Any vaccine of the invention, e.g., a vaccine comprising a particular gp120 epitope antigen or antigenic derivative or fragment thereof, or the corresponding nucleic acid vaccine, can be administered via any parenteral route, including but not limited to intramuscular, intraperitoneal, intravenous, and the like. Preferably, since the desired 20 result of vaccination is to elucidate an immune response to the antigen, and thereby to the pathogenic organism, administration directly, or by targeting or choice of a viral vector, indirectly, to lymphoid tissues, e.g., lymph nodes or spleen.

Passive immunity can be conferred to an animal subject suspected of suffering from, 25 or particular susceptible to a viral infection, preferably a retrovirus, and more preferably HIV infection, by administering antiserum, polyclonal antibodies, or a neutralizing monoclonal antibody against a particular gp120 epitope of the invention to the patient. Although passive immunity does not confer long term protection, it can be a valuable tool for the treatment of a subject who has not been vaccinated. 30 Preferably, the antibodies administered for passive immune therapy are autologous antibodies. For example, if the subject is a human, preferably the antibodies are of

human origin or have been "humanized," in order to minimize the possibility of an immune response against the antibodies.

An analogous therapy to passive immunization is administration of an amount of 5 solubilized DC-SIGN sufficient to inhibit the transport of HIV by dendritic cells to T cells. The required amount can be determined by one of ordinary skill using standard techniques.

The active or passive vaccines of the invention, or the administration of soluble DC- 10 SIGN, can be used to protect an animal subject from viral infection, preferably retrovirus invention, and more preferably, AIDS. Thus, a vaccine of the invention can be used in birds, such as chickens, turkeys, and pets; in mammals, preferably a human, although the vaccines of the invention are contemplated for use in other mammalian species, including but not limited to domesticated animals (canine and feline); farm 15 animals (bovine, ovine, equine, caprine, porcine, and the like); rodents; and undomesticated animals. In the case of AIDS, vaccination, of course, envisioned to be in humans.

Methods For Screening Drug Libraries For Compounds Useful  
in The Treatment and/or Prevention of HIV Infection

The present invention includes assays that are based on trans-enhancement of viral infection. Such assays can be used to screen for compounds including antibodies that inhibit the ability of DC-SIGN to enhance infection of target cells in trans. The assays can also be developed into test kits to monitor responses for preventive or therapeutic 25 vaccines. Such assays can utilize:

- (i) any of a variety of cell lines as target cells that express CD4 and a translocation promoting agent, including but not limited to CCR5 or CXCR4;
- (ii) a source of DC-SIGN, either on the surface of cells in membrane vesicles or soluble recombinant material; and
- 30 (iii) a recombinant form of HIV that encodes a reporter gene; e.g., luciferase or green fluorescent protein to permit a determination of the effective

infection of the target cells.

Examples of appropriate cell lines include, but are not limited to murine 3T3 cells, human HeLa, U87MG, HOS, and 293 cells that are transgenically manipulated to

5 express CD4. Additional human cell lines that do not normally express either CXCR4 or CKR-5 (such as SCL) can also be used. Furthermore, cell lines included in the Examples below, can also be used.

Cell lines transfected with DC-SIGN can be used in assays to capture gp120 or

10 infectious HIV particles. Cells expressing DC-SIGN can be pulsed with the reporter virus, washed and incubated with the target cells. Reporter activity can then be assayed in the cultured cells. In certain assays dendritic cells or THP-1 cells transfected to express DC-SIGN can be utilized as cells that express DC-SIGN.

15 Cell lines transfected with DC-SIGN can be used in assays to enhance target cell infection in trans. Mixtures of cells that express DC-SIGN and target cells can be incubated with appropriate titers of reporter virus, and reporter activity will then be measured. As controls for background infection, cells that do not express DC-SIGN are used.

20 Membrane vesicles containing DC-SIGN can also be used with target cells to capture reporter virus or to enhance infection of target cells in trans with reporter virus. One embodiment uses lipid monolayers to anchor DC-SIGN on a solid support. Reporter virus is then added. In a particular embodiment of this type, the membranes are then 25 washed. In either case, the target cells then added.

In another embodiment the anchored solid phase DC-SIGN is treated with soluble gp120 or gp140, washed, and then screened for antibodies that bind specifically to the DC-SIGN-gp120 or gp140 complex. In a preferred embodiment of this type, the 30 antibody does not bind to either DC-SIGN or gp120/140 alone. Antibodies identified in this matter can then be used to screen for compounds that block the binding of these

antibodies to solid phase DCS/gp120 or gp140 complexes. These antibodies are also part of the invention.

Soluble or secreted forms of DC-SIGN also can be used in the capture or enhancement assays disclosed herein. These forms of DC-SIGN can be prepared in bacteria or in eukaryotic expression systems including mammalian cell lines and insect cells using recombinant baculovirus. One means of preparing these forms of DC-SIGN is to link a signal peptide sequence to an epitope tag and to the N-terminal amino acid residue of the ectodomain (most membrane-proximal) and express this in mammalian cell lines. Another approach is to make a fusion protein with DC-SIGN and an extracellular domain of a transmembrane protein; *e.g.*, CD8-alpha, such that a protease cleavage site (*e.g.*, recognized by thrombin) separates that domain from an epitope-tagged form of DC-SIGN ectodomain. After purification on an anti-CD8-alpha affinity column, this protein can be cleaved with thrombin to yield the soluble forms of DC-SIGN. The resulting protein can be used as a monomer in the trans-enhancement assay or in multimeric form, possibly bound to beads or other solid support, in the capture and enhancement assays and in drug screens as described above with the membrane vesicles.

HIV and SIV vectors include, but are not limited to HIV or SIV-luciferase, HIV or SIV-alkaline phosphatase, HIV or SIV- CD24 and HIV or SIV-2 LTR-Green Fluorescent Protein. In such vectors, the env gene can be inactivated by frame shifting, and the reporter gene is then inserted to replace the Nef open reading frame. Additional vectors can be made for easier screening in murine cells, in which expression of HIV-LTR-driven reporters is only about 1% of the level in human cells. Such vectors are based on the HIV-gpt prototype, such that the reporter, *e.g.* luciferase is placed under control of the SV40 promoter within the *env* gene, ensuring high level expression following integration.

HIV-1 envelope glycoproteins whose tropism for CCRs and CXR4 that have been determined can be appropriate for screening. For example, CCR5-tropic envelope

glycoproteins ADA and YU-2, (which can also use CCR3) 92US715, and 91US005 and one dual tropic for CXCR4 and CXCR5 (92HT593) are also able to infect cells transfected with BOB. Two of the envelope proteins for primary HIV-1 strains (the dual tropic 92HT539 and CR5-tropic 92BRO25) also use Bonzo. In addition T-tropic 5 envelope glycoproteins include HXB2, 92UGO21, and 92HT599 also use BOB or Bonzo. Other CCR5-tropic envelope glycoproteins include BaL, 92UG975, 93HT966, 92RWO20, 93TH976, 92BRO20, and 93MW965. JRFL is a CCR5-tropic envelope glycoprotein that uses BOB only weakly. Envelope glycoproteins of SIV such as Mac1A11-Agm TY01, or Mac 239 can also be used to screen for receptors 10 that are used by SIV.

Identification of the role that DC-SIGN plays in HIV infection provides a unique set of protocols to identify specific agents that inhibit HIV infection. Accordingly, the present invention contemplates methods for identifying agonists and antagonists of 15 HIV entry using various screening assays known in the art. Such agonists or antagonists can competitively inhibit HIV binding, or more particularly, an HIV or SIV envelope protein binding to DC-SIGN.

In one such embodiment, cell lines expressing CD4 and one or more translocating 20 promoters, can be infected with an HIV-reporter virus or SIV-reporter virus that is pseudotyped with one or more selected envelope glycoproteins in the presence of DC-SIGN. Compound libraries can be assayed for their ability to inhibit infection of the cells by the pseudotyped virus. Candidate compounds are selected and then can be counter-screened for non-specific effects on infection with virus pseudotyped with 25 non-HIV or non-SIV envelope proteins such as MLV amphotropic env or with VSV-G env for example.

Any screening technique known in the art can be used to screen for antagonists of DC-SIGN-gp120 association. The present invention contemplates screens for small 30 organic compounds, as well as screens for natural ligands that bind to and antagonize such activity *in vivo*. For example, natural products libraries can be screened using

assays of the invention for molecules that antagonize HIV-DC-SIGN association.

Identification and screening of antagonists can be further facilitated by determining structural features of the protein, *e.g.*, using X-ray crystallography, neutron diffraction, 5 nuclear magnetic resonance spectrometry, and other techniques for structure determination. These techniques provide for the rational design or identification of agonists and antagonists.

Another approach uses recombinant bacteriophage to produce large libraries. Using 10 the "phage method" [Scott and Smith, 1990, *Science* 249:386-390 (1990); Cwirla, et al., *Proc. Natl. Acad. Sci.*, 87:6378-6382 (1990); Devlin et al., *Science*, 249:404-406 (1990)], very large libraries can be constructed ( $10^6$ - $10^8$  chemical entities). A second approach uses primarily chemical methods, of which the Geysen method [Geysen et al., *Molecular Immunology* 23:709-715 (1986); Geysen et al. *J. Immunologic Method* 15 102:259-274 (1987)] and the method of Fodor et al. [*Science* 251:767-773 (1991)] are examples. Furka et al. [*14th International Congress of Biochemistry, Volume 5*, Abstract FR:013 (1988); Furka, *Int. J. Peptide Protein Res.* 37:487-493 (1991)], Houghton [U.S. Patent No. 4,631,211, issued December 1986] and Rutter et al. [U.S. 20 Patent No. 5,010,175, issued April 23, 1991] describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

In another aspect, synthetic libraries [Needels et al., *Proc. Natl. Acad. Sci. USA* 90:10700-4 (1993); Ohlmeyer et al., *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Lam et al., International Patent Publication No. WO 92/00252; Kocis et al., 25 International Patent Publication No. WO 9428028, each of which is incorporated herein by reference in its entirety], and the like can be used to screen for inhibitors of DC-SIGN mediated HIV entry into T cells according to the present invention.

The screening can be performed with recombinant cells that express DC-SIGN, or 30 alternatively, using purified and preferably soluble protein, *e.g.*, produced recombinantly, as described above. For example, the ability of a labeled, soluble or

solubilized DC-SIGN that includes the gp120-binding portion of the molecule to bind gp120 can be used to screen libraries such as random phage libraries or chemical libraries, as described herein. Any of the numerous assays well known in the art and/or exemplified herein may be used.

5

The present invention therefore also includes compounds that interfere with the binding of gp120 to DC-SIGN (DCS). In a particular embodiment the compound has a structure based on that of an oligosaccharide. Alternatively, the compound can be an antibody specific for DC-SIGN or an antibody specific for particularly conserved regions of gp120 that are required for interacting with DC-SIGN. Such compounds interfere with infection, particularly with infection of cells that do not express DC-SIGN.

The present invention also provides compounds that interfere with DC-SIGN-dependent enhancement of HIV-target cell fusion. Such compounds include antibodies that bind to DC-SIGN and interfere with the trans-enhancement of HIV entry by way of CD4 and CCR5/CXCR4 on the target cell. Preferably such compounds or antibodies do not block the binding of gp120 to DC-SIGN.

20 In addition, one of the models suggested by the present results is based on the clustering of DC-SIGN being required for its activity in enhancing T cell infection. Therefore, even if the virus binds to DC-SIGN there needs to be appropriate clustering of the receptor on the surface of the dendritic cell. Selected compounds could block the clustering activity, even if binding of virus could still occur. Such compounds 25 would therefore be agents that block infection of T cells and monocytes.

Furthermore, compounds can be identified that block DC-SIGN processing of HIV-1 to permit persistence of virus (protection from decay in infectivity) and presentation in trans to enhance infection of T cells. The virus is protected from proteases after 30 interaction with dendritic cells or other cells transfected with DC-SIGN. Therefore, compounds that inhibit this protective mechanism of the virus after it binds to DC-

SIGN are part of the invention. Such compounds can be identified by using the capture and trans-enhancement assays described herein, with whole cells that express DC-SIGN. With the capture assay, the screen can be for compounds that inhibit infection of target cells that are added to the DC-SIGN expressing cells one or more 5 days after the DC-SIGN cells are pulsed with reporter virus (see Examples below).

The present invention further provides the use of soluble DC-SIGN to block infection *in vivo*. Certain forms of soluble DC-SIGN (e.g., modified to bind yet also prevent a conformational change) could block HIV infection while other forms could enhance 10 fusion. Such forms of DC-SIGN can be produced by performing mutagenesis to generate DC-SIGN variants that continue to bind gp120 but fail to transmit captured virus to T cells, and/or other target cells and/or to enhance infection of T cells and other target cells in trans. One particular approach is to perform random mutagenesis of the DC-SIGN extracellular domain using standard error-prone PCR, transfect or 15 retrovirally transduce the different mutant clones into an appropriate cell lines such as THP-1, sort for cells that bind gp120, using magnetic beads coated with anti-gp120 antibody or using FACS, and then test individual transfected clones for the ability to transmit virus to appropriate target cells expressing CD4/CCR5 or CD4/CXCR4. Mutant forms of DC-SIGN that cannot enhance entry in trans can be made into 20 soluble or secreted forms by one of the methods described above, and these can be tested for their ability to inhibit trans-enhancement in assays such as those described herein.

Based on the results disclosed herein, it appears that interaction of gp120 with DC- 25 SIGN results in a conformational change in envelope glycoprotein which would enhance fusogenic activity. Therefore compounds including antibodies that specifically interact with such an altered form of the envelope glycoprotein (gp120/gp41) induced by DC-SIGN binding and that, hence, block viral entry are also provided. Such small organic compounds or antibodies can be identified by screening 30 for drugs in a trans-enhancement assay or by using complexes of DC-SIGN and gp120 or oligomers of soluble gp140. For example, soluble DC-SIGN/gp120 can be used to

elicit monoclonal antibodies that will bind specifically only to a complex of these proteins or to a conformational epitope on gp120. Such complexes can also be used to screen for compounds that bind specifically to DC-SIGN/gp120 or DC-SIGN/gp140 or to the novel conformations of the envelope glycoproteins.

5

In addition, compounds or antibodies that specifically interact with an altered form of the envelope glycoprotein (gp220/gp41) not necessarily induced by DC-SIGN binding, but by specific routing of virus to intracellular compartments in which viral fusogenicity would be enhanced are included in the present invention. Such 10 compounds or antibodies can be identified by screening for drugs in a trans-enhancement assay (described above) or by using HIV particles that have been rendered more "fusogenic" by exposure to DC (or by other means that mimic DC exposure, *e.g.* low pH exposure). In addition, soluble envelope glycoprotein in a "fusion-enhanced" conformation can be used to elicit monoclonal antibodies that will 15 bind specifically only to a conformational epitope on gp120 or gp41. Such complexes can also be used to screen for compounds that bind specifically to novel conformations of the envelope glycoproteins.

To screen for such compounds, HIV particles can be exposed to various pH conditions

20 prior to return to neutral pH. If a particular pH condition enhances infectivity, compounds can be screened for their ability to inhibit infection. For example, pseudotyped virus (encoding a reporter gene, *e.g.*, firefly luciferase) can be pH activated, and then used to infect a target cell (*e.g.*, murine 3T3 cells expressing human CD4, human CCR5, and human cyclinT1; or other mouse or human cells with 25 the appropriate complement of receptors). Screens can be conducted for compounds that inhibit luciferase activity. Several controls can be incorporated to ensure that compounds are specific for activated viral conformations. For example, high concentration of non-pH-exposed pseudotype virus encoding Renilla luciferase can be included in the assay. The infectivity of this virus should not be affected by 30 compounds of interest. Alternatively, Renilla luciferase-encoding virus pseudotyped with VSV-G or murine amphotropic envelope glycoprotein similarly would not be

effected by desired compounds.

Still another approach employs the contents of purified early endosomes, which are then mixed with virus (e.g., HIV) to achieve increased infectivity (to supplement 5 and/or replace the lower pH conditions described previously). Compounds that block increased viral infectivity after such treatment can then be screened by the assays described above.

A different screen can be used to identify compounds that block interaction of a novel 10 conformer of HIV envelope glycoprotein (induced by low pH and/or endosomal environment) with CD4/chemokine receptor or with a conformer-specific mAb. The former can test binding of envelope to cells that express the receptor complex or to beads coated with lipid-associated forms of CD4 and CCR5 for example.

15 In addition, the finding that HIV internalization by dendritic cells directs virus to recycling endosomes (see Example 2) rather than lysosomes, identifies one of the key functions of DC-SIGN. Therefore, the present invention further provides compounds that inhibit HIV infection by redirecting HIV from recycling endosomes to the lysosomal compartment of dendritic cells (as well as other cells). Such compounds 20 reduce HIV infectivity and increase immunogenicity (and, hence, antiviral T cell immune responses). This can be achieved by interfering with the DC-SIGN interaction with intracellular endocytic machinery. Therefore, the present invention provides methods of identifying compounds and the compounds so identified which interfere with the binding of specific proteins to the cytoplasmic domain of DC-SIGN. 25 These proteins are essential for internalization of virus and for the ability of HIV to exploit dendritic cells.

Therefore, the present invention provides screens to test for compounds that inhibit internalization of DC-SIGN. One such screen is an antibody based screen. In a 30 particular embodiment, a labeled anti-DC-SIGN antibody is bound to an appropriate cell (a cell that expresses DC SIGN e.g., a THP-SIGN cell), and internalization is

induced by warming to 37°C or so for an appropriate period of time (e.g., 20-120 min). Surface-bound antibody is then stripped by acid pH or protease, and the cells are washed. The remaining label is then measured. Compounds that inhibit endocytosis of DC-SIGN would block accumulation of label. In one such 5 embodiment, the antibody has a fluorescent label. In a related embodiment, the antibody has a radioactive label.

In another screen provided by the present invention is an HIV-based screen. Such a screen could use a labeled HIV particle. These HIV particles can bind to an 10 appropriate cell (a cell that expresses DC SIGN e.g., a THP-SIGN cell), and internalization is induced by warming to 37°C or so for an appropriate period of time (e.g., 20-120 min). Surface-bound HIV can then be stripped by acid pH or protease, and the cells are washed. The remaining label can then be determined. In a particular embodiment the HIV particle is fluorescently labeled and the remaining fluorescence 15 is measured by FACS analysis or microscopy (monitoring fluorescent particles in endosomes).

Since internalization of virus into recycling endosomes results in enhanced infectivity of virus, the identification of compounds that interfere with DCs-dependent 20 enhancement of HIV-target cell fusion is important. One such method relies on identifying compounds that interfere with conformational changes in HIV envelope glycoprotein following endocytosis of viral particles. In a particular embodiment, these conformational changes are caused by pH-dependent conformational changes. Another method relies on identifying compounds that bind specifically to conformers 25 of HIV envelope glycoprotein after conformational modifications within endosomal compartments. In a particular embodiment of this type, the compounds are antibodies.

#### Administration of Antagonists of HIV Infection

According to the invention, the component or components of a therapeutic 30 composition of the invention may be introduced parenterally, transmucosally, e.g., orally, nasally, or rectally, or transdermally. Preferably, administration is parenteral,

e.g., via intravenous injection, and also including, but is not limited to, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. More preferably, where administration of an antagonist to the DC-SIGN -gp120 complex is administered to prevent or treat AIDS, it may be

5 introduced by injection into the blood. The antagonist may be a specific antibody raised against a particular epitope of the DC-SIGN -gp120 complex or a mimic to DC-SIGN, including a soluble form of DC-SIGN that competitively competes with DC-SIGN for the gp120.

10 In another embodiment, the therapeutic compound can be delivered in a vesicle, in particular a liposome [see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss: New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*]. To reduce its systemic side effects, this may be a preferred

15 method for introducing an antagonist to DC-SIGN- gp120 binding.

In yet another embodiment, the therapeutic compound can be delivered in a controlled release system. For example, an antibody as described above, may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one embodiment, a pump may be used [see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)]. In another embodiment, polymeric materials can be used [see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Press: Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley: New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)]. In yet another embodiment, a controlled release system

20 can be placed in proximity of a therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose [see, e.g., Goodson, in *Medical Applications of*

25

30

*Controlled Release, supra, vol. 2, pp. 115-138 (1984)].*

Other controlled release systems are discussed in the review by Langer [*Science* 249:1527-1533 (1990)].

5

Thus, the antagonist can be delivered by intravenous, intraarterial, intraperitoneal, intramuscular, or subcutaneous routes of administration. Alternatively, the antagonist, properly formulated, can be administered by nasal or oral administration. A constant supply of the antagonist can be ensured by providing a therapeutically effective dose

10 (i.e., a dose effective to induce metabolic changes in a subject) at the necessary intervals, e.g., daily, every 12 hours, etc. These parameters will depend on the severity of the disease condition being treated, other actions, such as diet modification, that are implemented, the weight, age, and sex of the subject, and other criteria, which can be readily determined according to standard good medical practice by those of

15 skill in the art.

A subject in whom administration of the antagonist is an effective therapeutic regimen for AIDS is preferably a human, but can be a primate with a related viral condition. Thus, as can be readily appreciated by one of ordinary skill in the art, the 20 methods and pharmaceutical compositions of the present invention are particularly suited to administration to any primate.

#### Transgenic Vectors and Inhibition of Expression

In one embodiment, a gene encoding a soluble DC-SIGN, or antisense or ribozyme 25 specific for DC-SIGN mRNA (termed herein an "antigene") is introduced *in vivo* in a viral vector. Such vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not 30 infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can

infect other cells. Thus macrophage can be specifically targeted. Examples of particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt et al., *Molec. Cell. Neurosci.* 2:320-330 (1991)], an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al. [*J. Clin. Invest.* 90:626-630 (1992)], and a defective adeno-associated virus vector [Samulski et al., *J. Virol.* 61:3096-3101 (1987); Samulski et al., *J. Virol.* 63:3822-3828 (1989)].

In another embodiment the gene or antigen can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., 1983, 10 *Cell* 33:153; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., 1988, *J. Virol.* 62:1120; Temin et al., U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995, by Dougherty et al.; and Kuo et al., 1993, *Blood* 82:845.

15 In one embodiment, specific PBMCs are removed from an HIV-positive subject animal (e.g., a human) and the gene encoding DC-SIGN, for example, is replaced by a modified DC-SIGN gene that retains its natural activity, binds ICAM-3 but cannot facilitate the entry of HIV into T cells. The subject animal is depleted of its corresponding PBMCs (e.g., if the gene modification was performed in a macrophage 20 or T-cell, then the macrophages or T-cell are depleted) and the modified PBMCs are reintroduced into the subject animal. Such an animal subject should then have macrophages or T-cells, which are capable of responding to the appropriate natural ligand for DC-SIGN, but which are no longer capable of facilitating the entry of HIV into a cell. In a related embodiment, a translocation promoting agent gene (such as 25 CC-CKR5 or CXCR4) is also modified to more fully block HIV translocation/infection.

Targeted gene delivery is described in International Patent Publication WO 95/28494, published October 1995.

30

Alternatively, the vector can be introduced *in vivo* by lipofection [Felgner, et. al.,

*Proc. Natl. Acad. Sci. U.S.A.* 84:7413-7417 (1987); *see* Mackey, et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:8027-8031 (1988); Felgner and Ringold, *Science* 337:387-388 (1989)]. Lipids may be chemically coupled to other molecules for the purpose of targeting [*see* Mackey, et. al., *supra*]. Targeted peptides, e.g., hormones or 5 neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

It is also possible to introduce the vector *in vivo* as a naked DNA plasmid. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods 10 known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter [*see, e.g.*, Wu et al., *J. Biol. Chem.* 267:963-967 (1992); Wu and Wu, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut et al.; Canadian Patent Application No. 2,012,311, filed March 15, 1990].

15 As noted above, the present invention extends to the preparation of antisense nucleotides and ribozymes that may be used to interfere with the expression of DC-SIGN at the translational level. This approach utilizes antisense nucleic acid and 20 ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme. Such antisense or ribozyme nucleic acids may be produced chemically, or may be expressed from an "antigen."

Antisense nucleic acids are DNA or RNA molecules that are complementary to at 25 least a portion of a specific mRNA molecule [*see* Marcus-Sekura, *Anal. Biochem.* 172:298 (1988)]. In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG 30 initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into organ

cells. Antisense methods have been used to inhibit the expression of many genes *in vitro* [Marcus-Sekura, 1988, *supra*; Hambor et al., *J. Exp. Med.* 168:1237 (1988)]. Preferably synthetic antisense nucleotides contain phosphoester analogs, such as phosphorothiolates, or thioesters, rather than natural phosphoester bonds. Such 5 phosphoester bond analogs are more resistant to degradation, increasing the stability, and therefore the efficacy, of the antisense nucleic acids.

Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction 10 endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it [Cech, *J. Am. Med. Assoc.* 259:260:3030 (1988)]. Because they are sequence-specific, only mRNAs with particular 15 sequences are inactivated.

Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type. *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer 20 the recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

25 The DNA sequences encoding the DC-SIGN can be used to prepare antisense molecules against and ribozymes that cleave mRNAs encoding DC-SIGN, thus inhibiting expression of the gene encoding the DC-SIGN, which can reduce the level of HIV entry in macrophages and T cells.

Cells on Solid Supports

Solid supports include glass beads, sugar beads (SEPHADEX, SEPHAROSE, Agarose, SEPHACEL etc.) magnetic beads, and dowex-type materials. Biological materials may be passed through cells bound to solid supports by common methods

5 know to any person skilled in the art including but not limited by batchwise, by centrifugation, pressure-membrane filtration (e.g. Amicon or Millipore filtration) and through various types of columns.

Transgenic Animals

10 T lymphocytes from mice transgenic for human CD4 and CCR5 can be infected *in vitro* with various strains of HIV but are not infected when virus is injected into the animals. The expression of human DC-SIGN in the murine dendritic cells permits mucosal uptake of virus by these cells, transport of virus to lymphatic organs and subsequent *in vivo* infection of the cells that express human CD4 and CCR5.

15 The transgenic mice of the present application can be produced as detailed previously [Killeen *et al.* *EMBO* 12:1547-1553 (1993)], which is hereby incorporated by reference. The construction of the human CD4<sup>+</sup> murine CD4<sup>-</sup> mice have been described [Killeen *et al.* *EMBO* 12:1547-1553 (1993)].

20 Generation of transgenic mice thus serve as a model system for HIV pathogenesis for development of vaccines and new therapeutics. Such mice express various combinations of human CD4 (SEQ ID NO:3), CCR5 (SEQ ID NO:5) or CXCR4 (SEQ ID NO:4) and cyclin T [SEQ ID NO:6; GenBank accession AF045161, Wei *et al.*, *Cell*, 92(4):452-462 (1998)] in all of their T cells, subsets of T cells and/or macrophages and monocytes. These types of animals have been generated using the CD4 regulatory sequences to direct expression in these types of cells. In addition, the mice express human DC-SIGN on the surface of their dendritic cells. This can be achieved by using a CD11c promoter to direct expression in this subset of cells

25 30 [Dziennis *et al.*, *Blood*, 85(2):310-329 (1995)]. Another approach is to use homologous recombination to introduce the DC-SIGN cDNA into the site for the

murine CX3CR1 coding region. The latter gene is expressed in dendritic cells, which allows for specific expression in dendritic cells of genes targeted to this site. A third method to achieve specific expression of human DC-SIGN in dendritic cells is to use homologous recombination to replace the murine DC-SIGN gene with human DC-

5 SIGN cDNA; a similar approach has been used to replace murine CXCR4 with the human CXCR4. Another method is to use the human DC-SIGN promoter consisting of sequences of up to 5 kb 5' to the first exon to drive expression in dendritic cells. This promoter is generated by cloning the sequence 5' to

"GAGTTCTGGACACTGGGGAGAGTGGGGTGACAT" (SEQ ID NO:13).

10

Additional Uses of the Invention

Since the present disclosure demonstrates that DC-SIGN binds gp120 with a high affinity and thereby HIV tightly, there are multiple ancillary uses provided by the present invention. For example, DC-SIGN or gp120 binding fragment thereof, either 15 alone, on a solid support or in the membrane of a cell can be used to bind HIV and similar viruses. Such binding can be used with electroporesis for example to filter blood products. Alternatively, a DC-SIGN derived product, as enumerated above, could be used in a vaginal prophylactic cream to prevent the transmission of virions, including HIV.

20

In addition, since DC-SIGN expressing cells are shown herein to not only facilitate viral transport to T cells but to also extend the longevity of virions, cells expressing DC-SIGN can be used in conjunction with viral vectors such as retroviral vectors (e.g., HIV) to enhance the effect of viral vectors during gene therapy, particularly in 25 protocols in which the gene transfer is to be performed in T cells.

Indeed, the present invention relates to the discovery that DC-SIGN binds and captures HIV virus, particularly through interaction or binding with the HIV gp120 in trans. This unique ability to capture HIV, particularly infectious HIV, and sequester 30 the virus *in vivo* or *in vitro* can be utilized in a variety of methods, applications and uses wherein capture of HIV is relevant or required. It is therefore contemplated that

DC-SIGN can be utilized to capture HIV viruses from a patient or in a patient sample. This could effectively concentrate virus for the purpose of further study, including but not limited to: evaluation of the infectivity of the isolated HIV; assessment of the drug sensitivity of the isolated HIV; analysis of the DNA sequence of the isolated HIV,

5 specific HIV genes or encoded polypeptide to determine or assess, for instance genetic drift and viral mutations; and other characterization of the HIV population in a patient. In addition, the DC-SIGN mediated capture methods can be utilized in purifying or removing HIV which is presumed or possibly present in a sample, particularly wherein such sample comprises a biologic/therapeutic material or compound or will be utilized

10 in the preparation or isolation of a biologic/therapeutic material or compound.

Biological/therapeutic materials or compounds isolated or purified from blood or blood components are a particular example, including Factor VIII, other coagulation factors, and blood cell components, wherein presumed or possible HIV, or other such blood-borne viruses must be removed or inactivated.

15

The DC-SIGN-mediated trans capture of HIV can be accomplished by providing DC-SIGN in trans in any form, medium or source wherein DC-SIGN is capable of binding to HIV to form a DC-SIGN-HIV complex or association and wherein the DC-SIGN-HIV complex or association can thereby be isolated or captured. For instance, any of

20 the following sources of DC-SIGN can be utilized, including cells or cell lines

expressing DC-SIGN, DC-SIGN in membrane vesicles or synthetic lipid or lipophilic carriers, soluble DC-SIGN, and DC-SIGN attached to a surface, separation material or medium (including for instance resins, beads and columns) directly or using lipid monolayers or lipid moieties to anchor DC-SIGN.

25

#### Isolation of Peptides Mimicking Carbohydrate

A major obstacle in the investigation of biological functions of carbohydrates is the availability of these compounds. They can often be isolated from biological sources in only minute amounts. A possible solution to this problem, is to mimic the

30 carbohydrate by other compounds that are easier to prepare, e.g. peptides. A

promising way to find such peptides is by use of the random peptide phage display

technology. Peptides which mimic the DC-SIGN lectin ligand or otherwise block DC-SIGN-mediated interactions or binding may be useful in the HIV prophylaxis, prevention or therapy. Peptide ligands identified by phage display screening frequently interact with natural binding site(s) on the target molecule, and often

- 5 resemble the target's natural ligand(s). Peptides mimicking carbohydrate epitopes or ligands have been isolated and work directed towards using peptide mimics in place of carbohydrate antigens has been reviewed by Kieber-Emmons and colleagues [Kieber-Emmons, *et al. Immunologic Res* 17:95-108 (1998)]. The demonstrated ability of a peptide to mimic a carbohydrate determinant indicates that, although mimicry is
- 10 accomplished using amino acids in place of sugars, the specificity pattern can be reproduced.

Screening phage-displayed random peptide libraries offers a rich source of molecular diversity and represents a powerful means of identifying peptide ligands that bind a

- 15 receptor molecule of interest (Cwirla *et al. PNAS* 86:637-682 (1990); Devlin *et al. Science* 249:404-406 (1990); Cortese *et al. Current Opin Biotech* 6:73-80 (1995)]. Phage expressing binding peptides are selected by affinity purification with the target of interest. Since each infectious phage encodes the random sequence expressed on its surface, a particular phage, when recovered from an affinity matrix, can be amplified
- 20 by another round of infection. Thus, selector molecules immobilized on a solid support or other capture means can be used to select peptides that bind to them. With regard to the present invention, DC-SIGN or gp120 may be utilized as a selector molecule in such systems. This procedure reveals a number of peptides that bind to the selector and that often display a common consensus amino acid sequence.
- 25 Biological amplification of selected library members and sequencing allows the determination of the primary structure of the peptide(s).

Peptides that mimic glycosphingolipids have been found using a phage peptide library. Two monoclonal antibodies that recognize lactotetraosylceramide (Lc4Cer) and its

- 30 isomer neolactotetraosylceramide (nLc4Cer) were used to find peptides that mimic the carbohydrate moieties of the two glycosphingolipids. It was also shown that the

peptides are biologically active, in that they could modulate the activity of  $\beta$ -galactosidase [Taki *et al.* *FEBS Lett* 418:219-223 (1997)]. The cell wall of the bacterial pathogen *Shigella flexneri* contains repeated saccharide units forming the O-antigen carbohydrate moiety of the capsular lipopolysaccharide. Peptide mimics of the 5 carbohydrate epitope were isolated using phage display technology and could act as immunogenic mimics and were capable of inducing specific anti-carbohydrate antibodies [Phalipon *et al.* *Eur J Immunol* 27:2620-2625 (1997)]. Peptides that mimic HIV-associated carbohydrate forms have also been reported. Mouse antisera were generated against peptides that mimic a mucin-related carbohydrate epitope expressed 10 on HIV. The authors showed that immunization with the peptide-mimics induces antibodies that cross-reacted with native HIV envelope proteins. The sera containing these antibodies could neutralise HIV-1 cell-free infection *in vitro* as well as the sera from patients infected with HIV-1 whereas normal human sera were ineffective in this viral neutralisation assay [Agadjanyan *et al.* *Nature Biotech* 15:547-551 (1997)].

15 Further such studies include: (a) a peptide mimic of a carbohydrate epitope of the Lewis Y antigen has been reported and contains the residues PWLY, which were shown to be critical for peptide binding to an antibody specific for the Lewis Y antigen [Hoess *et al.* *Gene* 128:43-49 (1993)] ; (b) peptides that mimic the capsular polysaccharide of *Neisseria meningitidis* serogroup C generated an immune response 20 that was able to protect mice against infection with a lethal dose of the encapsulated bacteria [Westerink *et al.* (1995) *PNAS* 92]; and (c) the carbohydrate binding site of the lectin concanavalin A was investigated and peptides that mimic the binding of methyl  $\alpha$ -D-mannopyranoside to ConA were identified by screening a phage-displayed random hexa- or decapeptide library [Scott *et al.* *PNAS* 89:5398-402 (1992); 25 Oldenburg *et al.* *PNAS* 89:5393-97 (1992)].

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the preferred embodiments of 30 the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

EXAMPLESEXAMPLE 1DC-SIGN, A DENDRITIC CELL-SPECIFIC HIV-1 BINDING  
5 PROTEIN ENHANCES TRANS-INFECTION OF T CELLSIntroduction

Dendritic cells (DC) capture microorganisms that enter peripheral mucosal tissues and then migrate to secondary lymphoid organs, where they present these in antigenic 10 form to resting T cells and thus initiate adaptive immune responses. The mechanism by which DC capture HIV-1 and promote infection of CD4<sup>+</sup> T cells has not been elucidated, and it has been unclear whether there is specificity in the interaction of DC with virus. Indeed heretofore, no specific dendritic cell receptor had been identified that was involved in HIV infection of T cells.

15

Methods

*Antibodies:* The antibodies (mAb) used are 2D7 (anti-CCR5; Becton and Dickinson & Co., Oxnard, CA) and anti-CD4 (RPA-T4; PharMingen, San Diego, CA). Anti-DC-SIGN mAb AZN-D1 and AZN-D2 were obtained by screening hybridoma 20 supernatants of human DC-immunized BALB/c mice for the ability to block adhesion of DC to ICAM-3, as measured by the fluorescent bead adhesion assay.

*Cells:* Immature dendritic cells (DC) were cultured from monocytes in the presence of IL4 and GM-CSF (500 and 1000 U/ml, respectively; Schering-Plough, Brussels, 25 Belgium) [Sallusto and Lanzavecchia, *J. Exp. Med.*, 179:1109-1118 (1994) and Romani *et al.* *J. Exp. Med.*, 180:83-93 (1994)]. At day 7 the phenotype of the cultured DC was confirmed by flowcytometric analysis. The DC express high levels of MHC class I and II,  $\alpha$ M $\beta$ 2 (CD11b),  $\alpha$ X $\beta$ 2 (CD11c) and ICAM-1, moderate levels of LFA-1 and CD80, and low levels of CD14. Stable K562 transfectants expressing 30 ICAM-3 (K562-ICAM-3) were generated by co-transfection of K562 with 10  $\mu$ g PCRII ICAM-3 plasmid and 2  $\mu$ g PGK-hyg vector [te Riele *et al.*, *Nature*

348:649-651 (1990)] by electroporation as described [Lub *et al.*, *Mol. Biol. Cell*, 8:719-728 (1997)]. Stable THP-1 transfectants expressing DC-SIGN were generated by transfection of THP-1 cells with pRc/CMV-DC-SIGN by electroporation similarly as described above for K562-ICAM-3.

5

*Isolation and expression of the cDNA encoding DC-SIGN:* Immunoprecipitated DC-SIGN was identified by peptide sequencing. Tryptic digestion, purification of the resulting peptides and sequence analysis was performed by Eurosequence BV (Groningen, The Netherlands). The cDNA encoding the placenta gp120 binding C-type lectin was amplified by RT-PCR on total RNA from DC. PCR primers were based on the nucleotide sequence of the placenta gp120 binding C-type lectin [accession no. M98457, Curtis *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89:8456-8360 (1992)] and the nucleotide sequences (5' to 3') are as follows:

10 XF29: AGAGTGGGGTGACATGAGTG (SEQ ID NO:11)  
15 XR1265: GAAGTTCTGCTACGCAGGAG (SEQ ID NO:12)

The nucleotide sequence of the cloned cDNA was identical to that of the placenta gp120 C-type [Curtis *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89:8456-8360 (1992)]. The cDNA was subsequently cloned into the eukaryotic expression vector pRc/CMV (pRc/CMV-DC-SIGN). Stable THP-1 transfectants expressing DC-SIGN were generated by transfection of THP-1 cells with pRc/CMV pRc/CMV-DC-SIGN by electroporation similarly as described above for K562-ICAM-3.

*Fluorescent bead adhesion assay:* Carboxylate-modified TransFluorSpheres (488/645 nm, 1.0  $\mu$ m; Molecular Probes, Eugene, OR) were coated with either ICAM-3-Fc or 25 M-tropic HIV-1<sub>MN</sub> envelope glycoprotein gp120 by standard methodology [Geijtenbeek *et al.*, *Blood*, 94(2):754-64 (1999)]. The fluorescent beads adhesion assay was performed as described by Geijtenbeek *et al.* [*Blood*, 94(2):754-64 (1999)]. Briefly, cells were resuspended in adhesion buffer (20 mM Tris-HCl pH 8.0, 150 mM 30 NaCl, 1 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, 0.5% BSA) at a final concentration of 5x10<sup>6</sup> cells/ml. 50,000 cells were pre-incubated with mAb (20  $\mu$ g/ml) for 10 min at room temperature (RT). Ligand-coated fluorescent beads (20 beads/cell) were added and

the suspension was incubated for 30 min at 37°C. Adhesion was determined by measuring the percentage of cells, which have bound fluorescent beads, by flowcytometry using the FACScan (Becton and Dickinson & Co., Oxnard, CA). For the M-tropic HIV-1<sub>MN</sub> envelope glycoprotein gp120 beads, streptavidin was 5 covalently coupled to the TransFluorSpheres as described previously [Geijtenbeek *et al.*, *Blood*, 94(2):754-64 (1999)]. Streptavidin-coated beads were incubated with biotinylated F(ab')2 fragment rabbit anti-sheep IgG (6 µg/ml; Jackson Immunoresearch) followed by an overnight incubation with sheep anti-gp120 antibody D7324 (Aalto Bio Reagents Ltd, Dublin, Ireland) at 4°C. The beads were 10 washed and incubated with 250 ng/ml purified HIV-1 gp120 (provided by Immunodiagnostics, Inc through the NIH AIDS Research and Reference Reagent Program) overnight at 4°C. The fluorescent beads adhesion assay was again performed as described by Geijtenbeek *et al.* [*Blood*, 94(2):754-64 (1999)].

15 *Heterotypic cell clustering and DC-induced T cell proliferation:* DC and ICAM-3 expressing cells ( $2 \times 10^6$  cells/ml) were labeled respectively with sulfluorescein (Molecular Probes; 50 µg/ml) and hydroethidine (Molecular Probes; 40 µg/ml) for 1 hour at 37°C. DC and the ICAM-3 expressing cells were mixed ( $50 \times 10^3$  cells each) and incubated at 37°C. At different time points the cells were fixed with 20 paraformaldehyde (0.5%) and heterotypic cell clustering was measured by flowcytometry. Clustering between DC with resting T cells was assessed by a different method. DC ( $50 \times 10^3$  cells) were pre-incubated with/without the anti-DC-SIGN mAb AZN-D1 and AZN-D2 (10 µg/ml) for 10 min. at RT. Allogeneic PBL ( $1 \times 10^6$  cells), labeled with the fluorescent dye Calcein-A (Molecular Probes; 25 µg/ $10^6$  cells/ml for 25 30 min. at 37°), were added and the cell mixture was incubated at 37°C. The clustering was determined by measuring percentage of DC which have bound fluorescent T cells by flowcytometry. Allogeneic responder T-lymphocytes ( $100 \times 10^3$ ) were added to DC ( $1.5 \times 10^3$ ) in the presence of blocking mAb (20 µg/ml). The cells 30 were cultured for 4 days. On day 4 the cells were pulsed for 16h with [<sup>3</sup>H]methyl-thymidine 1.52 TBq/mmol, 0.5 µCi/well; Amersham) and thymidine incorporation was quantified.

*HIV-1 infection of both DC and DC-SIGN transfectants:* The M-tropic strain HIV-1<sub>Ba-L</sub> was grown to high titer in monocyte-derived macrophages (MDM). Seven days after titration of the virus stock on MDM, TCID<sub>50</sub> was determined with a p24 antigen ELISA (Diagnostics Pasteur, Marnes la Coquette, France) and estimated as 5 10<sup>4</sup>/ml. DC (50x10<sup>3</sup>), pre-incubated with mAb against DC-SIGN (AZN-D1 and AZN-D2) or CD4 (RPA-T4) (20 µg/ml) or a combination of CCR5 specific chemokines (RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$ ; each 500 ng/ml) for 20 min. at RT, were pulsed for 2 hours with HIV-1<sub>Ba-L</sub> (at a multiplicity of infection of 10<sup>3</sup> infectious units per 10<sup>5</sup> cells), washed and co-cultured with activated PBMC (50x10<sup>3</sup>). No DC-T cell 10 syncytium formation was observed. The post-infection experiment was performed similarly except that the mAb or chemokines were added after the washing step of the HIV-1 pulse, together with the activated PBMC. Culture supernatants were collected at day 5, 6, 7, and 9 after DC-T cell co-culture and p24 antigen levels, as a measure of HIV-1 production were determined by a p24 antigen ELISA. PBMC were activated 15 by culturing them in the presence of IL-2 (10 U/ml) and PHA (10 µg/ml) for 2 days. Pseudotyped viral stocks were generated by calcium-phosphate transfections of 293T cells with the proviral plasmid pNL-Luc-E<sup>+</sup>R<sup>-</sup> (containing a luciferase reporter gene) or the proviral pHIV-eGFP (containing a GFP reporter gene) and expression plasmids for ADA, JRFL and JRCSF gp160 envelopes. The isolation, identification and... 20 construction of the plasmids encoding the primary virus envelopes from 92US715.6, 92BR020.4 and 93TH966.8 has been previously described [Bjorndal *et al.*, *J. Virol.*, 71(10):7478-87 (1997)]. Viral stocks were evaluated by limiting dilution on 293T-CD4-CCR5 cells. HIV-1 pseudotyped with murine leukemia virus (MLV) 25 amphotropic Env and vesicular stomatitis virus glycoprotein (VSV-G) were used to ensure target cell viability.

*Immunohistochemical analysis:* Cryosections (8 µm) of the tissues were fixed in 100% acetone (10 min), washed with PBS and incubated with the first antibody (10 µg/ml) for 60 min at 37°C. After washing, the final staining was performed with the 30 ABC-AP Vectastain kit (Vector Laboratories, Burlingame, CA) according to the manufacturer's protocol. Nuclear staining was performed with hematoxylin.

Results

A screen for molecules that bind to the adhesion molecule ICAM-3, which is expressed constitutively on T lymphocytes, was performed. A dendritic cell-specific C-type lectin that binds with high affinity to ICAM-3 was identified and designated 5 DC-SIGN. Monoclonal antibodies were prepared against dendritic cell surface molecules that blocked binding of ICAM-3 to the dendritic cells (DC). One such antibody was used to purify DC-SIGN and then clone the cDNA. Nucleotide sequence analysis of the cDNA indicated that this molecule is identical to a previously-described HIV-1 gp120-binding C-type lectin that was identified in a 10 screen of a placental cDNA library for HIV gp 120-binding cell surface proteins. [Curtis *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89:8456-8360 (1992); International Publication, WO 93/01820] which had a nucleotide sequence of SEQ ID NO:1, and an amino acid sequence of SEQ ID NO:2. A splice variant of this protein has been reported by others that has the nucleotide sequence of SEQ ID NO:16, and an amino 15 acid sequence of SEQ ID NO:17.

*DC-SIGN is a DC-specific HIV-1 binding protein:* DC-SIGN is now identified as a dendritic cell-specific ICAM-3 adhesion receptor that mediates dendritic cell (DC)-T cell interactions. Flow cytometric analysis of an extensive panel of hematopoietic 20 cells with anti-DC-SIGN antibodies demonstrates that DC-SIGN is preferentially expressed on *in vitro* cultured DC but not on other leukocytes such as monocytes and peripheral blood lymphocytes (PBL) (Figure 1A, Table 1). Identification of DC-SIGN by peptide amino acid sequencing of the 44 kD immunoprecipitated protein revealed it to be 100% identical in its amino acid sequence to the HIV-1 envelope glycoprotein 25 gp120-binding C-type lectin previously isolated from a placental cDNA library [Curtis *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89:8356-8360 (1992), SEQ ID NO:2]. To determine whether this molecule has a role in binding of HIV to DC, a flow cytometric adhesion assay was used [Geijtenbeek *et al.*, *Blood*, 94(2):754-64 (1999)] to examine the ability of HIV-1 gp120-coated fluorescent beads to bind to immature 30 DC (Figure 1B). The gp120-coated beads bound efficiently to the DC, and the binding was completely blocked by the anti-DC-SIGN antibodies AZN-D1 and

AZN-D2. In contrast, neutralizing anti-CD4 antibodies had no effect on gp120 binding to DC. This result indicates that, although the primary HIV-1 receptor CD4 is expressed on DC (Figures 1C-1D), HIV-1 gp120 preferentially binds to DC-SIGN. Similarly, the monocytic cell line THP-1, which lacks expression of both CD4 and 5 CCR5, bound the gp120-coated beads after it was transfected with a DC-SIGN expression vector (Figure 1C).

TABLE 1: Expression level of DC-SIGN on hematopoietic cells as determined by flowcytometric analyses and RT-PCR.

	Cell-type	DC-SIGN expression*	DC-SIGN mRNA**
5	monocytes	≤15	-
	immature DC day 7	980	+
	mature DC day 9†		
	LPS	489	+
	MCM/PGE2	445	+
10	TNF $\alpha$	420	+
	PBL	≤15	-
	T cells	≤15	-
	B cells	≤15	-
	thymocytes	≤15	-
15	granulocytes	≤15	-
	CD34+ cells	≤15	n.d.
	PBMC (activated#)	≤15	-
	T cell lines <sup>†</sup>	≤15	-
20	monocytic cell lines <sup>††</sup>	≤15	-

\* mean fluorescence of staining with AZN-D1

\*\* RT-PCR with the DC-SIGN-specific primers XF29 and XR1265 on total RNA isolated from the different cells

† immature DC were matured with GM-CSF, IL-4 and either TNF $\alpha$ , LPS or a combination of MCM and prostaglandin E2.

# activated with PHA (10  $\mu$ g/ml) and IL-2 (10 U/ml) for 2 days

† T cell lines : HSB, PEER, CEM and Jurkat

†† monocytic cell lines: THP-1, MM6 and U937

n.d., not determined

HIV-1 gp120 binding to this cell line, THP-DC-SIGN, was also blocked by anti-DC-SIGN antibodies, but not by anti-CD4 (Figure 1E). Binding of HIV-1 gp120 to DC-SIGN expressed on DC or THP-DC-SIGN was also inhibited by the carbohydrate mannan or EGTA, consistent with previous findings [Curtis *et al.*, *Proc. 5 Natl. Acad. Sci. U.S.A.*, 89:8356-8360 (1992)] and with the observation that DC-SIGN is homologous to other members of the  $\text{Ca}^{2+}$  binding mannose-type lectins [Weis *et al.*, *Immunol. Rev.*, 163:19-34 (1998)]. Together, these results demonstrate that DC-SIGN is a specific dendritic cell surface receptor for the HIV-1 envelope glycoprotein.

10

*DC-SIGN is required for efficient HIV-1 infection in DC-T cell co-cultures:* Because DC-SIGN is exclusively expressed on DC and has high affinity for HIV-1 gp120, it appeared reasonable to assume that it could play an important role in HIV-1 infection of DC or of T cells that make contact with DC. Immature DC, which express low 15 levels of CD4 and CCR5 and abundant DC-SIGN (Figures 1C-1D), were pulsed with the R5 isolate HIV-1<sub>BA-L</sub> for 2 hours, washed and cultured in the presence of activated T cells (Figures 2A and 2B). To determine the contribution of each of these receptors in this assay system, the effects of antibodies against CD4 and DC-SIGN and of a combination of three CCR5-specific chemokines (RANTES, MIP-1 $\alpha$  and MIP-1 $\beta$ ) 20 were examined. Pre-incubation of the immature DC with antibodies against DC-SIGN prior to infection resulted in significant inhibition of HIV-1 replication (Figure 2A). Neither anti-CD4 nor the CCR5-specific chemokines inhibited on their own, although a combination of these did block infection of DC as efficiently as anti-DC-SIGN antibodies (Fig. 2A). Activated T cells challenged with the same viral 25 load exhibited a weaker infection than those cultured with virus-pulsed DC.

Since DC-SIGN binds to ICAM-3 on T cells, it is possible that antibodies against DC-SIGN could interfere with the DC-T cell interaction and thereby prevent HIV-1 transmission. To examine this possibility, antibodies against DC-SIGN were added 30 after exposure of DC to HIV-1, but prior to the addition of activated T cells. In this setting, only CCR5-specific chemokines and anti-CD4 antibody strongly inhibited

HIV-1 infection of T cells, while antibodies against DC-SIGN had no effect (Figure 2C). These results thus suggest that DC-SIGN has an important function in propagation of HIV-1 in DC-T cell co-cultures and that this function is related to the ability of DC-SIGN to bind to gp120 and not to its interaction with ICAM-3.

5

*DC-SIGN does not mediate HIV-1 entry:* To investigate whether DC-SIGN acts as a receptor that permits HIV-1 entry, similar to CD4 plus CCR5, HIV-1 entry into 293T cells that expressed either DC-SIGN (293T-DC-SIGN) or CD4 and CCR5 (293T-CD4-CCR5) was examined. Cells were pulsed overnight with HIV<sub>BAL</sub>, washed 10 the next day, and p24 levels were determined. There was no detectable p24 protein in the culture supernatants harvested from 293-DC-SIGN cells several days after the HIV-1 pulse, whereas the 293T-CD4-CCR5 cells were readily infected (Figure 3A).

To examine the possibility that DC-SIGN may work in conjunction with either CD4 or 15 CCR5 to permit viral entry, the studies were extended by using HIV-1 pseudotyped with the envelope glycoprotein of the R5 isolate HIV-1<sub>ADA</sub>. A replication-defective HIV-1 genome that encoded a luciferase reporter gene was employed which allows a quantitative measure of the levels of single-round infection (Figure 3B) [Deng *et al.*, *Nature*, 381(6584):661-666. Transiently transfected 293T cells expressing either 20 CCR5 (293T-CCR5), CD4 (293T-CD4), or both (293T-CD4-CCR5), in the presence or absence of DC-SIGN, were infected with the reporter virus, and luciferase levels were determined after two days. As observed with replicating virus, HIV-1 entry was not detected in 293T cells that expressed only DC-SIGN (Figure 3B). No infection was observed if DC-SIGN was expressed with either CD4 or CCR5, indicating that 25 DC-SIGN does not form a complex with these molecules to permit viral entry. In contrast, high luciferase activity was obtained after infection of 293T cells expressing both CD4 and CCR5, and expression of DC-SIGN did not contribute further to viral entry into these cells (Figure 3B). Therefore, DC-SIGN cannot substitute for CD4 or CCR5 in the process of HIV-1 entry.

30

*DC-SIGN captures HIV-1 and facilitates infection of HIV-1 permissive cells in trans:*  
Because DC-SIGN did not appear to mediate virus entry into target cells, it seemed possible that in a DC-T cell co-culture (Figure 2A) DC-SIGN might facilitate both capture of HIV-1 on DC, independent from CD4 and CCR5, and the subsequent

5 transmission of HIV-1 to the CD4/CCR5-positive T cells. To test this, THP-DC-SIGN transfectants, which do not express CD4 or CCR5 (Figure 1C) and which cannot be infected by HIV-1, were pulsed with single-round HIV-luciferase virus pseudotyped with the HIV-1<sub>ADA</sub> envelope glycoprotein. After washing to remove unbound virus, the cells were co-cultured with CD4/CCR5-expressing 293 T

10 cells, which are permissive for HIV-1 infection, or activated T lymphocytes. THP-DC-SIGN cells were able to capture the pseudotyped virus and transmit it to the target cells that expressed the receptors required for viral entry (Figure 4A). HIV-1 capture was completely DC-SIGN dependent, as antibodies against DC-SIGN inhibited HIV-1 infection (Figure 4A) and DC-SIGN-negative parental THP-1 cells

15 were unable to capture and transmit HIV-1 (Figures 4A and 4B). DC-SIGN-mediated infection of the target cells was not due to DC-SIGN binding to ICAM-3, since 293T cells are ICAM-3-negative. These findings indicate that DC-SIGN expressed at the surface of heterologous cells can capture HIV-1 in a form that retains its capacity to subsequently infect HIV-1-permissive cells. The ability of DC-SIGN to capture and

20 transmit HIV-1 was also observed with HIV-luciferase viruses pseudotyped with envelope glycoproteins from an additional five CCR5-tropic isolates, including three primary isolates (Figure 4B) and from with HIV-luciferase viruses pseudotyped with envelope glycoproteins from CXCR4-tropic isolates .

25 Analysis of luciferase activity in both adherent (293T-CD4-CCR5) and non-adherent (THP-DC-SIGN) cell fractions after 2 days of co-culture demonstrated that productive HIV-1 infection occurred only in the HIV-1 permissive 293T-CD4-CCR5 cells. Similarly, by using a pseudotyped HIV-1 vector with the green fluorescent protein gene in place of Nef (HIV-eGFP), it was demonstrated that cells expressing

30 CD4/CCR5 and not those expressing DC-SIGN were infected in co-cultures. Thus, after co-culture of virus-pulsed THP-DC-SIGN cells with T cells, only the CD3<sup>+</sup> T

cells expressed virus-encoded GFP (Figure 4C).

Sexual transmission of HIV-1 is likely to require a means for small amounts of virus to gain access to cells that are permissive for viral replication. This may be achieved 5 because of the ability of virus to interact with DC, which can capture HIV-1 and present it to the permissive cells. To mimic *in-vivo* conditions in which HIV-1 levels are likely to be limiting, THP-1 transfectants were challenged with low titers of pseudotyped HIV-1 and subsequently co-cultured these cells with HIV-1 permissive cells, without washing away unbound virus (Figure 5A). As expected, neither 10 293T-CD4-CCR5 cells nor activated T cells were efficiently infected with the low titers of pseudotyped HIV-1 (Figure 5A). Strikingly, when these permissive cells were challenged with an identical amount of HIV-1 in the presence of THP-DC-SIGN, but not of the parental THP-1 cells, efficient HIV-1 infection was observed *in trans* (Figure 5A). The enhancement of HIV-1 infection of 293-CD4-CCR5 by DC-SIGN 15 was also observed with HIV-luciferase viruses pseudotyped with five other R5 envelopes, including three from primary virus isolates (Figure 5B). These results indicate that DC-SIGN not only sequesters HIV-1, but also enhances CD4-CCR5 mediated HIV-1 entry by presentation *in trans* to the HIV-1 receptor complex. Antibodies against DC-SIGN completely inhibited infection (Figure 5A), 20 demonstrating that the efficient enhancement of HIV-1 entry into CD4/CCR5 positive cells is DC-SIGN dependent.

*DC present in mucosal tissues at sites of HIV-1 exposure express DC-SIGN and are CCR5-negative:* Demonstration that cells which express DC-SIGN can capture HIV-1 25 and efficiently transmit the virus to other cells in *trans* suggested that DC that express this C-type lectin have a key role in viral infection *in vivo*. To determine whether such cells are indeed present *in vivo*, immunohistochemical analyses of mucosal tissues were performed that are the sites of first exposure during sexual transmission of HIV-1 (Figures 6A-6C). DC-SIGN was expressed on DC-like cells with large and 30 very irregular morphology that were present in the mucosal tissues, such as rectum, cervix and uterus (Figures 6A-6C respectively), in regions beneath the stratified

squamous epithelium in the lamina propria. Analyses of serial sections stained for CD3, CD20, CD14 and CD68 confirmed that DC-SIGN expressing cells were distinct from T cells, B cells, monocytes and macrophages. Similarly, staining of lymph nodes and skin shows DC-restricted expression of DC-SIGN. The comparison of the 5 expression of DC-SIGN, CD4 and CCR5 on DC in the mucosa of the uterus and rectum was made, and it was found that in serial sections that the majority of DC-SIGN-positive DC in these tissues co-expressed CD4 but lacked CCR5 (Figures 6D-6F). This indicates that DC present at mucosal sites that have first contact with HIV-1 during sexual transmission, are not infected with HIV-1 through usage of 10 CD4/CCR5. This observation is consistent with the recent demonstration that DC at sites of mucosal infection of non-human primates do not become infected [Stahl-Hennig *et al.*, *Science*, 285(5431):1261-1265 (1999)].

*DC-SIGN-bound HIV-1 retains infectivity after long-term culture:* If HIV-1 gains 15 access to secondary lymphoid organs by way of binding to DC, then virus would have to retain infectivity during the transport from the mucosal tissues to the T cell zones in draining lymph nodes. To determine if virus bound to DC-SIGN retains its infectivity for a prolonged period of time, a time-course experiment was first conducted to determine the length of time that HIV-1 gp120 remains bound to DC-SIGN that was 20 expressed on transfected THP-1 cells. gp120-coated beads was observed to remain bound to DC-SIGN for more than 60 hours (Figure 7A). Next, the length of time during which HIV-1-pulsed THP-DC-SIGN cells could retain infectious virus was investigated. The DC-SIGN expressing transfectants were pulsed with pseudotyped HIV-1 for 4 hours and then washed extensively. The pulsed cells were subsequently 25 placed in culture and were removed at defined intervals and co-cultured with activated T cells (Figure 7B). Unexpectedly, after four days the HIV-1 pulsed cells were still able to efficiently infect target cells. In contrast, virus in the absence of DC-SIGN positive cells lost its infectivity after one day (*see also* Figure 12). These findings support the hypothesis that limiting numbers of HIV-1 particles, captured by mucosal 30 DC that express DC-SIGN and CD4 but not CCR5, retain infectivity during and after migration to regional lymphoid tissues. T cells, which express CD4 and CCR5, would

then be productively infected due to DC-SIGN-mediated enhanced *trans*-infectivity of the small numbers of HIV-1 particles (Figure 7C).

The results described above have general applicability to all HIV strains and T cell types. Thus, Figure 8 shows that DC-SIGN mediates capture of SIV, CCR5, CXR4, and dual tropic HIV. Viruses encoding the reporter gene luciferase were pseudotyped with envelopes from the CCR5 tropic strains JRFL, ADA, and JRCSF; the CXR4 tropic strains HxB2 and LAI; the dual tropic strain 89.6; and SIV 1A11. THP or THP-DCSIGN cells were pulsed with these viruses, washed, and then added to target cells. Luciferase activity was measured as an indicator of viral infection of targets (Figure 8). As is readily apparent, in all cases a striking increase in luciferase activity was observed when the HIV capture was performed in the presence of a facilitator cell that expressed DC-SIGN. The same result was observed with HIV pseudotyped with envelopes from primary viral strains (Figure 9).

15

Figure 10 shows the enhancement of CXR4-tropic HIV infection of activated T cells. THP, THP-DCSIGN cells, DC, or DC preincubated with anti-DCSIGN antibody, were incubated with HxB2 pseudotyped virus encoding the luciferase reporter gene, followed by addition of activated T cell targets. These results further confirm that the enhancement due to dendritic cells is DC-SIGN dependent even when the co-receptor, *i.e.*, the translocating promoter, is CXR4. The enhancement of CXR4-tropic HIV infection is also found for unactivated T cells, albeit to a lesser extent than in activated T cells. Indeed, there is an almost twenty-fold increase in luciferase activity related to HIV capture by naive cells performed in the presence of THP-SIGN cells relative to that performed in the presence of THP cells that do not express DC-SIGN. Figure 12 shows that binding to cells expressing DC-SIGN significantly extends the longevity of HxB2, a CXR4-tropic virus. In this case, whereas the infectivity of virus rapidly decreases after one day, in the absence of a cell expressing DC-SIGN, in the presence of a cell expressing DC-SIGN the infectivity of the virus reaches a peak at three days and remains significant at least until five days.

Discussion

A novel dendritic cell-specific adhesion receptor, DC-SIGN, has been identified that is identical to the high affinity HIV-1 gp120 binding C-type lectin cloned from a human placental cDNA library [Curtis *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, **89**:8356-8360 5 (1992)]. However, the present results indicate that contrary to the prior observation, DC-SIGN is specifically expressed in dendritic cells (DC). Furthermore, DC that express both DC-SIGN and CD4 preferentially use DC-SIGN to capture HIV-1 *via* its high affinity for HIV-1 gp120. DC-SIGN not only efficiently recruits HIV-1 but also facilitates HIV-1 infection of CD4<sup>+</sup> T cells by a novel *in trans* mechanism. These 10 findings indicate that HIV-1 utilizes a novel receptor strategy which has not been previously described in other viral systems, and suggest that the virus exploits multiple cell surface receptor systems to ensure that it can establish a productive infection in its host organism. DC localized in the skin and mucosal tissues such as the rectum, uterus, and cervix have been proposed to play a role in initial HIV-1 infection. 15

DC constitute a heterogeneous population of cells that are present in minute numbers in various tissues just beneath the dermis or mucosal layer, and form a first-line defense against viruses and other pathogens. DC have previously been shown to sequester HIV-1 and efficiently transmit the virus to CD4<sup>+</sup> T cells. This property of 20 DC, as disclosed herein, can be ascribed to the ability of HIV-1 to bind specifically to these cells through the interaction of gp120 with DC-SIGN. DC thus efficiently capture HIV-1 through a specific interaction that is independent from binding of virus to CD4 and CCR5. DC-SIGN cannot mediate HIV-1 entry, but rather functions as a unique HIV-1 *trans*-receptor facilitating HIV-1 infection of CD4/CCR5-positive T 25 cells (Figures 4 and 5). At low virus titer, CD4/CCR5-expressing cells are not detectably infected without the help of DC-SIGN *in trans* (Figure 5A). Conditions in which the number of HIV-1 particles is limiting are likely to resemble those found *in vivo*, and the results thus suggest that DC-SIGN may be required for viruses to be transmitted from mucosa to T cells that express CD4 and chemokine receptors. In 30 addition, the present results demonstrate that virus bound to DC-SIGN is remarkably stable, and can thus retain infectivity for the prolonged periods of time required for

DC to traffic via lymphatics from mucosa to regional lymph nodes (Figures 7A and 7B).

*Mechanism of DC-SIGN-mediated enhancement of HIV-1 infectivity:* The

5 mechanisms by which HIV-1 exploits the machinery of DC and the properties of DC-SIGN to achieve efficient infection of cells that are competent for viral replication remain unclear. The process through which DC-SIGN promotes efficient infection in *trans* of cells through their CD4/chemokine receptor complex is of particular interest. Binding of the viral envelope glycoprotein to DC-SIGN may induce a conformational  
10 change that enables a more efficient interaction with CD4 and/or the chemokine receptor. As multiple conformational transitions are required before the envelope glycoprotein initiates fusion with target membranes [Chan and Kim, *Cell*, 93(5):681-684 (1997)], the binding of DC-SIGN to gp120 may facilitate or stabilize one of these transitions. Anti-gp120 antibodies that increase infectivity of viral particles have been  
15 described [Lee *et al.*, *J. Virol.*, 71(8):6037-6043 (1997)], and it is likely that DC-SIGN has a similar effect upon binding to the envelope glycoprotein. Alternatively, binding of viral particles to DC-SIGN may focus or concentrate them at the surface of the DC, and could thus increase the probability that entry will occur after they bind to the receptor complex on target cells. In any case, it is clear that DC-SIGN enhances the  
20 infection of T cells since at low multiplicity of infection (MOI) T cells are not infected in the absence of DC-SIGN.

Whether a transient quaternary complex is formed between DC-SIGN, HIV-1 Env, CD4 and CCR5 remains to be determined. Elucidation of the crystal structure of a  
25 gp120-CD4 complex has revealed that most glycosylation sites within gp120 reside in a ridge that flanks the CD4 binding pocket [Kwong *et al.*, *Nature*, 393(6686), 648-659 (1998)]. Since mannans block the binding of gp120 to DC-SIGN, it is likely that this C-type lectin binds to one or more carbohydrate moieties in gp120. It remains  
30 possible, however, that the lectin domain of DC-SIGN interacts with the polypeptide backbone of gp120. Mutant forms of gp120 and soluble DC-SIGN will aid in the elucidation of the mechanism of enhanced infectivity in *trans*.

DC-SIGN, as disclosed herein, binds to ICAM-3, which is expressed constitutively on the surface of T lymphocytes. Enhancement of target cell infectivity by DC-SIGN-bound HIV-1 is not dependent on the presence of ICAM-3 on target cells. However, enhancement of infectivity was consistently better when target cells were T 5 cells rather than 293-CD4-CCR5 cells. It remains possible that the efficiency of viral transmission from carrier DC to target T cells may also be enhanced by specific adhesive interactions other than the DC-SIGN-ICAM 3 interaction, such as LFA-1-ICAM-1 which predominates the adhesion between DC and activated T cells. Therefore, antibodies raised against DC-SIGN do not inhibit the DC-T cell 10 transmission of HIV-1 post-infection (Figure 2C).

*Role of DC in HIV infection in vivo:* The only HIV-1 receptors previously known to have a role in HIV-1 entry were CD4 and a subset of the G-protein coupled chemokine receptors, such as CCR5 and CXCR4. CCR5 functions as the major 15 receptor for strains of virus previously classified as "macrophage-tropic", and only those strains that can utilize this chemokine receptor can be efficiently transmitted between individuals [Littman, *Cell*, 93:677-80 (1998)]. Other gp120 binding receptors had been previously identified, including DC-SIGN and galactosyl ceramide [Harouse *et al.*, *Science*, 253(5017):320-323 (1991)], but these had not been shown to 20 be involved in viral entry. The present disclosure shows that DC-SIGN not only binds HIV-1, but also sequesters HIV-1 and thereby catalyzes its entry into cells that express CD4 and a chemokine receptor(s). The present results and the pattern of expression of the different receptors in mucosal tissues are consistent with DC-SIGN having a key function in the early stages of viral infection. Remarkably, the immunohistochemical 25 analyses, disclosed herein, clearly demonstrate that CCR5 is not expressed in the lamina propria of HIV-1 related mucosal tissue (Figure 6), whereas DC-SIGN is abundantly expressed. This observation confirms and extends the findings of Hladik *et al.*, who showed that DC present in the genital tract also lack CCR5 [Hladik *et al.*, *J. Virol.*, 73(7):5833-42], and the present results indicate that HIV-1 cannot infect DC 30 present at mucosal sites.

DC-SIGN therefore plays a crucial role in initial HIV-1 exposure by mediating viral binding to DC present in mucosal tissues, rather than infection of these cells. The high level of expression of DC-SIGN on immature DC and its high affinity for gp120, which exceeds that of CD4 [Curtis *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, **89**:8356-8360 (1992)], indicate that DC-SIGN is endowed with the ability to efficiently capture HIV-1, even when the virus is present in minute amounts. HIV-1 may subsequently exploit the migratory capacity of the DC to gain access to the T cell compartment in lymphoid tissues. DC must be activated to commence their migration, and it is hence possible that multimerization of DC-SIGN on the cell surface of DC by interaction with the multivalent virus particles may initiate this process. Interestingly, the time course of HIV-1 stability when associated with DC-SIGN shows that DC-SIGN is able to capture and bind to HIV-1 for more than 4 days, after which the virus can still infect permissive cells. This long-term preservation of HIV-1 in an infectious state would appear to allow sufficient time for it to be transported by DC trafficking from mucosal surfaces to lymphoid compartments, where virus can be transmitted (Fig. 7C) [see also Steinman *et al.*, *Immunol. Rev.*, **156**:25-37 (1997)]. Several groups have reported that DC can migrate from the periphery to draining lymph nodes within two days after antigen exposure or HIV-1 challenge [Barratt-Boyes *et al.*, *J. Immunol.*, **158**(10):4543-7 (1997); Stahl-Hennig *et al.*, *Science*, **285**(5431):1261-5 (1999)]. Viral particles have also been reported within endocytic vesicles of DC. This observation suggests that DC-SIGN-bound HIV-1 may be internalized and protected during the time required for the cells to complete their journey to the regional lymph nodes.

The present results indicate that after HIV-1 has been ferried by DC to the lymphoid compartment, DC-SIGN presents the bound viral particles to the CD4/CCR5 complex present on T cells and greatly enhances their entry into these cells (see schematic in Figure 7C). Monoclonal antibodies directed against DC-SIGN have been shown to block productive infection occurring in the T cell co-cultures with CD4/CCR5-positive monocyte-derived DC. Therefore, even in the presence of obligatory HIV-1 receptors present in *cis* on target cells, DC-SIGN functions as a *trans*-receptor for HIV-1 infection of T cells and is critical in the primary co-cultures.

This is the first example of such a receptor that works primarily *in trans*. Interestingly, CD4 can also facilitate HIV-1 infection of CD4-negative cells that express CCR5 by a *trans*-receptor mechanism, although it remains unclear whether this is an important route of infection *in vivo* [Speck *et al.*, *Curr. Biol.*, 9(10):547-50 5 (1999)]. In that case, interaction of envelope glycoprotein with CD4 results in a conformational change that permits binding of the virus to CCR5 on CD4-negative cells. Together with the results presented here, these studies indicate that HIV-1 can use receptors *in trans* to facilitate infection of cells which otherwise may be difficult to infect either because of lack of proper receptors or because of their anatomical 10 distribution relative to the sites of HIV-1 exposure. The discovery of the role of DC-SIGN in HIV-1 infection may have significant implications for understanding the mechanism of HIV-1 transmission and for developing strategies to prevent or block viral infection.

15

EXAMPLE 2UPTAKE OF HIV IN AN ENDOSOMAL COMPARTMENT

After pulsing THP-1 cells transfected with DC-SIGN (THP-SIGN cells) with HIV, the virus internalizes within about 20 minutes, and is thereby protected from treatment 20 with external proteases and/or subsequent washing steps. HIV obtained from these cells can then infect target T cells. In direct contrast, if protease treatment is carried out at t=0, there is no protection and no subsequent infection of target cells. These results indicate that HIV is taken up by endocytosis and subsequently released from the cells in infectious form. Similar results were obtained when primary dendritic 25 cells were used (Fig. 13). A time course of DC-SIGN-mediated internalization of gp120, and subsequent loss of gp120 trypsin sensitivity is shown in Figure 14B.

Uptake and subsequent release of HIV particles from THP-SIGN cells have kinetics similar to those of transferrin, which traffics through recycling endosomes (Figures 30 15A-15B). In addition, HIV particles are observed by confocal microscopy in endosomal vesicles distinct from LAMP+ lysosomes, which is consistent with DC-

SIGN-mediated uptake of HIV into recycling endosomes (Figures 16A-16B).

Therefore, THP-SIGN cells can capture HIV and increase its infectivity in trans. In contrast, THP-CD4+ cells, which can also capture HIV, cannot enhance infectivity in 5 trans. Because it is known that CD4 traffics to late endosomes and lysosomes, binding of HIV to this receptor would result in its uptake and degradation.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those 10 described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular 15 weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications are cited herein, the disclosures of which are all incorporated by references in their entireties.

WHAT IS CLAIMED IS:

1. An antibody that is specific for an antigenic fragment of gp120; wherein said antigenic fragment is obtained from a portion of gp120 selected from the group consisting of the portion of gp120 that binds to DC-SIGN and a portion of gp120 that is that is exposed upon gp120 binding of DC-SIGN due to the concomitant conformational change; wherein said antibody inhibits the trans-enhancement of HIV entry into a T cell or macrophage facilitated by dendritic cells.
- 10 2. The antibody of Claim 1 that is a monoclonal antibody.
3. An immortal cell line that produces the monoclonal antibody according to Claim 2.
- 15 4. An antibody that is specific for the DC-SIGN-gp120 binding complex; wherein said antibody inhibits the ability of dendritic cells to facilitate the trans-enhancement of HIV entry into a T cell or macrophage.
5. A soluble form of human DC-SIGN.
- 20 6. A pharmaceutical composition comprising the soluble form of human DC-SIGN of Claim 5 with a pharmaceutically acceptable carrier.
7. An immunogenic composition comprising an adjuvant and an antigenic fragment of gp120; wherein said antigenic fragment is obtained from a portion of gp120 selected from the group consisting of the portion of gp120 that binds to DC-SIGN and a portion of gp120 that is that is exposed upon gp120 binding of DC-SIGN due to the concomitant conformational change.
- 25 30 8. An immunogenic composition comprising an adjuvant and a DC-SIGN-gp120 binding complex.

9. A mammalian cell that is transfected with a vector encoding human DC-SIGN; wherein said cell can facilitate the trans-enhancement of HIV entry into a T cell or macrophage.

5 10. The mammalian cell of Claim 9 that is not a dendritic cell.

11. The mammalian cell of Claim 9 wherein said cell is attached to a solid support matrix.

10 12. A method of filtering a biological fluid to remove a virus expressing an HIV envelope glycoprotein that binds DC-SIGN comprising passing the biological fluid through the cell of Claim 11.

13. The mammalian cell of Claim 9 that is a human cell.

15

14. A transgenic non-human mammal comprising DNA constructs encoding human CD4, a human translocation promoting agent, and human DC-SIGN, wherein said transgenic non-human mammal is capable of mucosal uptake of HIV, transport of the HIV to lymphatic organs and infection of a target T cell and/or macrophage by HIV; and wherein said infection is greatly enhanced relative to a transgenic non-human mammal that does not contain a DNA construct encoding DC-SIGN.

20

15. The transgenic non-human mammal of Claim 14 further comprising a DNA construct encoding human cyclin T.

25

16. The transgenic non-human mammal of Claim 15 wherein the human translocation promoting agent is selected from the group consisting of CCR5, CXCR4, CCR2b, CCR3, Bob and Bonzo.

30

17. The transgenic non-human mammal of Claim 14 which is a mouse.

18. A method of treating or preventing HIV infection by inhibiting the trans-enhancement of HIV entry into a T cell or macrophage facilitated by dendritic cells comprising administering a humanized form of the antibody of Claim 1.

5 19. A method of identifying a compound that interferes with the trans-enhancement of HIV entry into a cell comprising:

(a) contacting a first cell with a vector in the presence of a test compound, wherein the vector comprises a viral envelope protein that binds DC-SIGN, wherein the first cell expresses DC-SIGN, and wherein a DC-SIGN-viral envelope protein

10 complex forms between the first cell and the vector in the absence of the test compound;

(b) removing unbound vector and test compound from the first cell;

(c) contacting a second cell with the first cell; wherein the second cell is susceptible to entry of vectors comprising the viral envelope protein; and

15 (d) determining the amount of vector that has entered the second cell; wherein a test compound is identified as a compound that interferes with the trans-enhancement of HIV entry into a cell when the amount of vector entry is less when the test compound is present in step (b) than when it is absent in step (b).

20 20. The method of Claim 19 wherein said removing of step (b) comprises washing the unbound vector and the test compound away from first cell.

21. The method of Claim 19 wherein the second cell is a T cell or macrophage.

25 22. The method of Claim 19 wherein the second cell expresses CD4 and a translocation promoting agent selected from the group consisting of CCR5, CXCR4, CCR2b, CCR3, Bonzo, and BOB.

23. The method of Claim 22 wherein the translocation promoting agent is CCR5

30 and the viral envelope protein is JRFL.

24. The method of Claim 19 wherein the vector contains a marker protein and step (c) is performed by detecting the amount of marker protein expressed in the cell.

25. The method of Claim 24 wherein the marker protein is selected from the group 5 consisting of luciferase and green fluorescent protein.

26. A compound identified by the method of Claim 19.

27. An assay for identifying an agent for use in the treatment or prevention of HIV 10 infection using the transgenic non-human mammal of Claim 16, comprising:

(a) administering a test compound to the transgenic non-human mammal;  
(b) infecting the transgenic non-human mammal with a virus having an HIV envelope glycoprotein; and  
(c) measuring the ability of the transgenic non-human mammal to resist 15 said infection; wherein a test compound is identified as an agent for use in the treatment or prevention of HIV infection when the measured ability of the transgenic mammal to resist said infection is statistically greater in the presence of said test compound than in the absence of said test compound.

20 28. A compound identified by the method of Claim 27.

29. A method of identifying a compound that interferes with the trans-enhancement of HIV entry into a cell comprising:

(a) contacting a first cell with a vector and a second cell in the presence of 25 a test compound, wherein the vector comprises a viral envelope protein that binds DC-SIGN, wherein the first cell expresses DC-SIGN, wherein a DC-SIGN-viral envelope protein complex forms between the first cell and the vector in the absence of the test compound; and wherein the second cell is susceptible to entry of vectors comprising the viral envelope protein; and  
(b) determining the amount of vector that has entered the second cell; 30 wherein a test compound is identified as a compound that interferes with the trans-

enhancement of HIV entry into a cell when the amount of vector entry is less in the presence of the test compound than in its absence.

30. The method of Claim 29 wherein the second cell is a T cell or macrophage.

5

31. The method of Claim 29 wherein the second cell expresses CD4 and a translocation promoting agent selected from the group consisting of CCR5, CXCR4, CCR2b, CCR3, Bonzo, and BOB.

10 32. The method of Claim 31 wherein the translocation promoting agent is CCR5 and the viral envelope protein is JRFL.

33. The method of Claim 29 wherein the vector contains a marker protein and step (b) is performed by detecting the amount of marker protein expressed in the cell.

15

34. The method of Claim 33 wherein the marker protein is selected from the group consisting of luciferase and green fluorescent protein.

35. A compound identified by the method of Claim 29.

20

36. A method of identifying a compound that interferes with HIV entry into a cell that expresses DC-SIGN comprising:

25 (a) contacting a cell that expresses DC-SIGN with a labeled anti-DC-SIGN antibody under conditions in which the anti-DC-SIGN antibody does not enter the cell; wherein the DC-SIGN is present on the surface of the cell and the anti-DC-SIGN antibody and the surface of the cell form a binding complex;

30 (b) inducing the antibody to enter the cell in the presence and absence of a compound; wherein in the absence of the compound the antibody enters the cell;

(c) removing the antibody that remains bound on the surface of the cell;

30 and

(d) determining the amount of labeled anti-DC-SIGN antibody that is in the

cell; wherein when the amount of labeled anti-DC-SIGN antibody in the cell is less in the presence of the compound relative to in its absence the compound is identified as a compound that interferes with HIV entry into a cell.

5 37. The method of Claim 36 wherein the labeled anti-DC-SIGN is fluorescent.

38. The method of Claim 36 wherein the labeled anti-DC-SIGN is radioactive.

39. The method of Claim 36 wherein the cell is a THP-1 cell that is transfected  
10 with DC-SIGN.

40 A compound identified by the method of Claim 36.

41. A method of identifying a compound that interferes with HIV entry into a cell  
15 that expresses DC-SIGN comprising:

(a) contacting a cell that expresses DC-SIGN with a labeled HIV particle under conditions in which the HIV particle does not enter the cell; wherein the DC-SIGN is present on the surface of the cell and the HIV particle and the surface of the cell form a binding complex;

20 (b) inducing the HIV particle to enter the cell in the presence and absence of a compound; wherein in the absence of the compound the HIV particle enters the cell;

(c) removing the HIV particle that remains bound on the surface of the cell; and

25 (d) determining the amount of labeled HIV particle that is in the cell; wherein when the amount of labeled HIV particle in the cell is less in the presence of the compound relative to in its absence the compound is identified as a compound that interferes with HIV entry into a cell.

30 42. The method of Claim 41 wherein the labeled HIV particle is fluorescent.

43. The method of Claim 42 wherein said determining is performed by FACS.
44. The method of Claim 41 wherein the labeled HIV particle is radioactive.
- 5 45. The method of Claim 41 wherein the cell is a THP-1 cell that is transfected with DC-SIGN.
46. A compound identified by the method of Claim 41.

1 / 20

FIG. 1A





FIG. 1B



2 / 20

FIG. 1C FIG. 1D





FIG. 1E



3 / 20

FIG. 2A




FIG. 2B





FIG. 2C



4 / 20

FIG. 3A






FIG. 3B



SUBSTITUTE SHEET (RULE 26)

5 / 20

FIG. 4A



6 / 20

FIG. 4B






FIG. 4C



SUBSTITUTE SHEET (RULE 26)


2 / 20

FIG. 5A



8 / 20

FIG. 5B



9 / 20

FIG. 6A



FIG. 6B



FIG. 6C




FIG. 6D

DC-SIGN




FIG. 6E

CD4



FIG. 6F

CCR5





FIG. 6G

FIG. 6H

FIG. 6I

FIG. 7A




FIG. 7B






FIG. 7C



11 / 20

FIG. 8


## DC-SIGN MEDIATED HIV-1 CAPTURE



SUBSTITUTE SHEET (RULE 26)

12 / 20


FIG. 9



SUBSTITUTE SHEET (RULE 26)


13 / 20

FIG. 10



14 / 20

FIG. 11  
181199  
NAIVE T CELLS INFECTION WITH HXB2 VIRUS



15 / 20

FIG. 12




FIG. 13A






FIG. 13B



17 / 20

FIG. 14A



SUBSTITUTE SHEET (RULE 26)

18 / 20

FIG. 14B




FIG. 15A





FIG. 15B




2 0 / 2 0

FIG. 16A



FIG. 16B



<110> Littman, Dan R.  
 Kwon, Douglas S.  
 van Kooyk, Yvette  
 Geijtenbeck, Theo

<120> METHODS OF USING A FACILITATOR OF RETROVIRAL ENTRY INTO CELLS

<130> 1049-1-017 PCT

<140> UNASSIGNED  
 <141> 2001-02-28

<150> 09/517,605  
 <151> 2000-03-02

<160> 17

<170> PatentIn Ver. 2.0

<210> 1  
 <211> 1312  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (42)..(1253)

<400> 1  
 ctaaaggcagg agttctggac actgggggag agtggggtgà c atg agt gac tcc aag 56  
 Met Ser Asp Ser Lys  
 1 5

gaa cca aga ctg cag cag ctg ggc ctc ctg gag gag gaa cag ctg aga 104  
 Glu Pro Arg Leu Gln Gln Leu Gly Leu Leu Glu Glu Gln Leu Arg  
 10 15 20

ggc ctt gga ttc cga cag act cga gga tac aag agc tta gca ggg tgt 152  
 Gly Leu Gly Phe Arg Gln Thr Arg Gly Tyr Lys Ser Leu Ala Gly Cys  
 25 30 35

ctt ggc cat ggt ccc ctg gtg ctg caa ctc ctc tcc ttc acg ctc ttg 200  
 Leu Gly His Gly Pro Leu Val Leu Gln Leu Leu Ser Phe Thr Leu Leu  
 40 45 50

gct ggg ctc ctt gtc caa gtg tcc aag gtc ccc agc tcc ata agt cag 248  
 Ala Gly Leu Leu Val Gln Val Ser Lys Val Pro Ser Ser Ile Ser Gln  
 55 60 65

gaa caa tcc agg caa gac gcg atc tac cag aac ctg acc cag ctt aaa 296  
 Glu Gln Ser Arg Gln Asp Ala Ile Tyr Gln Asn Leu Thr Gln Leu Lys  
 70 75 80 85

gct gca gtg ggt gag ctc tca gag aaa tcc aag ctg cag gag atc tac 344  
 Ala Ala Val Gly Glu Leu Ser Glu Lys Ser Lys Leu Gln Glu Ile Tyr  
 90 95 100

cag gag ctg acc cag ctg aag gct gca gtg ggt gag ctt cca gag aaa 392  
 Gln Glu Leu Thr Gln Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys  
 105 110 115

tct aag ctg cag gag atc tac cag gag ctg acc cgg ctg aag gct gca 440

Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala  
 120 125 130

gtg ggt gag ctt cca gag aaa tct aag ctg cag gag atc tac cag gag 488  
 Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu  
 135 140 145

ctg acc tgg ctg aag gct gca gtg ggt gag ctt cca gag aaa tct aag 536  
 Leu Thr Trp Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys  
 150 155 160 165

atg cag gag atc tac cag gag ctg act cgg ctg aag gct gca gtg ggt 584  
 Met Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly  
 170 175 180

gag ctt cca gag aaa tct aag cag cag gag atc tac cag gag ctg acc 632  
 Glu Leu Pro Glu Lys Ser Lys Gln Gln Glu Ile Tyr Gln Glu Leu Thr  
 185 190 195

cggtg aag gct gca gtg ggt gag ctt cca gag aaa tct aag cag cag 680  
 Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Gln Gln  
 200 205 210

gag atc tac cag gag ctg acc cgg ctg aag gct gca gtg ggt gag ctt 728  
 Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly Glu Leu  
 215 220 225

cca gag aaa tct aag cag cag gag atc tac cag gag ctg acc cag ctg 776  
 Pro Glu Lys Ser Lys Gln Gln Glu Ile Tyr Gln Glu Leu Thr Gln Leu  
 230 235 240 245

aag gct gca gtg gaa cgc ctg tgc cac ccc tgt ccc tgg gaa tgg aca 824  
 Lys Ala Ala Val Glu Arg Leu Cys His Pro Cys Pro Trp Glu Trp Thr  
 250 255 260

ttc ttc caa gga aac tgt tac ttc atg tct aac tcc cag cgg aac tgg 872  
 Phe Phe Gln Gly Asn Cys Tyr Phe Met Ser Asn Ser Gln Arg Asn Trp  
 265 270 275

cac gac tcc atc acc gcc tgc aaa gaa gtg ggg gcc cag ctc gtc gta 920  
 His Asp Ser Ile Thr Ala Cys Lys Glu Val Gly Ala Gln Leu Val Val  
 280 285 290

atc aaa agt gct gag gag cag aac ttc cta cag ctg cag tct tcc aga 968  
 Ile Lys Ser Ala Glu Glu Gln Asn Phe Leu Gln Leu Gln Ser Ser Arg  
 295 300 305

agt aac cgc ttc acc tgg atg gga ctt tca gat cta aat cag gaa ggc 1016  
 Ser Asn Arg Phe Thr Trp Met Gly Leu Ser Asp Leu Asn Gln Glu Gly  
 310 315 320 325

acg tgg caa tgg gtg gac ggc tca cct ctg ttg ccc agc ttc aag cag 1064  
 Thr Trp Gln Trp Val Asp Gly Ser Pro Leu Leu Pro Ser Phe Lys Gln  
 330 335 340

tat tgg aac aga gga gag ccc aac aac gtt ggg gag gaa gac tgc gcg 1112  
 Tyr Trp Asn Arg Gly Glu Pro Asn Asn Val Gly Glu Glu Asp Cys Ala  
 345 350 355

gaa ttt agt ggc aat ggc tgg aac gac gac aaa tgt aat ctt gcc aaa 1160  
 Glu Phe Ser Gly Asn Gly Trp Asn Asp Asp Lys Cys Asn Leu Ala Lys  
 360 365 370

ttc tgg atc tgc aaa aag tcc gca gcc tcc tgc tcc agg gat gaa gaa 1208

Phe Trp Ile Cys Lys Lys Ser Ala Ala Ser Cys Ser Arg Asp Glu Glu  
 375 380 385  
 cag ttt ctt tct cca gcc cct gcc acc cca aac ccc cct cct gcg 1253  
 Gln Phe Leu Ser Pro Ala Pro Ala Thr Pro Asn Pro Pro Pro Ala  
 390 395 400  
 tagcagaact tcacccctt ttaagctaca gttccttctc tccatccttc gaccttag 1312

<210> 2  
 <211> 404  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Met Ser Asp Ser Lys Glu Pro Arg Leu Gln Gln Leu Gly Leu Leu Glu  
 1 5 10 15

Glu Glu Gln Leu Arg Gly Leu Gly Phe Arg Gln Thr Arg Gly Tyr Lys  
 20 25 30

Ser Leu Ala Gly Cys Leu Gly His Gly Pro Leu Val Leu Gln Leu Leu  
 35 40 45

Ser Phe Thr Leu Leu Ala Gly Leu Leu Val Gln Val Ser Lys Val Pro  
 50 55 60

Ser Ser Ile Ser Gln Glu Gln Ser Arg Gln Asp Ala Ile Tyr Gln Asn  
 65 70 75 80

Leu Thr Gln Leu Lys Ala Ala Val Gly Glu Leu Ser Glu Lys Ser Lys  
 85 90 95

Leu Gln Glu Ile Tyr Gln Glu Leu Thr Gln Leu Lys Ala Ala Val Gly  
 100 105 110

Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr  
 115 120 125

Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln  
 130 135 140

Glu Ile Tyr Gln Glu Leu Thr Trp Leu Lys Ala Ala Val Gly Glu Leu  
 145 150 155 160

Pro Glu Lys Ser Lys Met Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu  
 165 170 175

Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Gln Gln Glu Ile  
 180 185 190

Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu  
 195 200 205

Lys Ser Lys Gln Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala  
 210 215 220

Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Gln Gln Glu Ile Tyr Gln  
 225 230 235 240

Glu Leu Thr Gln Leu Lys Ala Ala Val Glu Arg Leu Cys His Pro Cys  
 245 250 255

Pro Trp Glu Trp Thr Phe Phe Gln Gly Asn Cys Tyr Phe Met Ser Asn  
 260 265 270  
 Ser Gln Arg Asn Trp His Asp Ser Ile Thr Ala Cys Lys Glu Val Gly  
 275 280 285  
 Ala Gln Leu Val Val Ile Lys Ser Ala Glu Glu Gln Asn Phe Leu Gln  
 290 295 300  
 Leu Gln Ser Ser Arg Ser Asn Arg Phe Thr Trp Met Gly Leu Ser Asp  
 305 310 315 320  
 Leu Asn Gln Glu Gly Thr Trp Gln Trp Val Asp Gly Ser Pro Leu Leu  
 325 330 335  
 Pro Ser Phe Lys Gln Tyr Trp Asn Arg Gly Glu Pro Asn Asn Val Gly  
 340 345 350  
 Glu Glu Asp Cys Ala Glu Phe Ser Gly Asn Gly Trp Asn Asp Asp Lys  
 355 360 365  
 Cys Asn Leu Ala Lys Phe Trp Ile Cys Lys Ser Ala Ala Ser Cys  
 370 375 380  
 Ser Arg Asp Glu Glu Gln Phe Leu Ser Pro Ala Pro Ala Thr Pro Asn  
 385 390 395 400  
 Pro Pro Pro Ala

<210> 3  
 <211> 458  
 <212> PRT  
 <213> Homo sapiens

<400> 3  
 Met Asn Arg Gly Val Pro Phe Arg His Leu Leu Leu Val Leu Gln Leu  
 1 5 10 15  
 Ala Leu Leu Pro Ala Ala Thr Gln Gly Lys Lys Val Val Leu Gly Lys  
 20 25 30  
 Lys Gly Asp Thr Val Glu Leu Thr Cys Thr Ala Ser Gln Lys Lys Ser  
 35 40 45  
 Ile Gln Phe His Trp Lys Asn Ser Asn Gln Ile Lys Ile Leu Gly Asn  
 50 55 60  
 Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala  
 65 70 75 80  
 Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly Asn Phe Pro Leu Ile Ile  
 85 90 95  
 Lys Asn Leu Lys Ile Glu Asp Ser Asp Thr Tyr Ile Cys Glu Val Glu  
 100 105 110  
 Asp Gln Lys Glu Glu Val Gln Leu Leu Val Phe Gly Leu Thr Ala Asn  
 115 120 125  
 Ser Asp Thr His Leu Leu Gln Gly Gln Ser Leu Thr Leu Thr Leu Glu  
 130 135 140

Ser Pro Pro Gly Ser Ser Pro Ser Val Gln Cys Arg Ser Pro Arg Gly  
 145 150 155 160  
 Lys Asn Ile Gln Gly Gly Lys Thr Leu Ser Val Ser Gln Leu Glu Leu  
 165 170 175  
 Gln Asp Ser Gly Thr Trp Thr Cys Thr Val Leu Gln Asn Gln Lys Lys  
 180 185 190  
 Val Glu Phe Lys Ile Asp Ile Val Val Leu Ala Phe Gln Lys Ala Ser  
 195 200 205  
 Ser Ile Val Tyr Lys Lys Glu Gly Glu Gln Val Glu Phe Ser Phe Pro  
 210 215 220  
 Leu Ala Phe Thr Val Glu Lys Leu Thr Gly Ser Gly Glu Leu Trp Trp  
 225 230 235 240  
 Gln Ala Glu Arg Ala Ser Ser Ser Lys Ser Trp Ile Thr Phe Asp Leu  
 245 250 255  
 Lys Asn Lys Glu Val Ser Val Lys Trp Val Thr Gln Asp Pro Lys Leu  
 260 265 270  
 Gln Met Gly Lys Lys Leu Pro Leu His Leu Thr Leu Pro Gln Ala Leu  
 275 280 285  
 Pro Gln Tyr Ala Gly Ser Gly Asn Leu Thr Leu Ala Leu Glu Ala Lys  
 290 295 300  
 Thr Gly Lys Leu His Gln Glu Val Asn Leu Val Val Met Arg Ala Thr  
 305 310 315 320  
 Gln Leu Gln Lys Asn Leu Thr Cys Glu Val Trp Gly Pro Thr Ser Pro  
 325 330 335  
 Lys Leu Met Leu Ser Leu Lys Leu Glu Asn Lys Glu Ala Lys Val Ser  
 340 345 350  
 Lys Arg Glu Lys Ala Val Trp Val Leu Asn Pro Glu Ala Gly Met Trp  
 355 360 365  
 Gln Cys Leu Leu Ser Asp Ser Gly Gln Val Leu Leu Glu Ser Asn Ile  
 370 375 380  
 Lys Val Leu Pro Thr Trp Ser Thr Pro Val Gln Pro Met Ala Leu Ile  
 385 390 395 400  
 Val Leu Gly Gly Val Ala Gly Leu Leu Phe Ile Gly Leu Gly Ile  
 405 410 415  
 Phe Phe Cys Val Arg Cys Arg His Arg Arg Arg Gln Ala Glu Arg Met  
 420 425 430  
 Ser Gln Ile Lys Arg Leu Leu Ser Glu Lys Lys Thr Cys Gln Cys Pro  
 435 440 445  
 His Arg Phe Gln Lys Thr Cys Ser Pro Ile  
 450 455

<210> 4  
 <211> 352  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

Met Glu Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu Met  
 1 . . . . . 5 . . . . . 10 . . . . . 15 . . . . .

Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys Phe Arg Glu Glu  
 20 . . . . . 25 . . . . . 30 . . .

Asn Ala Asn Phe Asn Lys Ile Phe Leu Pro Thr Ile Tyr Ser Ile Ile  
 35 . . . . . 40 . . . . . 45 . . .

Phe Leu Thr Gly Ile Val Gly Asn Gly Leu Val Ile Leu Val Met Gly  
 50 . . . . . 55 . . . . . 60 . . .

Tyr Gln Lys Lys Leu Arg Ser Met Thr Asp Lys Tyr Arg Leu His Leu  
 65 . . . . . 70 . . . . . 75 . . . . . 80 . . .

Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro Phe Trp Ala Val  
 85 . . . . . 90 . . . . . 95 . . .

Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn Phe Leu Cys Lys Ala Val  
 100 . . . . . 105 . . . . . 110 . . .

His Val Ile Tyr Thr Val Asn Leu Tyr Ser Ser Val Leu Ile Leu Ala  
 115 . . . . . 120 . . . . . 125 . . .

Phe Ile Ser Leu Asp Arg Tyr Leu Ala Ile Val His Ala Thr Asn Ser  
 130 . . . . . 135 . . . . . 140 . . .

Gln Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val Tyr Val Gly Val  
 145 . . . . . 150 . . . . . 155 . . . . . 160 . . .

Trp Ile Pro Ala Leu Leu Leu Thr Ile Pro Asp Phe Ile Phe Ala Asn  
 165 . . . . . 170 . . . . . 175 . . .

Val Ser Glu Ala Asp Asp Arg Tyr Ile Cys Asp Arg Phe Tyr Pro Asn  
 180 . . . . . 185 . . . . . 190 . . .

Asp Leu Trp Val Val Val Phe Gln Phe Gln His Ile Met Val Gly Leu  
 195 . . . . . 200 . . . . . 205 . . .

Ile Leu Pro Gly Ile Val Ile Leu Ser Cys Tyr Cys Ile Ile Ile Ser  
 210 . . . . . 215 . . . . . 220 . . .

Lys Leu Ser His Ser Lys Gly His Gln Lys Arg Lys Ala Leu Lys Thr  
 225 . . . . . 230 . . . . . 235 . . . . . 240 . . .

Thr Val Ile Leu Ile Leu Ala Phe Phe Ala Cys Trp Leu Pro Tyr Tyr  
 245 . . . . . 250 . . . . . 255 . . .

Ile Gly Ile Ser Ile Asp Ser Phe Ile Leu Leu Glu Ile Ile Lys Gln  
 260 . . . . . 265 . . . . . 270 . . .

Gly Cys Glu Phe Gln Asn Thr Val His Lys Trp Ile Ser Ile Thr Glu  
 275 . . . . . 280 . . . . . 285 . . .

Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile Leu Tyr Ala Phe  
 290 . . . . . 295 . . . . . 300 . . .

Leu Gly Ala Lys Phe Lys Thr Ser Ala Gln His Ala Leu Thr Ser Val  
 305 . . . . . 310 . . . . . 315 . . . . . 320 . . .

Ser Arg Gly Ser Ser Leu Lys Ile Leu Ser Lys Gly Lys Arg Gly Gly

325

330

335

His Ser Ser Val Ser Thr Glu Ser Glu Ser Ser Ser Phe His Ser Ser  
 340 345 350

<210> 5  
 <211> 352  
 <212> PRT  
 <213> Homo sapiens

<400> 5  
 Met Asp Tyr Gln Val Ser Ser Pro Thr Tyr Asp Ile Asp Tyr Asp Thr  
 1 5 10 15

Ser Glu Pro Cys Gln Lys Ile Asn Val Lys Gln Ile Ala Ala Arg Leu  
 20 25 30

Leu Pro Pro Leu Tyr Ser Leu Val Phe Ile Phe Gly Phe Val Gly Asn  
 35 40 45

Met Leu Val Ile Leu Val Leu Ile Asn Cys Lys Arg Leu Lys Ser Met  
 50 55 60

Thr Asp Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp Leu Phe Phe Leu  
 65 70 75 80

Leu Thr Val Pro Phe Trp Ala His Tyr Ala Ala Ala Gln Trp Asp Phe  
 85 90 95

Gly Asn Thr Met Cys Gln Leu Leu Thr Gly Leu Tyr Phe Ile Gly Phe  
 100 105 110

Phe Ser Gly Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu  
 115 120 125

Ala Ile Val His Ala Val Phe Ala Leu Lys Ala Arg Thr Val Thr Phe  
 130 135 140

Gly Val Val Thr Ser Val Ile Thr Trp Val Val Ala Val Phe Ala Ser  
 145 150 155 160

Leu Pro Gly Ile Ile Phe Thr Arg Ser Gln Lys Glu Gly Leu His Tyr  
 165 170 175

Thr Cys Ser Ser His Phe Pro Tyr Ser Gln Tyr Gln Phe Trp Lys Asn  
 180 185 190

Phe Gln Thr Leu Lys Ile Val Ile Leu Gly Leu Val Leu Pro Leu Leu  
 195 200 205

Val Met Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu Leu Arg Cys  
 210 215 220

Arg Asn Glu Lys Lys Arg His Arg Ala Val Arg Leu Ile Phe Thr Ile  
 225 230 235 240

Met Ile Val Tyr Phe Leu Phe Trp Ala Pro Tyr Asn Ile Val Leu Leu  
 245 250 255

Leu Asn Thr Phe Gln Glu Phe Phe Gly Leu Asn Asn Cys Ser Ser Ser

260

265

270

Asn	Arg	Leu	Asp	Gln	Ala	Met	Gln	Val	Thr	Glu	Thr	Leu	Gly	Met	Thr
275							280					285			
His	Cys	Cys	Ile	Asn	Pro	Ile	Ile	Tyr	Ala	Phe	Val	Gly	Glu	Lys	Phe
290						295					300				
Arg	Asn	Tyr	Leu	Leu	Val	Phe	Phe	Gln	Lys	His	Ile	Ala	Lys	His	Phe
305						310				315				320	
Cys	Lys	Cys	Cys	Ser	Ile	Phe	Gln	Gln	Glu	Ala	Pro	Glu	Arg	Ala	Ser
						325			330				335		
Ser	Val	Tyr	Thr	Arg	Ser	Thr	Gly	Glu	Gln	Glu	Ile	Ser	Val	Gly	Leu
						340			345				350		

&lt;210&gt; 6

&lt;211&gt; 726

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

Met	Glu	Gly	Glu	Arg	Lys	Asn	Asn	Asn	Lys	Arg	Trp	Tyr	Phe	Thr	Arg
1					5				10					15	

Glu	Gln	Leu	Glu	Asn	Ser	Pro	Ser	Arg	Arg	Phe	Gly	Val	Asp	Pro	Asp
								20	25				30		

Lys	Glu	Leu	Ser	Tyr	Arg	Gln	Gln	Ala	Ala	Asn	Leu	Leu	Gln	Asp	Met
								35	40				45		

Gly	Gln	Arg	Leu	Asn	Val	Ser	Gln	Leu	Thr	Ile	Asn	Thr	Ala	Ile	Val
								50	55				60		

Tyr	Met	His	Arg	Phe	Tyr	Met	Ile	Gln	Ser	Phe	Thr	Gln	Phe	Pro	Gly
							65	70		75			80		

Asn	Ser	Val	Ala	Pro	Ala	Ala	Leu	Phe	Leu	Ala	Ala	Lys	Val	Glu	Glu
								85	90				95		

Gln	Pro	Lys	Lys	Leu	Glu	His	Val	Ile	Lys	Val	Ala	His	Thr	Cys	Leu
								100	105				110		

His	Pro	Gln	Glu	Ser	Leu	Pro	Asp	Thr	Arg	Ser	Glu	Ala	Tyr	Leu	Gln
								115	120				125		

Gln	Val	Gln	Asp	Leu	Val	Ile	Leu	Glu	Ser	Ile	Ile	Leu	Gln	Thr	Leu
								130	135				140		

Gly	Phe	Glu	Leu	Thr	Ile	Asp	His	Pro	His	Thr	His	Val	Val	Lys	Cys
								145	150				155		160

Thr	Gln	Leu	Val	Arg	Ala	Ser	Lys	Asp	Leu	Ala	Gln	Thr	Ser	Tyr	Phe
								165	170				175		

Met	Ala	Thr	Asn	Ser	Leu	His	Leu	Thr	Thr	Phe	Ser	Leu	Gln	Tyr	Thr
								180	185				190		

Pro	Pro	Val	Val	Ala	Cys	Val	Cys	Ile	His	Leu	Ala	Cys	Lys	Trp	Ser
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

195	200	205	
Asn Trp Glu Ile Pro Val Ser Thr Asp Gly Lys His Trp Trp Glu Tyr			
210	215	220	
Val Asp Ala Thr Val Thr Leu Glu Leu Leu Asp Glu Leu Thr His Glu			
225	230	235	240
Phe Leu Gln Ile Leu Glu Lys Thr Pro Asn Arg Leu Lys Arg Ile Trp			
245	250	255	
Asn Trp Arg Ala Cys Glu Ala Ala Lys Lys Thr Lys Ala Asp Asp Arg			
260	265	270	
Gly Thr Asp Glu Lys Thr Ser Glu Gln Thr Ile Leu Asn Met Ile Ser			
275	280	285	
Gln Ser Ser Ser Asp Thr Thr Ile Ala Gly Leu Met Ser Met Ser Thr			
290	295	300	
Ser Thr Thr Ser Ala Val Pro Ser Leu Pro Val Ser Glu Glu Ser Ser			
305	310	315	320
Ser Asn Leu Thr Ser Val Glu Met Leu Pro Gly Lys Arg Trp Leu Ser			
325	330	335	
Ser Gln Pro Ser Phe Lys Leu Glu Pro Thr Gln Gly His Arg Thr Ser			
340	345	350	
Glu Asn Leu Ala Leu Thr Gly Val Asp His Ser Leu Pro Gln Asp Gly			
355	360	365	
Ser Asn Ala Phe Ile Ser Gln Lys Gln Asn Ser Lys Ser Val Pro Ser			
370	375	380	
Ala Lys Val Ser Leu Lys Glu Tyr Arg Ala Lys His Ala Glu Glu Leu			
385	390	395	400
Ala Ala Gln Lys Arg Gln Leu Glu Asn Met Glu Ala Asn Val Lys Ser			
405	410	415	
Gln Tyr Ala Tyr Ala Ala Gln Asn Leu Leu Ser His His Asp Ser His			
420	425	430	
Ser Ser Val Ile Leu Lys Met Pro Ile Glu Gly Ser Glu Asn Pro Glu			
435	440	445	
Arg Pro Phe Leu Glu Lys Ala Asp Lys Thr Ala Leu Lys Met Arg Ile			
450	455	460	
Pro Val Ala Gly Gly Asp Lys Ala Ala Ser Ser Lys Pro Glu Glu Ile			
465	470	475	480
Lys Met Arg Ile Lys Val His Ala Ala Asp Lys His Asn Ser Val			
485	490	495	
Glu Asp Ser Val Thr Lys Ser Arg Glu His Lys Glu Lys His Lys Thr			
500	505	510	
His Pro Ser Asn His His His Asn His His Ser His Lys His			
515	520	525	
Ser His Ser Gln Leu Pro Val Gly Thr Gly Asn Lys Arg Pro Gly Asp			
530	535	540	

Pro Lys His Ser Ser Gln Thr Ser Asn Leu Ala His Lys Thr Tyr Ser  
 545 550 555 560  
 Leu Ser Ser Ser Phe Ser Ser Ser Ser Thr Arg Lys Arg Gly Pro  
 565 570 575  
 Ser Glu Glu Thr Gly Gly Ala Val Phe Asp His Pro Ala Lys Ile Ala  
 580 585 590  
 Lys Ser Thr Lys Ser Ser Leu Asn Phe Ser Phe Pro Ser Leu Pro  
 595 600 605  
 Thr Met Gly Gln Met Pro Gly His Ser Ser Asp Thr Ser Gly Leu Ser  
 610 615 620  
 Phe Ser Gln Pro Ser Cys Lys Thr Arg Val Pro His Ser Lys Leu Asp  
 625 630 635 640  
 Lys Gly Pro Thr Gly Ala Asn Gly His Asn Thr Thr Gln Thr Ile Asp  
 645 650 655  
 Tyr Gln Asp Thr Val Asn Met Leu His Ser Leu Leu Ser Ala Gln Gly  
 660 665 670  
 Val Gln Pro Thr Gln Pro Thr Ala Phe Glu Phe Val Arg Pro Tyr Ser  
 675 680 685  
 Asp Tyr Leu Asn Pro Arg Ser Gly Gly Ile Ser Ser Arg Ser Gly Asn  
 690 695 700  
 Thr Asp Lys Pro Arg Pro Pro Pro Leu Pro Ser Glu Pro Pro Pro Pro  
 705 710 715 720  
 Leu Pro Pro Leu Pro Lys  
 725

<210> 7  
 <211> 1742  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 caagccccaga gcccgtccat ttctgtgggc tcaggtccct actgctcagc cccttcctcc 60  
 ctcggcaagg ccacaatgaa cggggagtc ccttttaggc acttgcttct ggtgctgcaa 120  
 ctggcgctcc tcccagcagc cactcaggga aagaaagtgg tgctgggcaa aaaaggggat 180  
 acagtggAAC tgacctgtac agtttcccag aagaagagca tacaattcca ctggaaaaac 240  
 tccaaaccaga taaagattct gggaaatcag ggctccttct taactaaagg tccatccaag 300  
 ctgaatgatc gcgctgactc aagaagaagc ctttgggacc aaggaaactt cccccctgatc 360  
 atcaagaatc ttaagataga agactcagat acttacatct gtgaagtgg a gaccagaag 420  
 gaggaggtgc aattgtctgt gttcggattt actgccaact ctgacaccca cctgctttag 480  
 gggcagagcc tgaccctgac cttggagac cccccctggta gtagccccctc agtgcaatgt 540  
 aggagtccaa ggggtaaaaa catacagggg gggaaagaccc tctccgtgtc tcagctggag 600

ctccaggata gtggcacctg gacatgcact gtcttcaga accagaagaa ggtggagttc 660  
 aaaaatagaca tcgtggtgct agctttccag aaggcctcca gcatagtcta taagaaaagag 720  
 ggggaacagg tggagttctc cttccactc gccttacag ttgaaaagct gacgggcagt 780  
 ggcgagctgt ggtggcaggc ggagagggct tcttcctcca agtcttggat caccttgac 840  
 ctgaagaaca aggaagtgtc tgtaaaatgg gttacccagg accctaagct ccagatggc 900  
 aagaagctcc cgctccaccc caccctgccc caggccttgc ctcagttatgc tggctctgga 960  
 aacccacccc tggcccttga agcggaaaaca gggaaagttgc atcaggaagt gaaacctggg 1020  
 gtgatgagag ccactcagct ccagaaaaat ttgacctgtg aggtgtgggg acccacctcc 1080  
 cctaagctga tgctgagctt gaaactggag aacaaggagg caaagggtctc gaagcgggag 1140  
 aaggcgggtgt ggggtgctgaa ccctgaggcg gggatgtggc agtgtctgtct gagtgactcg 1200  
 ggacagggtcc tgctggaatc caacatcaag gttctgccc catggtccac cccggtgcag 1260  
 ccaatggccc tgatttgtgct gggggcgctc gccggcctcc tgctttcat tgggcttaggc 1320  
 atcttcttct gtgtcaggtg cccgcaccga aggcgcctc accggttca gaagacatgt 1380  
 aagagactcc tcagtgagaa gaagacctgc cagtgcctc accggttca gaagacatgt 1440  
 agccccatcc gaggcacgag gccaggcaga tcccacttgc agcctccca ggtgtctgcc 1500  
 cccgcgtttcc tgcctgcca ccagatgaat gtagcagatc ccacgctctg gcctcctgtt 1560  
 cgtcctccct acaatttgcc attgtttctc ctgggttagg cccggcttc actggttgag 1620  
 tgggtcttc tagttccag aggcttaatc acaccgtctt ccacgcccatt tccctttctt 1680  
 tcaaggcttag cccttctctc attatttctc tctgaccctc tccctactgc tcatttggat 1740  
 cc 1742

<210> 8  
 <211> 1059  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
 atggattatc aagtgtcaag tccaaacctat gacatcgatt atgatacatc ggagccctgc 60  
 caaaaaatca atgtgaagca aatcgacgc cgcctctgc ctccactcta ctcaactgggt 120  
 ttcatcttgc gttttgtggg caacatgtg gtcatcctcg tctgtataaa ctgcaaaagg 180  
 ctgaagagca tgactgacat ctacctgctc aacctggcca tctctgaccc 240  
 cttactgtcc cttctgggc tcaactacgct gctgcccagt gggactttgg aaatacaatg 300  
 tgcacttgc tgcacggctt ctatttata ggcttcttctt ctggatctt ctcatcatc 360  
 ctccgtacaa tgcatacgata cctagctatc gtccatgctg tgggtgtttt aaaagccagg 420  
 acggtcaccc ttgggttagt gacaagtgtg atcaacttggg tgggtggctgt gtttgcac 480  
 ctcccaaggaa tcatcttac cagatctcaa aaagaaggc ttcattacac ctgcagctct 540

cattttccat acagtcagta tcaattctgg aagaatttcc agacattaaa gatagtcatc 600  
 ttggggctgg tcctgcgcgt gcttgcgt gtcatctgt actcgggaat cctaaaaact 660  
 ctgcgttcgggt gtcgaaacga gaagaagagg cacagggctg tgaggcttat cttcaccatc 720  
 atgattgttt atttctctt ctgggctccc tacaacattt tccttctcctt gaacaccc 780  
 caggaattct ttggcctgaa taattgcagt agctctaaca ggttggacca agccatgcag 840  
 gtgacagaga ctcttggat gacgcactgc tgcataacc ccatcatcta tgccttgc 900  
 ggggagaagt tcagaaacta cctcttagtc ttcttccaaa agcatattgc caaacactc 960  
 tgcaaatgtt gttctatccc ccagcaagag gctcccgagc gagcaagctc agtttacact 1020  
 cgatccactg gggagcagga aatatcggtt ggcttgc 1059

<210> 9  
 <211> 342  
 <212> PRT  
 <213> Homo sapiens

<400> 9  
 Met Ala Glu His Asp Tyr His Glu Asp Tyr Gly Phe Ser Ser Phe Asn  
 1 5 10 15  
 Asp Ser Ser Gln Glu Glu His Gln Asp Phe Leu Gln Phe Ser Lys Val  
 20 25 30  
 Phe Leu Pro Cys Met Tyr Leu Val Val Phe Val Cys Gly Leu Val Gly  
 35 40 45  
 Asn Ser Leu Val Leu Val Ile Ser Ile Phe Tyr His Lys Leu Gln Ser  
 50 55 60  
 Leu Thr Asp Val Phe Leu Val Asn Leu Pro Leu Ala Asp Leu Val Phe  
 65 70 75 80  
 Val Cys Thr Leu Pro Phe Trp Ala Tyr Ala Gly Ile His Glu Trp Val  
 85 90 95  
 Phe Gly Gln Val Met Cys Lys Ser Leu Leu Gly Ile Tyr Thr Ile Asn  
 100 105 110  
 Phe Tyr Thr Ser Met Leu Ile Leu Thr Cys Ile Thr Val Asp Arg Phe  
 115 120 125  
 Ile Val Val Val Lys Ala Thr Lys Ala Tyr Asn Gln Gln Ala Lys Arg  
 130 135 140  
 Met Thr Trp Gly Lys Val Thr Ser Leu Leu Ile Trp Val Ile Ser Leu  
 145 150 155 160  
 Leu Val Ser Leu Pro Gln Ile Ile Tyr Gly Asn Val Phe Asn Leu Asp  
 165 170 175  
 Lys Leu Ile Cys Gly Tyr His Asp Glu Ala Ile Ser Thr Val Val Leu  
 180 185 190  
 Ala Thr Gln Met Thr Leu Gly Phe Phe Leu Pro Leu Leu Thr Met Ile  
 195 200 205

Val Cys Tyr Ser Val Ile Ile Lys Thr Leu Leu His Ala Gly Gly Phe  
 210 215 220  
 Gln Lys His Arg Ser Leu Lys Ile Ile Phe Leu Val Met Ala Val Phe  
 225 230 235 240  
 Leu Leu Thr Gln Met Pro Phe Asn Leu Met Lys Phe Ile Arg Ser Thr  
 245 250 255  
 His Trp Glu Tyr Tyr Ala Met Thr Ser Phe His Tyr Thr Ile Met Val  
 260 265 270  
 Thr Glu Ala Ile Ala Tyr Leu Arg Ala Cys Leu Asn Pro Val Leu Tyr  
 275 280 285  
 Ala Phe Val Ser Leu Lys Phe Arg Lys Asn Phe Trp Lys Leu Val Lys  
 290 295 300  
 Asp Ile Gly Cys Leu Pro Tyr Leu Gly Val Ser His Gln Trp Lys Ser  
 305 310 315 320  
 Ser Glu Asp Asn Ser Lys Thr Phe Ser Ala Ser His Asn Val Glu Ala  
 325 330 335  
 Thr Ser Met Phe Gln Leu  
 340

<210> 10  
 <211> 360  
 <212> PRT  
 <213> Homo sapiens

<400> 10  
 Met Asp Pro Glu Glu Thr Ser Val Tyr Leu Asp Tyr Tyr Tyr Ala Thr  
 1 5 10 15  
 Ser Pro Asn Ser Asp Ile Arg Glu Thr His Ser His Val Pro Tyr Thr  
 20 25 30  
 Ser Val Phe Leu Pro Val Phe Tyr Thr Ala Val Phe Leu Thr Gly Val  
 35 40 45  
 Leu Gly Asn Leu Val Leu Met Gly Ala Leu His Phe Lys Pro Gly Ser  
 50 55 60  
 Arg Arg Leu Ile Asp Ile Phe Ile Ile Asn Leu Ala Ala Ser Asp Phe  
 65 70 75 80  
 Ile Phe Leu Val Thr Leu Pro Leu Trp Val Asp Lys Glu Ala Ser Leu  
 85 90 95  
 Gly Leu Trp Arg Thr Gly Ser Phe Leu Cys Lys Gly Ser Ser Tyr Met  
 100 105 110  
 Ile Ser Val Asn Met His Cys Ser Val Leu Leu Leu Thr Cys Met Ser  
 115 120 125  
 Val Asp Arg Tyr Leu Ala Ile Val Trp Pro Val Val Ser Arg Lys Phe  
 130 135 140  
 Arg Arg Thr Asp Cys Ala Tyr Val Val Cys Ala Ser Ile Trp Phe Ile  
 145 150 155 160

Ser Cys Leu Leu Gly Leu Pro Thr Leu Leu Ser Arg Glu Leu Thr Leu  
 165 170 175  
 Ile Asp Asp Lys Pro Tyr Cys Ala Glu Lys Lys Ala Thr Pro Ile Lys  
 180 185 190  
 Leu Ile Trp Ser Leu Val Ala Leu Phe Thr Phe Phe Val Pro Leu  
 195 200 205  
 Leu Ser Ile Val Thr Cys Tyr Cys Cys Ile Ala Arg Lys Leu Cys Ala  
 210 215 220  
 His Tyr Gln Gln Ser Gly Lys His Asn Lys Lys Leu Lys Lys Ser Ile  
 225 230 235 240  
 Lys Ile Ile Phe Ile Val Val Ala Ala Phe Leu Val Ser Trp Leu Pro  
 245 250 255  
 Phe Asn Thr Phe Lys Phe Leu Ala Ile Val Ser Gly Leu Arg Gln Glu  
 260 265 270  
 His Tyr Leu Pro Ser Ala Ile Leu Gln Leu Gly Met Glu Val Ser Gly  
 275 280 285  
 Pro Leu Ala Phe Ala Asn Ser Cys Val Asn Pro Phe Ile Tyr Tyr Ile  
 290 295 300  
 Phe Asp Ser Tyr Ile Arg Arg Ala Ile Val His Cys Leu Cys Pro Cys  
 305 310 315 320  
 Leu Lys Asn Tyr Asp Phe Gly Ser Ser Thr Glu Thr Ser Asp Ser His  
 325 330 335  
 Leu Thr Lys Ala Leu Ser Thr Phe Ile His Ala Glu Asp Phe Ala Arg  
 340 345 350  
 Arg Arg Lys Arg Ser Val Ser Leu  
 355 360

<210> 11  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Primer  
  
 <400> 11  
 agagtggtt gacatgagtg

20

<210> 12  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Primer  
  
 <400> 12  
 gaagttctgc tacgcaggag

20

<210> 13  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 13  
gagttctggaa cactggggaa gagtgggtg acat

34

<210> 14  
<211> 1679  
<212> DNA  
<213> Homo sapiens

<400> 14  
gtttgttggc tgccggcagca ggttagcaaag tgacgcccag ggcctgagtg ctccagtagc 60  
caccgcacatc ggagaaccag cggttaccat ggaggggatc agtatataca cttcagataa 120  
ctacacccgag gaaatgggct caggggacta tgactccatg aaggaaccct gtttccgtga 180  
agaaaaatgtt aatttcaata aaatcttctt gcccaccatc tactccatca tcttcttaac 240  
tggcattgtg ggcaatggat tggtcattctt ggtcatgggt taccagaaga aactgagaag 300  
catgacggac aagtacaggc tgcacctgtc agtggccgac ctcccttttgc tcatcacgt 360  
tcccttctgg gcagttgatc ccgtggcaaa ctggtactttt gggaaacttcc tatgcaaggc 420  
agtccatgtc atctacacag tcaacctcta cagcagtgtc ctcatcctgg ctttcatcag 480  
tctggaccgc tacctggcca tcgtccacgc caccacagt cagaggccaa ggaagctgtt 540  
ggctgaaaag gtggctatg ttggcgtctg gatccctgcc ctccctgtga ctattccca 600  
cttcatcttt gccaacgtca gtgaggcaga tgacagatat atctgtgacc gcttctaccc 660  
caatgacttg tgggtggttt tggccatgtt tcagcacatc atggttggcc ttatcctgcc 720  
tggtattgtc atcctgtctt gctattgtcat tatcatctcc aagctgtcac actccaagg 780  
ccaccagaag cgcaaggccc tcaagaccac agtcacccatc atcctggctt tcttcgcctg 840  
ttggcgtcct tactacattt ggatcagcat cgactccatc atcctcctgg aaatcatcaa 900  
gcaagggtgt gagttgaga acactgtgca caagtggatt tccatcacgg agggccctagc 960  
tttcttccac tggctatgtc accccatctt ctatgtttc ctggagccaa aatttaaaac 1020  
ctctgcccac cacgcactca cctctgtgag cagagggtcc agcctcaaga tccctctccaa 1080  
aggaaaagcga ggtggacatt catctgtttc cactgagttt gagtcttcaa gttttcactc 1140  
cagctaacac agatgtaaaaa gactttttt tatacgataa ataaactttt tttaagttac 1200  
acatttttca gatataaaag actgaccaat attgtacagt ttttattgtc tggtggattt 1260  
ttgtcttggc tttctttagt ttttggcagaa tttaattgtac ttatattat aaatttttt 1320  
tgtttcataat tgatgtgtgt ctaggcagga cctgtggcca agttcttagt tgctgtatgt 1380

ctcgtggtag gactgttagaa aaggaaactg aacatccag agcgtgtagt gaatcacgta 1440  
aagctagaaa tgatccccag ctgttatgc atagataatc tctccattcc cgtgaaacgt 1500  
tttcctgtt cttaaagacgt gatTTTgctg tagaagatgg cacttataac caaagccaa 1560  
agtggatatag aaatgtggt tttcagtt tcaggagtgg gttgatttca gcacctacag 1620  
tgtacagtct tgtatatagt tgttaataaa agtacatgtt aaacttactt agtgttatg 1679

<210> 15  
<211> 2181  
<212> DNA  
<213> Homo sapiens

<400> 15  
atggagggag agaggaagaa caacaacaaa cgggtggatt tcactcgaga acagctggaa 60  
aatagcccat cccgtcgttt tggcggtggac ccagataaag aactttctta tcgcccagcag 120  
gcggccaatc tgcttcagga catggggcag cgtcttaacg tctcacaatt gactatcaac 180  
actgctatag tatacatgca tcgattctac atgattcagt cttcacaca gttccctgga 240  
aattctgtgg ctccagcagc cttgtttcta gcagctaaag tggaggagca gccccaaaaaa 300  
ttggaacatg tcatcaaggt agcacatact tgtctccatc ctcaggaatc cttcctgat 360  
actagaagtg aggcttattt gcaacaagtt caagatctgg tcattttaga aagcataatt 420  
ttgcagactt taggcttga actaacaatt gatcacccac atactcatgt agtaaagtgc 480  
actcaacttg ttcgagcaag caaggactta gcacagactt cttacttcat ggcaaccqac 540  
agcctgcatt tgaccacatt tagcctgcag tacacacctc ctgtggtggc ctgtgtctgc 600  
atccacctgg cttgcaagtg gtccaaattgg gagatcccag tctcaactga cgggaagcac 660  
tggtggaggt atgttgcgc cactgtgacc ttgaaacttt tagatgaact gacacatgag 720  
tttctacaga ttttggagaa aactcccac aggctcaac gcatttggaa ttggaggcga 780  
tgcgaggctg ccaagaaaac aaaagcagat gaccgaggaa cagatgaaaa gacttcagag 840  
cagacaatcc tcaatatgat ttcccagagc tcttcagaca caaccattgc aggtttaatg 900  
agcatgtcaa cttctaccac aagtgcagtg cttccctgc cagtctccga agagtcatcc 960  
agcaacttaa ccagtgtgga gatgttgcgg ggcaagcggt ggctgtcctc ccaaccttct 1020  
ttcaaacttag aacctactca gggtcatcggt actagtgaga atttagcact tacaggagtt 1080  
gatcattccct taccacagga tggttcaaattt gcatttattt cccagaagca gaatagtaag 1140  
agtgtgccat cagctaaagt gtcactgaaa gaataccgcg cgaagcatgc aagaagaattg 1200  
gctgcccaga agaggcaact ggagaacatg gaaagccatg tgaagtcaca atatgcataat 1260  
gctgcccaga atctcccttc tcatcatgat agccattctt cagtcattct aaaaatgccc 1320  
atagagggtt cagaaaaccc cgagcggcct tttctggaaa aggctgacaa aacagctctc 1380

aaaaatgagaa tcccagtggc aggtggagat aaagctgcgt cttcaaaacc agaggagata 1440  
 aaaaatgcgc aaaaagtcca tgctgcagat gataagcaca attctgtaga ggacagtgtt 1500  
 acaaaagagcc gagagcacaa agaaaagcac aagactcacc catctaata tcatacatcat 1560  
 cataatcacc actcacacaa gcactctcat tcccaacttc cagttggta tggaaacaaa 1620  
 cgtcctggtg atccaaaaca tagtagccag acaagcaact tagcacataa aacctatagc 1680  
 ttgtctagtt cttttcctc ttccagttt actcgtaaaa ggggaccctc tgaagagact 1740  
 ggaggggctg tgtttgcata tccagccaag attgccaaga gtactaaatc ctcttcctc 1800  
 aatttctcct tcccttcact tcctacaatg ggtcagatgc ctgggcatag ctcagacaca 1860  
 agtggcctt cttttcaca gcccagctgt aaaaactcgta tccctcatc gaaactggat 1920  
 aaaggccca ctggggccaa tggtcacaac acgacccaga caatagacta tcaagacact 1980  
 gtgaatatgc ttcaactccct gtcagtgcc caggggtt acggccactca gcctactgca 2040  
 tttgaatttg ttgcgtcctta tagtgactat ctgaatccctc ggtctgggtt aatctcctcg 2100  
 agatctggca atacagacaa accccggccca ccacctctgc catcagaacc tcctccacca 2160  
 ctcccaccc ttcctaagta a 2181

<210> 16  
 <211> 1643  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (25)..(915)

<400> 16  
 aacatctggg gacagcggga aaac atg agt gac tcc aag gaa cca agg gtg 51  
 Met Ser Asp Ser Lys Glu Pro Arg Val  
 1 5

cag cag ctg ggc ctc ctg ggg tgg ctt ggc cat ggc gcc ctg gtg ctg 99  
 Gln Gln Leu Gly Leu Leu Gly Cys Leu Gly His Gly Ala Leu Val Leu  
 10 15 20 25

caa ctc ctc tcc ttc atg ctc ttg gct ggg gtc ctg gtg gcc atc ctt 147  
 Gln Leu Leu Ser Phe Met Leu Leu Ala Gly Val Leu Val Ala Ile Leu  
 30 35 40

gtc caa gtg tcc aag gtc ccc agc tcc cta agt cag gaa caa tcc gag 195  
 Val Gln Val Ser Lys Val Pro Ser Ser Leu Ser Gln Glu Gln Ser Glu  
 45 50 55

caa gac gca atc tac cag aac ctg acc cag ctt aaa gct gca gtg ggt 243  
 Gln Asp Ala Ile Tyr Gln Asn Leu Thr Gln Leu Lys Ala Ala Val Gly  
 60 65 70

gag ctc tca gag aaa tcc aag ctg cag gag atc tac cag gag ctg acc 291  
 Glu Leu Ser Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr  
 75 80 85

cag ctg aag gct gca gtg ggt gag ttg cca gag aaa tcc aag ctg cag 339

Gln Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln  
 90 95 100 105  
 gag atc tac cag gag ctg acc cgg ctg aag gct gca gtg ggt gag ttg 387  
 Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly Glu Leu  
 110 115 120  
 cca gag aaa tcc aag ctg cag gag atc tac cag gag ctg acc cgg ctg 435  
 Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu  
 125 130 135  
 aag gct gca gtg ggt gag ttg cca gag aaa tcc aag ctg cag gag atc 483  
 Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile  
 140 145 150  
 tac cag gag ctg acc cgg ctg aag gct gca gtg ggt gag ttg cca gag 531  
 Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu  
 155 160 165  
 aaa tcc aag ctg cag gag atc tac cag gag ctg acg gag ctg aag gct 579  
 Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr Glu Leu Lys Ala  
 170 175 180 185  
 gca gtg ggt gag ttg cca gag aaa tcc aag ctg cag gag atc tac cag 627  
 Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln  
 190 195 200  
 gag ctg acc cag ctg aag gct gca gtg ggt gag ttg cca gac cag tcc 675  
 Glu Leu Thr Gln Leu Lys Ala Ala Val Gly Glu Leu Pro Asp Gln Ser  
 205 210 215  
 aag cag cag caa atc tat caa gaa ctg acc gat ttg aag act gca ttt 723  
 Lys Gln Gln Ile Tyr Gln Glu Leu Thr Asp Leu Lys Thr Ala Phe  
 220 225 230  
 gaa cgc ctg tgc cgc cac tgt ccc aag gac tgg aca ttc ttc caa gga 771  
 Glu Arg Leu Cys Arg His Cys Pro Lys Asp Trp Thr Phe Phe Gln Gly  
 235 240 245  
 aac tgt tac ttg atg tct aac tcc cag cgg aac tgg cac gaa tcc gtc 819  
 Asn Cys Tyr Phe Met Ser Asn Ser Gln Arg Asn Trp His Asp Ser Val  
 250 255 260 265  
 acc gcc tgc cag gaa gtg agg gcc cag ctc gtc gta atc aaa act get 867  
 Thr Ala Cys Gln Glu Val Arg Ala Gln Leu Val Val Ile Lys Thr Ala  
 270 275 280  
 gag gag cag ctt cca gcg gta ctg gaa cag tgg aga acc caa caa tag 915  
 Glu Glu Gln Leu Pro Ala Val Leu Glu Gln Trp Arg Thr Gln Gln  
 285 290 295  
 cggaaatgaa gactgtgcgg aatttagtgg cagtggctgg aacgacaatc gatgtgacgt 975  
 tgacaattac tggatctgca aaaagccgc agcctgcttc agagacgaat agttgtttcc 1035  
 ctgcttagcct cagcctccat tggatctgca aaaaagccgc agcctgcttc agagacgaat agttgtttcc 1095  
 tcttctctcc atccttggac cttcacaaat gcccgtggac ggttctctgt tcgatcttcc 1155  
 atccccatgt aacctgggtc ttatctgtc cttctgtgc ctccaaatgtt ccctgggtgt 1215  
 gagcttgtgt tcttggccca tccttggagc tttataatgt acctgagtgg gatgcattta 1275  
 gggggcgggc ttggatgtt gtatgaatcc actctctgtt cttttggag attagactat 1335

ttggattcat gtgttagctgc cctgtccctt ggggctttat ctcatccatg caaactacca 1395  
 tctgctcaac ttccagctac accccgtgca ccctttgac tggggacttg ctggttgaag 1455  
 gagctcatct tgcaggctgg aagcaccagg gaattaattc ccccagtcaa ccaatggcat 1515  
 ccagagaggg catggaggct ccataacaacc tcttccaccc ccacatctt ctttgtccta 1575  
 tacatgtctt ccatttggct gtttctgagt tgtagcctt ataataaaagt ggttaaatgtt 1635  
 gtaactgc 1643

<210> 17  
 <211> 296  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 Met Ser Asp Ser Lys Glu Pro Arg Val Gln Gln Leu Gly Leu Leu Gly  
 1 5 10 15  
 Cys Leu Gly His Gly Ala Leu Val Leu Gln Leu Leu Ser Phe Met Leu  
 20 25 30  
 Leu Ala Gly Val Leu Val Ala Ile Leu Val Gln Val Ser Lys Val Pro  
 35 40 45  
 Ser Ser Leu Ser Gln Glu Gln Ser Glu Gln Asp Ala Ile Tyr Gln Asn  
 50 55 60  
 Leu Thr Gln Leu Lys Ala Ala Val Gly Glu Leu Ser Glu Lys Ser Lys  
 65 70 75 80  
 Leu Gln Glu Ile Tyr Gln Glu Leu Thr Gln Leu Lys Ala Ala Val Gly  
 85 90 95  
 Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr  
 100 105 110  
 Arg Leu Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln  
 115 120 125  
 Glu Ile Tyr Gln Glu Leu Thr Arg Leu Lys Ala Ala Val Gly Glu Leu  
 130 135 140  
 Pro Glu Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr Arg Leu  
 145 150 155 160  
 Lys Ala Ala Val Gly Glu Leu Pro Glu Lys Ser Lys Leu Gln Glu Ile  
 165 170 175  
 Tyr Gln Glu Leu Thr Glu Leu Lys Ala Ala Val Gly Glu Leu Pro Glu  
 180 185 190  
 Lys Ser Lys Leu Gln Glu Ile Tyr Gln Glu Leu Thr Gln Leu Lys Ala  
 195 200 205  
 Ala Val Gly Glu Leu Pro Asp Gln Ser Lys Gln Gln Ile Tyr Gln  
 210 215 220  
 Glu Leu Thr Asp Leu Lys Thr Ala Phe Glu Arg Leu Cys Arg His Cys  
 225 230 235 240

Pro Lys Asp Trp Thr Phe Phe Gln Gly Asn Cys Tyr Phe Met Ser Asn  
245 250 255

Ser Gln Arg Asn Trp His Asp Ser Val Thr Ala Cys Gln Glu Val Arg  
260 265 270

Ala Gln Leu Val Val Ile Lys Thr Ala Glu Glu Gln Leu Pro Ala Val  
275 280 285

Leu Glu Gln Trp Arg Thr Gln Gln  
290 295

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number  
WO 01/64752 A3

(51) International Patent Classification<sup>7</sup>: C07K 16/10,  
C12N 5/20, A61K 39/21, 39/39, 39/00, A01K 67/027,  
A61K 39/395, C07K 14/705, A61K 38/17, C12N 5/10,  
G01N 33/53, A61P 31/18

Leydenlaan 25, NL-6525 EX Nijmegen (NL). GEIJTEN-BEEK, Teunis [NL/NL]; Tumor Immunology Laboratory, University Hospital Nijmegen, Philips van Leydenlaan 25, NL-6525 EX Nijmegen (NL).

(21) International Application Number: PCT/US01/06322

(74) Agent: DAVIS, Michael, A.: Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).

(22) International Filing Date: 28 February 2001 (28.02.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

(30) Priority Data:  
09/517,605 2 March 2000 (02.03.2000) US

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

(88) Date of publication of the international search report:  
18 April 2002

US 09/517,605 (CIP)  
Filed on 2 March 2000 (02.03.2000)

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicants (for all designated States except US): NEW YORK UNIVERSITY [US/US]; 70 Washington Square South, New York, NY 10012 (US). KATHOLIEKE UNIVERSITEIT NIJMEGEN [NL/NL]; Posibus 9101, NL-6500 HB Nijmegen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LITTMAN, Dan, R. [US/US]; 29 Washington Square Park West, Apt. 14D, New York, NY 10011 (US). KWON, Douglas [US/US]; 35-13 30th Street, Apt. 2RR, Long Island City, NY 11106 (US). VAN KOOYK, Yvette [NL/NL]; Tumor Immunology Laboratory, University Hospital Nijmegen, Philips van

WO 01/64752 A3

(54) Title: ANTIBODY INHIBITING THE BINDING BETWEEN GP120 AND DC-SIGN AND SCREENING METHODS

(57) Abstract: The present invention demonstrates that a receptor, named DC-SIGN, is specifically expressed on dendritic cells, and facilitates infection of T lymphocytes with HIV. Assays for identifying compounds that modulate the interaction of DC-SIGN and HIV and/or T cells and macrophage are provided. Compounds so identified are also part of the present invention.

## INT'L NATIONAL SEARCH REPORT

Internal Application No  
PCT/US 01/06322

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7	C07K16/10	C12N5/20	A61K39/21	A61K39/39
	A01K67/027	A61K39/395	C07K14/705	A61K38/17
	G01N33/53	A61P31/18		C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, WPI Data, PAJ, EPO-Internal, SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>B. CURTIS ET AL.: "Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 89, September 1992 (1992-09), pages 8356-8360, XP002118177 Washington, DC, USA cited in the application material and methods - stable transfection of HeLa cells figure 2</p> <p style="text-align: center;">-/-</p>	9, 10

 Further documents are listed in the continuation of box C Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*A\* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 February 2002	11/02/2002

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl  
 Fax (+31-70) 340-3016

Authorized officer

Nooij, F

5

## INT'L NATIONAL SEARCH REPORT

Internal Application No	PCT/US 01/06322
-------------------------	-----------------

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. BROWNING ET AL.: "Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 94, December 1997 (1997-12), pages 14637-14641, XP002925294 Washington, DC, USA abstract	14-17
A	WO 98 46734 A (JAPAN SCIENCE AND TECHNOLOGY CORPORATION) 22 October 1998 (1998-10-22) claims	14-17
A	WO 99 03888 A (NEW YORK UNIVERSITY) 28 January 1999 (1999-01-28) claims	14-17
A	N. SULLIVAN ET AL.: "CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization." JOURNAL OF VIROLOGY, vol. 72, no. 6, June 1998 (1998-06), pages 4694-4703, XP002144408 USA abstract	1-4, 18
A	R. LACASSE ET AL.: "Fusion-competent vaccines: Broad neutralization of primary isolates of HIV." SCIENCE, vol. 283, no. 5400, 15 January 1999 (1999-01-15), pages 357-362, XP002120812 Washington, DC, USA the whole document	1-4, 18
A	T. GEIJTENBEEK ET AL.: "DC-SIGN, a novel dendritic cell-specific adhesion receptor for ICAM-3 mediates DC-T cell interactions and HIV-1 infection of DC." BLOOD, vol. 94, no. 10 suppl. 1 (part 1 of 2), 15 November 1999 (1999-11-15), page 434a XP000929231 Philadelphia, PA, USA abstract# 1928	1-27, 29-39, 41-46
		-/-

## INT'L NATIONAL SEARCH REPORT

Internal Application No  
PCT/US 01/06322

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	R. STEINMAN: "DC-SIGN: A guide to some mysteries of dendritic cells." CELL, vol. 100, no. 5, 3 March 2000 (2000-03-03), pages 491-494, XP000929196 Cambridge, MA, USA the whole document	1-27, 29-39, 41-46
P,A	J. COHEN: "Novel protein delivers HIV to target cells." SCIENCE, vol. 287, 3 March 2000 (2000-03-03), page 1567 XP000929199 Washington, DC, USA the whole document	1-27, 29-39, 41-46

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 28 and 40 (both completely), 26, 35 and 46 (all partially)

Present claims 26 and 35 each relate to a compound defined by reference to a desirable characteristic or property, namely the capability to interfere with trans-enhancement of HIV into a cell. Present claim 46 relates to a compound defined by reference to a desirable characteristic or property, namely the capability to interfere with HIV entry into a cell that expresses DC-SIGN.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those claims which appear to be clear, supported and disclosed, namely antibodies against DC-SIGN, antibodies against CD4 and the CCR5 chemokines RANTES, MIP-1alpha and MIP-1beta, as disclosed in example 1. Present claim 28 relates to a compound defined by a desired characteristic or property, namely the capability for use in the treatment or prevention of HIV infection using a transgenic non-human animal. Present claim 40 relates to a compound defined to a desired characteristic or property, namely the capability to interfere with HIV entry into a cell that expresses DC-SIGN.

The claims cover all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any of the compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has not been carried out for present claims 28 and 40.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-4,18

Inhibiting antibody specific for the DC-SIGN-binding portion of gp120, for a portion of gp120 exposed upon binding of gp120 to DC-SIGN, or for the DC-SIGN/gp120 complex, and its use for treatment or prevention of HIV infection. Immortal cell that produces said antibody.

2. Claims: 5,6

Soluble form of human DC-SIGN, and pharmaceutical composition comprising said soluble form

3. Claim : 7

Immunogenic composition comprising an adjuvant and an antigenic fragment of gp120.

4. Claim : 8

Immunogenic composition comprising an adjuvant and a DC-SIGN/gp120 binding complex.

5. Claims: 9-13

Mammalian cell transfected with a vector encoding human DC-SIGN, and its use to filter a biological fluid.

6. Claims: 14-17,27,28

Transgenic non-human mammal comprising DNA constructs encoding CD4, a human translocation promoting agent, and human DC-SIGN, and its use for identifying an agent for use in the treatment or prevention of HIV infection.

7. Claims: 19-26,29-35

Method of identifying a compound that interferes with the trans-enhancement of HIV entry into a cell.

8. Claims: 36-46

Method of identifying a compound that interferes with HIV entry into a cell that expresses DC-SIGN.

## INT'L NATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/06322

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9846734	A 22-10-1998	AU 6853298 A		11-11-1998
		EP 0975746 A1		02-02-2000
		WO 9846734 A1		22-10-1998
		JP 2000513584 T		17-10-2000
		US 6255555 B1		03-07-2001
WO 9903888	A 28-01-1999	WO 9903888 A1		28-01-1999

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.